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Both cortisol and corticosterone circulate in human plasma however corticosterone has 
been relatively neglected in human research to date. There is evidence of distinct 
regulation within different tissues with the transmembrane transporter ABCB1, highly 
expressed in the brain, exporting cortisol but not corticosterone. This may account for 
the relative accumulation of corticosterone in the CNS. In contrast, ABCC1, highly 
expressed in adipose tissue and skeletal muscle, exports corticosterone but not cortisol, 
suggesting cortisol is the principal glucocorticoid acting in these tissues.  
We tested the hypotheses that: (i) corticosterone physiology in humans is different to 
that of cortisol; (ii) inhibition of ABCC1 increases binding of corticosterone to 
corticosteroid receptors in adipose tissue and skeletal muscle but has no central CNS 
effect; and (iii) corticosterone is superior to cortisol as a basis for glucocorticoid 
replacement therapy with fewer metabolic side effects.  
We compared paired salivary and plasma samples from 10 healthy individuals. Plasma 
corticosterone showed a similar diurnal variation to cortisol but salivary corticosterone 
was low and did not correlate with plasma concentrations.  
A placebo-controlled randomised crossover study was carried out in 14 healthy 
individuals comparing receptor occupancy of glucocorticoids centrally and 
peripherally with and without ABCC1 inhibition. Receptor occupancy was assessed 
through displacement with MR and GR antagonists potassium canrenoate and 
mifepristone. Centrally, ABCC1 inhibition caused increased activation of the HPA 
 





axis after MR and GR antagonism. Peripherally, we were unable to show displacement 
from adipose tissue or skeletal muscle.  
A further placebo-controlled randomised crossover study is still ongoing in 16 patients 
with congenital adrenal hyperplasia, comparing metabolic effects of placebo, cortisol 
and corticosterone infusions over 6 hours. We present interim data for n=8. ACTH and 
17-OHP were suppressed with corticosterone. Metabolic parameters were similar 
between placebo, cortisol and corticosterone phases. 
These data suggest corticosterone physiology is distinct compared with cortisol in 
humans. We have shown ABCC1 inhibition alters the HPA axis after receptor 
antagonism which suggests ABCC1 may play more of a key role centrally than 
previously thought. Corticosterone suppresses ACTH and 17-OHP in the short term in 
congenital adrenal hyperplasia, highlighting the possibility of its use as an alternative 
glucocorticoid replacement therapy in the future. 
  
 






Natural steroids, called glucocorticoids, are produced by the adrenal glands and play a 
major role in the response to stress, fighting infection and inflammation and 
controlling metabolism. Synthetic glucocorticoids are prescribed by doctors for the 
treatment of numerous conditions such as allergic skin disease and asthma. They are 
also given to people whose adrenal glands are unable to make sufficient natural 
glucocorticoids. Although taking glucocorticoids is very effective, side effects are 
numerous, including weight gain, increased blood pressure and high cholesterol.  
There are two main glucocorticoids in humans, cortisol and corticosterone. Cortisol 
circulates at higher levels than corticosterone in blood and has therefore been regarded 
as more important. To date, research in humans has focussed on cortisol and most of 
the synthetic glucocorticoids given to patients are similar to cortisol. We know much 
less about corticosterone in health and disease but evidence is mounting that cortisol 
and corticosterone differ in certain important aspects. For example, corticosterone is 
present at relatively higher levels in the brain and lower levels in fat tissue than in 
blood. In contrast, cortisol is present at relatively higher levels in fat tissue and lower 
levels in brain. This is because in the brain, a pump (named ABCB1) removes only 
cortisol from cells whereas in fat tissue, a pump (named ABCC1) removes only 
corticosterone. Given that we think a lot of the side effects of glucocorticoids are due 
to their effects on fat tissue, we wished to investigate whether corticosterone may be a 
better basis for synthetic glucocorticoid treatment. 
 





First, we compared corticosterone and cortisol levels in blood, saliva and hair of 
healthy individuals. We then investigated whether blocking the corticosterone pumps 
in fat tissue changed the body’s response to glucocorticoids.  Finally, we investigated 
the potential to use corticosterone as a treatment for patients who cannot produce 
glucocorticoids naturally by comparing effects with cortisol. 
We found that corticosterone levels did not simply mimic cortisol, highlighting it is a 
distinct glucocorticoid with its own characteristics.  The corticosterone pumps play a 
significant role in glucocorticoid production and response.  Corticosterone was 
comparable to cortisol in replacement therapy over the short term. This highlights the 
possibility of using corticosterone as an alternative glucocorticoid replacement therapy 
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1.1 Glucocorticoid physiology 
Glucocorticoids are catabolic steroid hormones secreted by the adrenal cortex with 
major effects on carbohydrate, protein and lipid metabolism as well as significant anti-
inflammatory and immunological actions (Sapolsky et al. 2000).  Glucocorticoids play 
a major role in maintaining homeostasis through energy storage and conservation, 
immune system modulation and memory formation. They are central to stimulation of 
cardiovascular responses, promoting energy mobilisation and modulating immune 
response which are particularly relevant during stress (Vegiopoulos & Herzig 2007; 
Cain & Cidlowski 2017; de Quervain et al. 2016). 
Circulating concentrations of the more abundant glucocorticoid in humans, cortisol, 
are closely regulated by a negative feedback system with elevations in times of acute 
stress. This adaptive response allows activation of the afore-mentioned pathways to 
respond to a stressful stimulus. If elevated circulating cortisol is sustained in the 
absence of continued stressful stimuli, the response is maladaptive and results in 
features of Cushing’s syndrome such as hypertension and hyperglycaemia. In 
conditions of impaired glucocorticoid production, synthetic glucocorticoids based on 
cortisol are administered. Although effective, doses are often supra-physiological and 
result in similar Cushingoid features. Determining the mechanisms behind 
maladaptive excess of cortisol and improving synthetic glucocorticoid administration 
has been a focus of clinical research.  
Corticosterone is another, less abundant, human glucocorticoid which has been 
relatively neglected in the field of human research to date. The extent to which 
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corticosterone mirrors the maladaptive responses of cortisol and the consequences of 
corticosterone excess are not well defined.   
This thesis explores the regulation of cortisol and corticosterone in different tissues 
and compares their effects in glucocorticoid replacement therapy.  
1.1.1 Structure 
Glucocorticoids are steroid hormones derived from cholesterol which have a typical 
molecular configuration. The steroid core structure has seventeen carbon atoms, 
arranged in four fused rings (named A-D) of which three are cyclohexane and the other 
cyclopentane (Figure 1-1). The four carbon rings are conventionally labelled by letters 
and the individual carbon atoms by numbers. Steroids are defined by the functional 
groups attached to this basic structure. Substituents and hydrogens are designated 
according to the number of the carbon atom to which they are attached. These are 
labelled α or β according to their positioning above or below the plane. Cortisol is 
defined by its hydroxyl group at position 11 while in comparison corticosterone differs 
only with the absence of a hydroxyl group at position 17. 
Figure 1-1: Basic steroid structure 
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1.1.2 The hypothalamic-pituitary-adrenal (HPA) axis 
Glucocorticoids are produced in the adrenal cortex by the zona fasciculata and 
reticularis. They are under tight regulation by the hypothalamic-pituitary-adrenal 
(HPA) axis which is a negative feedback system (Figure 1-2). Highly lipophilic, they 
cannot be stored in vesicles and must be produced de novo when required. 
Corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) are secreted 
from the paraventricular nucleus (PVN) of the hypothalamus which stimulates release 
of adrenocorticotrophic hormone (ACTH) from the pituitary gland via activation of 
pituitary pro-opiomelanocortin (POMC) gene transcription (Vegiopoulos & Herzig 
2007). ACTH acts at the adrenal cortex to stimulate steroidogenesis. Glucocorticoids 
regulate their own production through a number of negative feedback mechanisms. 
There is inhibition of the synthesis and release of ACTH from the anterior pituitary 
via interference with POMC transcription and in addition, inhibition of CRH gene 
expression and secretion in the hypothalamus. This is through direct modulation of 
neuronal activity in the PVN and other areas of the brain such as the hippocampus, 
amygdala and prefrontal cortex.  
In the zona fasciculata, ACTH binds to the melanocortin type-2 receptor (MC2R), 
leading to activation of adenylyl cyclase and subsequent increase in cyclic adenosine 
mono phosphate (cAMP) which activates downstream pathways such as protein kinase 
A (PKA) (Spiga & Lightman 2015). Activation of the PKA pathway causes rapid 
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Figure 1-2: Hypothalamic-pituitary-adrenal axis 
 
This process is regulated by steroidogenic acute regulatory protein (StAR) which 
controls delivery of cholesterol to the mitochondria where steroidogenesis occurs 
(Clark et al. 1994). This is a rate-limiting step, without which, steroidogenesis is 
severely impaired which manifests clinically as congenital lipoid adrenal hyperplasia 
(Bose et al. 1996). Cholesterol is converted to pregnenolone by side-chain cleavage 
enzyme, the product of CYP11A1. Pregnenolone is then converted to progesterone by 
3β-hydroxysteroid dehydrogenase encoded by HSD3B1. 11-deoxycorticosterone is 
produced from progesterone through enzymatic conversion by 21-hydroxylase from 
CYP21A2. 
Thereafter, corticosterone and aldosterone are produced after enzymatic conversion by 
11β-hydroxylase and aldosterone synthase respectively, both produced by CYP11B2. 
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This occurs primarily in the zona glomerulosa whereas in the zona fasciculata, 17α-
hydroxylation of pregnenolone and progesterone leads to a parallel pathway. 17-
hydroxypregnenolone is converted to 17-hydroxyprogesterone by 3β-hydroxysteroid 
dehydrogenase and further to 11-deoxycortisol by 21-hydroxylase. Cortisol is 
produced from the final conversion of 11-deoxycortisol by 11β-hydroxylase (Hum & 
Miller 1993).  
Figure 1-3: Steroidogenesis pathway  
 
1.1.2.1 Pattern of glucocorticoid release 
Glucocorticoids are released in a pulsatile manner with both circadian and ultradian 
rhythm. This roughly 24 hour cycle exists in many organisms and aims to achieve 
homeostasis by anticipation and preparation for changes in environment (Panda et al. 
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2002). The suprachiasmatic nucleus (SCN) is responsible for driving this by receiving 
light signals via the retino-hypothalamic tract, triggering a signalling cascade within 
SCN neurons. This alters gene expression (Dickmeis 2009) and augments the CRH 
drive through afferents projecting to the paraventricular nucleus and median eminence 
(Engeland & Arnhold 2005).  
Glucocorticoid release varies according to the timing of activity and therefore the 
circadian peak occurs in the early morning in humans and in the early night in rodents 
(Dickmeis 2009; Lightman & Conway-Campbell 2010).  In humans, the pattern of 
glucocorticoid release begins to rise around 3am, reaching a peak at approximately 
9am before gradually falling throughout the day to a nadir around midnight (Henley 
& Lightman 2014). 
Within the circadian rhythm, there is a further pulsatile profile, the ultradian rhythm, 
characterised by distinct pulses at approximately 1-hour intervals. There is 
considerable inter-individual variability in pulse frequency and amplitude and these 
are subject to further change by normal physiological events such as puberty, lactation 
and ageing (Windle et al. 1997; Evuarherhe et al. 2009; Conway-Campbell et al. 2012). 
The origin of this pulsatility was assumed to be hypothalamic however pulsatility was 
observed to be retained in sheep after hypothalamic disconnection, suggesting a 
peripheral source (Engler et al. 1990). A mathematical model has since been proposed 
describing the linear relationship between the delay in feed forward signal from the 
pituitary to the adrenal and the rapid non-linear feedback from the adrenal to the 
pituitary (Walker et al. 2010). This suggests an innate oscillatory system which exists 
solely between the pituitary and adrenal and is crucially dependent on the rate of 
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production and clearance of glucocorticoid. The significance of pulsatile ACTH 
release was established by Spiga et al where pulsatile but not continuous infusion of 
ACTH at equivalent doses to HPA-suppressed rats resulted in pulsatile corticosterone 
release (Spiga et al. 2011).  
Disturbances in ultradian dynamics of the HPA axis have been observed in a number 
of medical conditions (Henley & Lightman 2014). Frequent blood sampling in patients 
with obstructive sleep apnoea demonstrated ACTH and cortisol pulses of prolonged 
amplitude resulting in elevated total cortisol production. Interestingly, these changes 
were ameliorated after treatment with positive airways pressure after 3 months (Henley 
et al. 2009).  In Cushing’s syndrome, there was greater irregularity of release of both 
cortisol and ACTH when compared to healthy controls (van den Berg et al. 1997). 
Depression is associated with enhanced pulse magnitude which results in loss of 
circadian rhythm and changes the pattern of exposure of glucocorticoids to tissues 
(Young et al. 2004).  
It remains unclear whether these changes in HPA pulsatile patterns are caused by or 
as a consequence of these chronic conditions. It does seem clear that changes in 
glucocorticoid exposure through changes in secretory profile has an effect on 
metabolic, cognitive and behavioural well-being. It has been hypothesised that 
alterations in ultradian rhythms may contribute to the pathogenesis of cardio-metabolic 
risk (Sarabdjitsingh et al. 2012; Henley & Lightman 2014).  
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1.1.3 Glucocorticoid transport 
Transport of glucocorticoids to target receptors is principally via corticosteroid 
binding globulin (CBG), a monomeric glycoprotein synthesised mainly in the liver 
(Gagliardi et al. 2010). Under normal conditions, 80-90% of cortisol is bound to CBG, 
with 10-15% bound to albumin with lower affinity and the remaining 5-10% unbound 
or free. Only free cortisol is biologically active. At peaks of cortisol release, CBG is 
saturated and therefore the free portion increases exponentially above 400-500nmol/l 
(Ballard 1979). CBG acts as a buffer during secretory surges of glucocorticoid release 
and as a reservoir during times of trough (Hammond et al. 1990). In times of acute 
inflammation, CBG is cleaved locally by neutrophil elastase to release cortisol and 
allow anti-inflammatory effects (Lin et al. 2010). 
1.1.4 Receptor binding and signalling 
Glucocorticoid biological activity is mediated by two nuclear receptors. The 
mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) are members of the 
nuclear receptor subfamily 3, group C, located on chromosome 5. They are closely 
related to the progesterone and androgen receptors, sharing a common domain 
structure (Weikum et al. 2017). Both MR and GR remain in the cytoplasm until 
activated whereupon they translocate to the nucleus and bind to DNA sequences (MR 
and GR response elements) or other DNA-bound transcription factors to allow trans-
activation or trans-repression of target genes (Moraitis et al. 2016). In addition, non-
genomic effects are mediated in the cytoplasm and mitochondria (Groeneweg et al. 
2011) . It is increasingly recognised that GR is highly dynamic in action and this 
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stochastic mode of action links with the pulsatile availability of glucocorticoid in vivo 
(Conway-Campbell et al. 2010).  
Despite their commonly used names, both GR and MR recognise a number of natural 
ligands including cortisol, corticosterone, aldosterone and progesterone. GR is almost 
ubiquitously expressed whereas MR is present in fewer cell types. Classically MR is 
present in aldosterone sensitive tissues such as the kidney, colon and parotid (Funder 
2005). GR has a relatively low affinity for glucocorticoids (Kd =10-25 nM) suggesting 
it plays a key role when glucocorticoid levels peak such as in the morning or during 
times of stress (Reul & de Kloet 1985; Hellal-Levy et al. 1999). In contrast, MR has a 
higher affinity for both glucocorticoids and aldosterone (Kd = 0.5-2 nM) and therefore 
acts at times of lower glucocorticoid levels in the evening and overnight (Arriza et al. 
1987; Hellal-Levy et al. 1999).  
The more abundant glucocorticoid in humans, cortisol, circulates roughly 1000-fold 
higher concentrations than aldosterone. The presence of the enzyme 11β-
hydroxysteroid dehydrogenase type 2 (11β-HSD2) plays a critical role in protecting 
MR from over-activation by glucocorticoids in target tissues such as the kidney 
(Funder et al. 1988; Edwards et al. 1987). This enzyme catalyses the nicotinamide 
adenine dinucleotide (NAD+)-dependent oxidation of cortisol to its inactive form, 
cortisone thereby allowing aldosterone to bind to MR in the presence of much higher 
concentrations of glucocorticoid (Stewart et al. 1988).  
Tissue glucocorticoid levels are also controlled by another isozyme 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) which acts predominantly as a 
reductase in vivo, converting inactive cortisone to cortisol. This allows tissue-specific 
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regeneration of glucocorticoids independently of HPA axis production, particularly in 
tissues such as liver, skeletal muscle and adipose (Seckl & Walker 2001). 
Dysregulation of these enzymes has significant impact on cortisol clearance in a 
variety of clinical settings. Inactivating mutations in 11β-HSD2 result in the disorder 
of apparent mineralocorticoid excess where MR are activated by glucocorticoids, 
which are not inactivated by 11β-HSD2, in MR target tissues manifesting in sodium 
and water retention, hypokalaemia and severe hypertension (Stewart et al. 1988; 
Stewart et al. 1987). Conversely, inactivation of 11β-HSD1 or ‘relative cortisone 
reductase deficiency’ leads to a relative excess of cortisone compared to cortisol and 
results in impaired negative feedback of the HPA axis. This manifests clinically with 
hirsutism as a result of adrenal androgen excess (Phillipov et al. 1996; Jamieson et al. 
1999).   
1.1.5 Negative feedback of the HPA axis 
Negative feedback of the HPA axis is a vital function of the system, aiming to limit 
exposure to the catabolic actions of glucocorticoids. There are distinct time domains 
in which this occurs. Fast feedback is measured in seconds to minutes while 
intermediate and slow effects occur over hours to days. The rapidity of this initial 
response suggests protein synthesis is not involved and therefore appears to be 
mediated by non-genomic signalling pathways (Evanson et al. 2010). In contrast, 
delayed negative feedback is mediated by changes in gene expression through 
activation of GR and MR (Keller-Wood & Dallman 1984).  
Glucocorticoid feedback can occur at the level of the pituitary, hypothalamus and 
within the hippocampus, paraventricular thalamus and pre-frontal cortex (Hill & 
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Tasker 2012; Spiga & Lightman 2015). At the pituitary, glucocorticoids act initially to 
suppress the release of ACTH via rapid feedback effects and thereafter to inhibit 
synthesis of ACTH via genomic mechanisms (Jones et al. 1977). Within the brain, 
there is a complex process of rapid and delayed effects acting on the PVN to suppress 
secretion of CRH and down-regulation of CRH and vasopressin mRNA transcription 
respectively (Hill & Tasker 2012). The involvement of the higher limbic areas in 
negative feedback appear to be limited to psychological rather than physical stimuli 
(Furay et al. 2008). In contrast, brainstem structures influence the HPA axis through 
detection of physiological stressors such as inflammation or hypotension (Ulrich-Lai 
& Herman 2009). 
1.1.6 Clearance 
Glucocorticoids are cleared irreversibly from the circulation via the A-ring reductase 
enzymes, 5α- and 5β-reductase, acting primarily in the liver to form the dihydro-
product (Nixon et al. 2012). These metabolites are then reduced further by 3α-
hydroxysteroid dehydrogenase (3α-HSD) and excreted mainly as the tetrahydro-
corticosteroids while a proportion are further reduced by 20α/β-hydroxysteroid 
dehydrogenase (20α/β-HSD) to form cortols and cortolones (Figure 1-4). These 
metabolites are conjugated with glucuronic acid or sulphate to facilitate renal 
excretion.  
Analysis of 24-hour urinary excretion in healthy individuals suggests 50% of secreted 
cortisol is excreted as α/β-tetrahydrocortisol and cortisone, 25% as cortols and 
cortolones, 10% as C19 steroids and 10% as cortolic and cortolonic acids. The 
remaining portion is excreted as free unconjugated steroids (Tomlinson et al. 2004).  
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Figure 1-4: Metabolism of cortisol 
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1.2 Measuring glucocorticoids in humans 
1.2.1 Plasma 
Measurement of glucocorticoids in plasma or serum is the most common method of 
assessing adrenal function in humans. Given the circadian rhythm of glucocorticoids, 
timing of sampling is significant and given circulating concentrations are influenced 
by production and clearance, these parameters must be considered when interpreting 
random samples.  Early morning samples can be used clinically to determine adequate 
glucocorticoid levels while late night samples are useful in excluding glucocorticoid 
excess. It can be difficult to draw any conclusion regarding glucocorticoid metabolism 
from a single plasma measurement however and the gold standard for assessing HPA 
axis function is through dynamic testing. Adrenal insufficiency can be assessed by an 
insulin tolerance test however recent clinical guidelines favour the short synacthen test 
as a more reliable and practical alternative (Wood et al. 1965; Bornstein et al. 2016).  
Synthetic ACTH1-24 is given by intramuscular or intravenous injection and a plasma or 
serum cortisol measurement is taken at baseline and 30 minutes after the injection. The 
threshold for an adequate response is determined locally. 
Cortisol measured in peripheral blood provides a value for the total circulating pool 
which includes both bound and unbound fractions. This may become clinically 
relevant in patients with conditions affecting plasma protein concentrations such as 
liver cirrhosis. The fraction of bound cortisol is less and therefore lower total 
concentration is measured. As a result of higher circulating free cortisol, there is 
increased negative feedback and a resultant fall in HPA drive. In these patients, free 
plasma concentration is more indicative of adrenal function (Fede et al. 2012). The 
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free portion of plasma cortisol can be measured by ultrafiltration, equilibrium dialysis 
or gel filtration but these procedures are time consuming and complex and are 
therefore unsuitable for routine use. An alternative method has been performed by 
quantifying total plasma cortisol and plasma CBG and calculating free cortisol, but is 
limited due to the variable binding affinity for CBG (Turpeinen & Hämäläinen 2013).  
The analytical method of detecting cortisol has largely involved immunoassay, gas 
chromatography mass spectrometry (GC-MS) or liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Immunoassays are particularly susceptible to cross 
reactivity with both endogenous and exogenous steroids of similar structure leading to 
falsely elevated results (Shackleton 2010). LC-MS/MS has the advantages of high 
sensitivity, specificity and high throughput (Hawley & Keevil 2016). Unlike 
immunoassay, LC-MS/MS allows simultaneous measurement of whole steroid 
profiles in a single run. Despite this, few clinical laboratories employ LC-MS/MS for 
cortisol analysis due to the long run times, extensive sample preparation and expense 
(Taylor et al. 2015). In contrast, glucocorticoid assessment by LC-MS/MS is 
increasingly becoming a necessity in clinical research as the superior sensitivity and 
selectivity allows more accurate assessment of glucocorticoids in various biological 
samples (Taylor et al. 2015).   
1.2.2 Saliva 
In recent years, the validity of measuring salivary glucocorticoids has been recognised. 
Changes in binding proteins such as CBG and albumin can greatly affect total plasma 
glucocorticoid levels. Saliva is an ultrafiltrate of plasma and reflects the biologically 
active, non-protein bound pool of glucocorticoids in plasma (Hawley & Keevil 2016).  
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Salivary cortisol follows a circadian rhythm and late night salivary cortisol is a 
common screening test for Cushing’s syndrome which is highly sensitive and specific 
(>90%) (Newell-Price et al. 2006). Measuring salivary cortisol has been suggested as 
an alternative to plasma in dynamic testing of the HPA axis to detect hypoadrenalism 
(Perogamvros, Owen, et al. 2010) It has also been proposed as a useful monitoring tool 
for patients taking glucocorticoid replacement therapy such as in Addison’s disease or 
Congenital Adrenal Hyperplasia (Turpeinen & Hämäläinen 2013). As a non-invasive 
and easy-to-collect biological fluid, salivary cortisol is ideal in paediatric populations. 
Samples are stable and can be stored at room temperature for 1-2 days (Turpeinen & 
Hämäläinen 2013).  
Salivary cortisol is well characterised in humans and indeed salivary cortisone has 
been proposed as a superior measure of plasma cortisol concentrations due to the 
significant activity of 11β-HSD2 in the parotid gland (Perogamvros, Keevil, et al. 
2010).  
1.2.3 Urine 
Urinary cortisol concentration also reflects the unbound portion in the circulation, 
freely filtered at the glomerulus (Hawley & Keevil 2016). Metabolites of 
glucocorticoid metabolism may also be measured in urine allowing assessment of 
clearance. A 24-hour urinary collection of urine is preferred to assess urinary free 
cortisol to allow for diurnal variation and benefits from the lack of confounding by 
plasma proteins (Newell-Price et al. 2006). This is recommended as one of the 
commonly used diagnostic tests in the assessment of Cushing’s syndrome (Nieman et 
al. 2008) Analytical methods include immunoassay, high performance liquid 
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chromatography (HPLC), GC-MS or LC-MS/MS. As previously described, 
immunoassay is limited in specificity due to the cross reactivity of the many 
glucocorticoid metabolites present in urine and often over-estimates true urinary free 
cortisol values. Solvent extraction and separation by chromatography are necessary to 
reduce interference and improve accuracy (Turpeinen & Hämäläinen 2013). 
1.2.4 Hair 
Hair has been used by forensic scientists as a method of detecting drugs and banned 
substances for many years. While methods to detect both endogenous and exogenous 
glucocorticoids were developed to detect performance-enhancing doping amongst 
athletes in the late 1990s and early 2000s, it wasn’t until a decade later that this was 
employed as a technique to assess exposure to endogenous glucocorticoids (Cirimele 
et al. 2000; Raul et al. 2004; Thomson et al. 2010). Hair measurement has the 
significant benefit of assessing long term glucocorticoid exposure which is not 
possible with plasma and saliva assessments. 
The mechanism by which glucocorticoids are incorporated into hair is not yet clearly 
defined. It is likely to involve a combination of diffusion from the blood supply to the 
hair follicle and absorption from surrounding sebaceous gland secretions and sweat 
(Meyer & Novak 2012). Hair is sampled in segments of 1cm which corresponds to 
approximately one month of growth, thereby allowing a timeline of glucocorticoid 
exposure to be created (LeBeau et al. 2011). There is debate over whether there is a 
washout effect with samples taken further from the follicle and this appears to depend 
on the method of sample preparation (Russell et al. 2012). A number of studies have 
investigated the effects of hair colour, gender and hair treatments (e.g. hair product 
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use, dyeing etc). Hair colour appears to have no contribution to glucocorticoid 
concentration however the effect of hair dye use is unclear and may lead to lower 
glucocorticoid measurement (Manenschijn et al. 2011; Kirschbaum et al. 2009).  
Hair cortisol measurements have been shown to correlate with plasma and saliva 
glucocorticoid concentrations in healthy individuals and patients with known 
hypercortisolism (Manenschijn et al. 2011; Xie et al. 2011). It is particularly relevant 
in the assessment of patients with suspected cyclical Cushing’s syndrome 
(Manenschijn et al. 2012). In addition, raised hair cortisol is associated with metabolic 
syndrome and cardiovascular disease (Stalder et al. 2013; Manenschijn et al. 2013). 
Measurement of long term glucocorticoid exposure has been of interest in evaluation 
of chronic stress and has been shown to be a valuable biomarker in assessment of 
disease (Russell et al. 2012). 
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1.3 Glucocorticoids in disease 
1.3.1 Cushing’s syndrome 
Cushing’s syndrome results from exposure to excess glucocorticoids from an 
exogenous or endogenous source. There is widespread use of synthetic corticosteroids 
to treat a myriad of conditions such as rheumatoid arthritis, inflammatory bowel 
disease and asthma and therefore Cushingoid features due to exogenous use are 
relatively common. Endogenous sources of glucocorticoid excess are rarer and may be 
ACTH dependent or independent. The different aetiologies of Cushing’s syndrome are 
described in Table 1-1. Endogenous Cushing’s syndrome has an estimated incidence 
of 0.2-5 per million people per year and a prevalence of 39-79 per million with a female 
preponderance of 3:1 (Lacroix et al. 2015).  
Table 1-1: Causes of endogenous Cushing’s syndrome 
Type (Proportion)  
ACTH dependent (70-80%) Cushing’s disease 
Ectopic ACTH 
Ectopic CRH 
ACTH independent (20-30%) Unilateral adrenal adenoma/carcinoma 
Bilateral adrenal adenoma/carcinoma 
Bilateral macronodular adrenal 
hyperplasia 




The clinical features of Cushing’s syndrome are summarised in Table 1-2. Many 
manifestations such as lethargy, weight gain, hypertension and menstrual irregularity 
are common in the general population which can make diagnosis difficult. Features 
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such as proximal muscle weakness, skin thinning and bruising and rapid onset of 
symptoms are more specific (Nieman et al. 2008).  
Table 1-2: Clinical features of Cushing’s syndrome 
Body System Clinical Features 
General Appearance Moon Face 
Hirsutism with frontal balding 




Gastrointestinal Gastric ulcer 
Endocrine Type 2 diabetes mellitus (T2DM) 
Locomotor Osteoporosis 
Proximal muscle weakness 









Increased risk of infection 
Increased thrombotic risk 
 
Cushing’s syndrome, regardless of the aetiology, is associated with increased 
mortality. Excluding malignant causes, Cushing’s syndrome has a standardised 
mortality ratio (SMR) of between 2-4 (Feelders et al. 2012; Bolland et al. 2011). 
Cardiovascular deaths are the most common (Lindholm et al. 2001). Considerable 
morbidity is associated with the common manifestations of obesity, hypertension, 
diabetes and hyperlipidaemia leading to myocardial infarction, left ventricular 
dysfunction and cerebrovascular disease (Lacroix et al. 2015). The increased risk of 
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thrombosis also predisposes to thromboembolic disease. In long term remission, 
cardiovascular risk factors may be improved but do not necessarily return to baseline 
levels (Geer et al. 2012; Feelders et al. 2012).  
1.3.2 Association of cortisol with metabolic syndrome 
Metabolic syndrome is a collective term to describe a constellation of metabolic risk 
factors such as hypertension, hypercholesterolaemia, obesity and type two diabetes 
mellitus (T2DM) (Reaven 1988). The metabolic changes found in these conditions 
mimic those seen in Cushing’s syndrome and Bjorntorp et al hypothesised that subtle 
changes in the HPA axis may link pathogenesis and adverse metabolic outcomes in 
these conditions (Bjorntorp et al. 1999). 
Data from a number of studies support the association of hyperactivity of the HPA axis 
and the development of metabolic syndrome. These associations are demonstrated 
with significant increases in fasting cortisol levels, urinary free cortisol excretion, 
response to dexamethasone suppression test and lack of cortisol pulsatility (Phillips et 
al. 1998; Weigensberg et al. 2008; Pasquali et al. 2002; Rosmond et al. 1998). 
1.3.2.1 Obesity   
While metabolic syndrome as a spectrum of disease is associated with raised morning 
plasma cortisol levels, obesity has been associated with normal or even lower morning 
cortisol levels despite increased cortisol production (Reynolds et al. 2001; Abraham et 
al. 2013). This paradoxical finding may be explained by a change in metabolic 
clearance rate of cortisol (Strain et al. 1982) with evidence of increased clearance in 
rodent models (Livingstone et al. 2000). Human studies of cortisol metabolism in 
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obesity also showed evidence of increased clearance with urinary steroid profiles 
(Andrew et al. 1998). This appears to be driven by enhanced activity of A-ring 
reductases in the liver and impaired cortisol regeneration via 11β-HSD1 (Rask et al. 
2001).   
In most obese rodents, 11β-HSD1 expression is increased in adipose tissue and 
reduced in the liver (Livingstone et al. 2000). A similar pattern is seen in obese humans 
(Rask et al. 2001). Clinical studies using micro dialysis have shown increased cortisol 
generation in subcutaneous adipose tissue (Sandeep et al. 2005). This appears to be 
balanced by a reduction in hepatic cortisol production however and highlights that 
there are tissue specific changes in cortisol metabolism (Stewart et al. 1999; Rask et 
al. 2001; Walker & Andrew 2006). 
Enhanced clearance in obesity is also significant when we consider the regulation of 
ultradian rhythm via the feed-forward interplay between pituitary and adrenal. Subtle 
changes in glucocorticoid metabolism may have a significant impact on the 
maintenance of this pulsatile activation of GR. Changes to ultradian rhythmicity has 
been demonstrated in obstructive sleep apnoea and Cushing’s syndrome (Henley et al. 
2009; van den Berg et al. 1997). Loss of ultradian rhythmicity of cortisol may be 
another mechanism by which obesity is associated with adverse outcomes. 
1.3.2.2 Insulin resistance 
Insulin resistance is a significant metabolic consequence of excess fat deposition and 
often leads to the development of T2DM. Defined as an inadequate response of target 
tissues to circulating insulin, this is characterised by reduced glucose uptake by 
 
Catriona Kyle PhD Thesis, 2018 
 
 Chapter 1: Introduction 
23 
 
skeletal muscle, impaired insulin-mediated inhibition of liver gluconeogenesis and 
reduced inhibition of lipolysis in adipose tissue (Capurso & Capurso 2012).  
A number of studies have shown positive association of cortisol with markers of 
insulin resistance such as fasting glucose and Homeostasis Model Assessment- Insulin 
Resistance (HOMA-IR) (Walker et al. 2000a; Reynolds et al. 2001; Kamba et al. 2016; 
Phillips et al. 1998). Interestingly, there is a female predisposition for cortisol and 
fasting insulin association (Stolk et al. 1996).  
1.3.2.3 Hypertension 
Hypertension is a common manifestation within the metabolic syndrome and a number 
of studies have reported an association between cortisol levels and both systolic and 
diastolic blood pressure (Phillips et al. 1998; Weigensberg et al. 2008; Walker et al. 
2000a).  The underlying mechanism for this correlation is likely to be multifactorial, 
secondary to the physiological effects of increased plasma volume, increased 
peripheral vascular resistance and elevated cardiac output (Anagnostis et al. 2009). A 
reduction in nitric oxide production limits vasodilation and may also contribute to 
hypertension (Mitchell & Webb 2002).   
1.3.2.4 Dyslipidaemia 
Glucocorticoids have complex effects on lipid metabolism resulting in inconsistent 
associations of dyslipidaemia with Cushing’s syndrome (Macfarlane et al. 2008).  
There has been no consistent relationship between morning plasma cortisol and HDL 
cholesterol (Walker et al. 2000b; Maggio et al. 2006; Reynolds et al. 2010). Varma et 
al found cortisol to positively correlate with high density lipoprotein (HDL) 
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cholesterol however others have found the opposite effect (Varma et al. 1995; Fraser 
et al. 1999). Triglycerides have positive associations with cortisol in most studies 
(Phillips et al. 1998; Ward et al. 2003) with a few exceptions (Maggio et al. 2006; 
Abraham et al. 2013). 
1.3.2.5 Metabolic syndrome 
Changes in 11β-HSD1 have been observed in both animal and human studies of 
metabolic syndrome. Mouse models over-expressing 11β-HSD1 selectively in adipose 
tissue have normal systemic serum corticosterone but increased adipose corticosterone 
concentrations and develop a metabolic syndrome phenotype (Masuzaki et al. 2001). 
This finding led to the hypothesis that in humans, increased local cortisol 
concentrations in adipose tissue drive the development of metabolic syndrome and are 
therefore a potential target for manipulation. 11β-HSD1 inhibitors have been 
developed by our group (Hughes et al. 2008) and have entered phase 2 trials. A number 
of pharmaceutical agents have been studied with limited effect on glycated 
haemoglobin (HbA1c), blood pressure and body weight but no effect on fasting blood 
glucose (Rosenstock et al. 2010; Shah et al. 2011; Neghab et al. 2015). These relatively 
limited and disappointing outcomes might be secondary to the bidirectional activity of 
11β-HSD1 (Hughes et al. 2012; Anderson 2017).   
1.3.3 Congenital adrenal hyperplasia 
Congenital adrenal hyperplasia (CAH) is the most common genetic endocrine 
condition characterised by disruption of the steroidogenesis pathway. The incidence 
of classic CAH in Caucasian populations ranges from 1:10 000 to 1:20 000 births while 
non-classic is more common at 1:2500 live births (Van der Kamp et al. 2001; Speiser 
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et al. 2010). There are wide variations according to ethnicity however with much lower 
incidence in Chinese and African American populations and higher in Yupik Eskimos 
(Lee et al. 2000; Therrell et al. 1998; Pang et al. 1982). The most common mutation 
accounting for 95% of cases is of the CYP21A2 gene, causing deficiency of the enzyme 
21-hydroxylase (Han et al. 2014). This leads to impaired cortisol synthesis, limited 
negative feedback suppression of the HPA axis and subsequent build-up of 
steroidogenesis intermediates leading to excess production of adrenal androgens. Up 
to 75% of patients also have impaired mineralocorticoid production leading to salt-
wasting (Speiser & White 2003). Classification of CAH relates to the severity of the 
mutation with classic CAH the more severe form and non-classic CAH, the mild or 
late-onset form. Classic CAH is further classified regarding the presence or absence of 
aldosterone deficiency as either salt-wasting or simple virilising respectively. Most 
patients are compound heterozygotes with different mutations on each allele. The 
phenotype is normally related to the less severe mutation and therefore the residual 21-
hydroxylase activity (Merke & Bornstein 2005). There is some correlation between 
genotype and phenotype with regard to severity of disease, in particular the likelihood 
of mineralocorticoid deficiency however there is a less convincing correlation with 
degree of virilisation (Krone et al. 2007). 
Diagnosis of classic, salt-wasting 21-hydroxylase deficiency is often made in the first 
few weeks of life, commonly presenting as either ambiguous genitalia in females or a 
salt-wasting crisis in either sex. Other manifestations include failure to thrive, 
precocious pseudo puberty and short stature. Patients with non-classic CAH are 
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generally diagnosed later in life and often present with hirsutism and menstrual 
irregularity (Speiser & White 2003).  
The aim in treatment of CAH is to replace deficient glucocorticoid and limit the 
consequences of excess adrenal androgens. Plasma 17 hydroxyprogesterone (17-
OHP), testosterone and androstenedione levels are measured as markers of control 
(Speiser et al. 2010). Management goals change throughout different life periods; 
growth and development are central in infancy and childhood while limiting 
cardiovascular risk is key later in life. In addition, patients may wish to optimise 
fertility during early adulthood. Choice of glucocorticoid and treatment regimen 
depends on age, gender and desire for fertility (Han et al. 2014).  
The key to managing CAH is maintaining a fine balance between adequate 
glucocorticoid +/- mineralocorticoid replacement and sufficient suppression of adrenal 
androgen secretion. This is often challenging as strictly physiological glucocorticoid 
replacement doses are often inadequate to suppress excess adrenal androgens and 
doses which do suppress androgens can result in side effects such as obesity, 
osteoporosis and cardiovascular disease (Han et al. 2014). 
A number of studies have shown both objective and subjective markers of health to be 
poor in this patient cohort. There is a high prevalence of obesity, hypertension, 
hypercholesterolaemia and osteoporosis (Arlt et al. 2010). Glucocorticoid treatment 
regimens varies greatly and there is evidence of overtreatment with suppressed 
androgen levels, abdominal striae and reduced bone mineral density (Han, Stimson, et 
al. 2013). Quality of life scores are poor with obesity and compromised sex life a 
source of anxiety more than short stature or concern about long term health (Han, 
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Krone, et al. 2013). In male patients, there is increased risk of testicular adrenal rest 
tumours (TART) which can affect fertility (Han et al. 2014). Mortality in CAH has 
been reported to be higher than age and sex matched controls with a hazard ratio of 
2.3 in males and 3.5 in females. Causes of death included adrenal crisis, cardiovascular 
disease and cancer (Falhammar et al. 2014).  
1.3.4 Addison’s disease 
Addison’s disease is characterised by primary adrenal insufficiency and was first 
described by Thomas Addison in 1855 (Addison 1855). Addison described primary 
adrenal failure secondary to tuberculous infiltration however today, autoimmune 
destruction of the adrenal gland is the most common cause of Addison’s disease (Kong 
& Jeffcoate 1994; Zelissen et al. 1995). It was a fatal condition until corticosteroid 
preparations became available in the 1930s (Simpson 1938).  
Prevalence in white European populations are estimated at 110-140 per million 
although an even higher prevalence of 220 per million was reported recently in Iceland 
(M M. Erichsen et al. 2009; Mitchell & Pearce 2012; Olafsson & Sigurjonsdottir 
2016). Presentation of Addison’s disease is often insidious and non-specific. As 
evidenced by large case series, clinical features include fatigue, loss of appetite, weight 
loss and nausea (Erichsen et al. 2009; Mitchell & Pearce 2012). Other more specific 
features include skin hyperpigmentation, salt craving and postural hypotension. 
Biochemical abnormalities include hyponatraemia and hyperkalaemia. The gold 
standard test for diagnosing adrenal insufficiency as advised by the Endocrine Society 
is the ACTH stimulation or short synacthen test (Bornstein et al. 2016). Management 
is based on replacement of absent glucocorticoids and mineralocorticoids.  
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Historically, the prognosis for Addison’s disease was considered similar to the 
background population for those appropriately diagnosed and treated (Mason et al. 
1968). More recent studies however have highlighted that standardised mortality rates 
for patients with adrenal insufficiency are more than double those of age and sex-
matched controls (Bensing et al. 2008; Bergthorsdottir et al. 2006). Adrenal crisis 
remains a significant cause of death, particularly in patients under the age of 40 years 
(Erichsen et al. 2009). In addition to objective health outcomes, patients with adrenal 
insufficiency have impaired quality of life with increased anxiety levels and impaired 
feelings of well-being (Hahner et al. 2007). The cause of higher observed mortality 
may be due to suboptimal glucocorticoid replacement therapy with supra-
physiological doses resulting in increased metabolic and cardiovascular side effects 
(Bensing et al. 2016). 
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1.4 Corticosterone in humans 
Cortisol is commonly described as the principal glucocorticoid in humans and 
corticosterone as the principal glucocorticoid in rats and mice. In fact, humans produce 
both cortisol and corticosterone from the adrenal cortex although cortisol circulates at 
substantially higher concentration in plasma (Seckl et al. 1990; Karssen et al. 2001; 
Peitzsch et al. 2015). While corticosterone was included in early human glucocorticoid 
research, it has increasingly been neglected as cortisol was regarded as the more 
significant. Corticosterone had been assumed to mimic cortisol in action and effect but 
to a much lesser extent due to lower circulating concentrations. In fact, both historical 
and more recent evidence suggests corticosterone has distinct physiology compared to 
cortisol. 
1.4.1 Physiology of corticosterone in humans 
Corticosterone was the first steroid isolated from the adrenal gland in 1937 by Hench, 
Kendall and Reichstein, who were subsequently jointly awarded the Nobel Prize for 
Physiology or Medicine in 1950 for their work. This has since led to a significant body 
of research identifying and characterising the actions of each hormone released from 
the adrenal and in developing sensitive and specific methods to accurately detect these 
hormones in plasma.  
1.4.1.1 Measuring plasma corticosterone 
Conn observed in 1950 that corticosterone caused sodium, chloride and water retention 
and potassium diuresis. He also noted increased resistance to insulin and reduced 
carbohydrate tolerance. Interestingly, he concluded that corticosterone was a superior 
substitute replacement therapy compared to cortisone and deoxycorticosterone as 
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clinical improvement was ‘rapid and excellent’ and the dose requirement was less 
(Conn 1950; Conn 1951). A method of chloroform extraction followed by 
chromatographic quantitation by fluorescence was developed by Sweat and formed the 
basis of method development for the next 20 years (Sweat 1955). Early studies 
estimated plasma corticosterone at higher values than we would consider normal today 
(Sweat 1955; Peterson 1957; Ely et al. 1958) and may reflect the lack of specificity of 
these early methods. These are summarised in Table 1-3 below.  
Radioimmunoassay determination of corticosterone following extraction and 
separation with chromatography was developed from the 1970s. An increasing 
demand for rapid throughput assays led to the development of direct immunoassays 
which sacrificed accuracy and validity for economy of time and money (Handelsman 
& Wartofsky 2013).  
Mass spectrometry became the gold standard for steroid analysis as sensitivity and 
expense improved throughout the 1980s and 1990s (Shackleton 2010).  From the more 
recent publications, plasma corticosterone circulates at concentrations 10-20 fold less 
than cortisol at concentrations of approximately 16-40 nmol/L (Seckl et al. 1990; 
Karssen et al. 2001). Raubenheimer et al reported higher concentrations (~60 nmol/L) 
however this was in the context of patients about to undergo an invasive procedure 
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Table 1-3: Literature review of corticosterone measurements in human plasma  
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1.4.1.2 Corticosterone and the HPA axis 
While it was noted that cortisol circulated at higher concentration than corticosterone, 
both remained subject to ongoing investigation and early observations were made of 
differences in metabolism. Both Peterson and Fraser observed a reduction in the 
corticosterone: cortisol ratio after ACTH administration and this was further 
confirmed by Nishida et al in 1977 (Peterson 1957; Fraser & James 1968; Nishida et 
al. 1977). Some studies found minimal response of corticosterone to ACTH however 
which perhaps reflects the wide range of analytical methods at the time (Ely et al. 
1958). An enhanced response of corticosterone to surgical stress compared to cortisol 
has also been reported (Fraser & James 1968; Hamanaka et al. 1970) with similar 
findings after insulin induced hypoglycaemia (Fraser & James 1968). Suppression of 
corticosterone after dexamethasone administration was blunted compared to cortisol, 
suggesting that there are differences in the regulation of cortisol and corticosterone 
secretion (Newsome et al. 1972; Nishida et al. 1977). 
1.4.1.3 Pre-receptor metabolism 
Similar to cortisol, corticosterone is metabolised by the 11β-HSD enzymes to catalyse 
the conversion between active and inactive forms. Corticosterone is converted to its 
inactive derivative, 11-dehydrocorticosterone by NAD+-dependent 11β-HSD2 
(Monder & Lakshmi 1989).  
A number of studies have measured the affinity of corticosterone and cortisol for each 
isozyme of 11β-HSD. There are consistent reports of corticosterone having greater 
affinity for 11β-HSD2 than cortisol (Albiston et al. 1994; Gong et al. 2008; Maser et 
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al. 2002). Michaelis-Menten plots were created using this data and suggest that given 
the basal circulating concentrations of corticosterone and cortisol, 11β-HSD2 
inactivation of each glucocorticoid is comparable (Mackenzie 2015).  
The activity of 11β-HSD1 depends on the cells or tissue used in analysis. Comparing 
affinity of cortisone and 11-dehydrocorticosterone in human HEK-293 cells, 
Arampatzis et al report similar Km of 519±71 and 420±87 nM respectively 
(Arampatzis et al. 2005). Dissociation constants of 11β-HSD1 in human liver samples 
for cortisone and 11-dehydrocorticosterone are reported to be 13.9 and 19.7 μM 
respectively (Maser et al. 2002). Plotting enzyme kinetics, the Km of 11β-HSD1 is 
above physiological circulating concentrations of both glucocorticoids and at the 
concentrations studied, cortisol production exceeded that of corticosterone (Mackenzie 
2015). 
1.4.1.4 Receptor binding 
Binding affinity of corticosterone was measured initially in rat studies. De Kloet et al 
reported corticosterone had the highest affinity for corticosteroid receptors in the rat 
brain compared to progesterone, deoxycorticosterone (DOC), dexamethasone and 
aldosterone (de Kloet et al. 1984). Specific binding assays for human MR through 
molecular cloning in the 1980s compared its affinity for aldosterone, corticosterone, 
DOC and cortisol and found these were all very similar at approximately 1.3 nM 
(Arriza et al. 1987). A further study in 1999 found corticosterone had reduced 
transactivation via MR compared to cortisol but binding affinity was not measured 
(Hellal-Levy et al. 1999). More recently, Odermatt’s group in Switzerland compared 
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binding affinity of cortisol, corticosterone and aldosterone with wild type and mutant 
GR and MR. Binding affinities were not statistically different compared between 
corticosteroids but corticosterone appeared to have higher affinity for MR than cortisol 
(Ki 0.39 nM vs Ki 1.63 nM respectively) (Mani et al. 2016).   
Limited studies have been carried out comparing binding affinity of GR. Giannopolous 
et al compared binding of different glucocorticoids to GR in a variety of species 
(Giannopoulos & Keichline 1981). In cortisol-secreting species such as humans and 
guinea pigs, cortisol had 1.5-3 times higher affinity for GR compared to corticosterone 
whereas corticosterone-dominant species such as rodents, had a 3-4 fold higher affinity 
than cortisol. Mani et al found a similar difference in affinity with cortisol binding 
human GR at Ki 103 nM and corticosterone at Ki 175 nM (Mani et al. 2016).  
There are conflicting reports of GR and MR binding affinities in the literature but the 
most recent data would suggest cortisol has a higher affinity for GR while 
corticosterone has higher binding affinity to MR. 
1.4.1.5 Production and clearance 
Cortisol and corticosterone both display a circadian rhythm, peaking in the morning 
and with a nadir in the evening and overnight (Peterson 1957; Martin & Martin 1968; 
Hamanaka et al. 1970).  
The secretion rate of corticosterone has been estimated using tritium labelled 
corticosterone and measuring isotope dilution. The estimated rate of production is 
relatively consistent at approximately 10-11 μmol/day (Peterson 1957; Peterson 1959; 
New et al. 1969). This is 5-10 fold less than the approximate secretion rate of cortisol, 
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estimated at between 50-80 μmol/day (Silber et al. 1958; Bondy & Upton 1957; New 
et al. 1969). The relative difference in production rate is less than the difference in 
circulating concentration and therefore suggests enhanced clearance of corticosterone. 
This is consistent with evidence that infusions of corticosterone were reported to have 
a shorter half-life (0.5-1.5 hours) than cortisol (1.5-2 hours) after bolus infusion (Ely 
et al. 1958; Peterson 1959; Peterson & Pierce 1960). This is likely to reflect higher 
affinity for hepatic reductases and less efficient regeneration of corticosterone by 11β-
HSD1. A difference in CBG binding may also explain this difference in production 
rate and circulating concentration however the binding affinity of cortisol and 
corticosterone for CBG was measured using equilibrium dialysis and found to be 
comparable (Stroupe et al. 1978).  
Clearance of corticosterone follows a similar pathway to cortisol with A-ring reduction 
in the liver to 5α-tetrahydro products and lesser amounts of 3α,5β-corticosterone 
excreted in the urine (New et al. 1969). Over and above this however, corticosterone 
and its 5α-A Ring reduced metabolites are also excreted in the bile, passing into the 
gut where they are converted to 21-dehydroxylated products 11β-OH-progesterone 
and 11β-OH-3α,5α-progesterone by anaerobic bacteria (Shackleton et al. 1979).  
1.4.1.6 Corticosterone in saliva and hair 
Salivary corticosterone is not well studied and there are limited published data to 
review. McVie et al measured paired plasma and saliva concentrations of cortisol, 
corticosterone and aldosterone at baseline and after ACTH stimulation. Measured by 
radioimmunoassay, mean salivary corticosterone was 0.5 nmol/L compared to mean 
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plasma corticosterone of 12 nmol/L (McVie et al. 1979). Since the concentration of 
both cortisol and corticosterone are approximately 10-fold less than plasma, 
immunoassay is limited not only by cross-reactivity with other steroids but also by 
limit of detection. In a more recent study assessing the effects on exercise on 
circulating glucocorticoids, salivary corticosterone was not detectable using 
radioimmunoassay (Del Corral et al. 2016). While we have some indication that 
salivary corticosterone can be measured from McVie et al, this was with a dated 
analytical method and provides no information regarding diurnal variation.  
A literature search did not reveal any evidence that corticosterone has been measured 
in hair. The reported values of hair cortisol are low (5-91 pg/mg) (Raul et al. 2004; 
Manenschijn et al. 2012) and assuming the ratio of cortisol to corticosterone is similar 
to plasma, it may not be possible to detect with current methods.  
1.4.2 Transmembrane transport 
As discussed above, corticosterone circulates at lower concentration in plasma, 
appears to have an enhanced response to ACTH and surgical stress and has a shorter 
half-life compared to cortisol. In addition to these observations, tissue specific 
differences in corticosterone and cortisol concentrations have been described, 
suggesting distinct regulation of transport across the cell membrane. 
An interesting observation was made by Karssen et al when investigating the 
regulation of cortisol at the blood brain barrier. Corticosterone concentrations were 
relatively higher in post mortem brain tissue samples than in corresponding plasma 
samples (Karssen et al. 2001). This was supported by findings that corticosterone 
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concentration in cerebrospinal fluid (CSF) was similarly higher than in plasma 
(Raubenheimer et al. 2006). Since both cortisol and corticosterone are highly lipophilic 
and enter cells by diffusion, tissue concentrations should reflect circulating 
concentrations unless there is active export across the cell membrane. These findings 
suggest cortisol and corticosterone are under differential transport from cells in a tissue 
specific manner. 
1.4.2.1 ABC transporters 
ATP-binding Cassette (ABC) transporters were first identified in the 1980s when 
investigating multi-drug resistance in cancer patients (Gros et al. 1986). There are 7 
sub-groups, named A-G, of which ABCB1 and ABCC1 have significance in 
glucocorticoid handling (Webster & Carlstedt-Duke 2002).  
ABC transporters have a typical configuration of two trans-membrane domains (TMD) 
and two nucleotide binding domains (NBD) as shown in Figure 1-5. The NBD at the 
C-terminus is involved in hydrolysing adenosine triphosphate (ATP) to facilitate 
transport of substrates. 
ABCB1 is most highly expressed in the adrenal gland but is also expressed in the 
kidney, brain and small intestine (Nishimura & Naito 2005). Expression of ABCB1 at 
the blood brain barrier (BBB) is particularly relevant as it plays an important role in 
protecting the brain from endogenous and exogenous toxins. ABCB1 is principally 
expressed at the luminal membrane of capillary epithelial cells and acts as a 
neuroprotective and detoxifying efflux pump (Cordon-Cardo et al. 1989). 
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Physiologically, ABCB1 exports endogenous substrates as well as ingested or acquired 
neurotoxic substances which can present a challenge to effective drug delivery (Begley 
2004).   
Figure 1-5: Molecular structure of ABC Transporters ABCB1 and ABCC1 
ABCB1 has two transmembrane domains (TMD) and two nucleotide binding domains (NBD) while 
ABCC1 has an additional TMD.  
 
Expression of ABCB1 at the BBB limits access of synthetic glucocorticoid, 
dexamethasone to the brain in rodents (Meijer et al. 1998). Corticosterone, the 
principal glucocorticoid in rodents, readily gains access to brain in the mouse however 
cortisol, as the more abundant glucocorticoid in humans, is actively exported at the 
BBB (Ueda et al. 1992). It has been demonstrated in vitro and in vivo that ABCB1 
limits access of endogenous cortisol but not corticosterone to the brain (Karssen et al. 
 




Chapter 1: Introduction 
2001; Webster & Carlstedt-Duke 2002).   
ABCC1 has an additional TMD comprising five transmembrane segments (Figure 1-5) 
and is expressed more widely than ABCB1 (Nishimura & Naito 2005; Yu et al. 2013). 
Adipose tissue and skeletal muscle have relatively high ABCC1 expression (Nixon et 
al. 2016) and our unpublished data suggest a similar situation to these tissues with 
higher ABCC1 expression compared to ABCB1 in human bone and bone marrow 
(Mark Nixon, unpublished). ABCC1 transports drug conjugates of glutathione, 
leukotrienes and other organic anions and causes significant resistance to drugs such 
as doxorubicin and vincristine (Dean et al. 2001).  In vitro studies have demonstrated 
that ABCC1 exports corticosterone but not cortisol from a mouse cell line and is 
inhibited by the ABCC1 inhibitor probenecid (Webster & Carlstedt-Duke 2002). 
Further, Nixon et al describe ABCC1, but not ABCB1, expression in human adipose 
tissue and that inhibition of ABCC1 increases intracellular corticosterone in human 
adipocytes with no effect on intracellular cortisol. Mice with pharmacological and 
genetic inhibition of ABCC1 accumulated more corticosterone and increased 
glucocorticoid responsive transcripts in adipose (Nixon et al. 2016). 
1.4.2.2 ABCB1 and the HPA axis 
The presence of ABCB1 at the BBB plays a significant role in protecting the brain 
from exposure to toxins. In particular, many drugs are exported at the BBB making 
some chemotherapy agents less effective. The export of dexamethasone is another 
example of neuro-protection but the exclusion of endogenous cortisol is more 
surprising. Since corticosterone is not affected by ABCB1 transport, relative 
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concentrations within the central nervous system (CNS) are likely to be higher than in 
the circulation and this was demonstrated in post mortem brain samples (Karssen et al. 
2001). This suggests corticosterone may play a more important role in HPA axis 
negative feedback at the level of the hypothalamus than previously thought. Human in 
vivo experiments confirmed corticosterone was relatively more abundant in CSF than 
plasma (approximately 40% in CSF and 7% in plasma of total active glucocorticoids) 
(Raubenheimer et al. 2006). A comparison of ACTH suppression by cortisol or 
corticosterone in healthy volunteers given metyrapone showed no difference between 
cortisol and corticosterone at a bolus of 0.15 and 0.04 mg/kg (Raubenheimer et al. 
2006). While this study did not support the hypothesis that corticosterone is the 
predominant centrally-acting glucocorticoid, this may only relate to acute situations, 
and the study was limited by differences in the pharmacokinetics of cortisol and 
corticosterone resulting in different plasma exposure of each. With confirmation that 
there is relatively higher concentration of corticosterone in CSF, there remains the 
question of whether corticosterone plays a significant role at lower circulating 
concentrations when MR activation is predominant.   
1.4.2.3 ABCC1 in adipose tissue and skeletal muscle 
The role of ABCC1 in adipose tissue and skeletal muscle has not been well defined 
until recently. Nixon et al demonstrated higher expression of ABCC1 than ABCB1 in 
human adipose tissue of healthy individuals with corticosterone levels below or near 
the limit of detection (Nixon et al. 2016). The authors went on to test the potency of 
corticosterone compared to cortisol in inducing metabolic effects via adipose tissue. 
In a randomised crossover study of patients with Addison’s disease, deuterated 
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glucocorticoids, D4-cortisol and D8-corticosterone, were infused at sequential steady 
state concentrations for 270 minutes. Again, there was no difference between 
glucocorticoid for ACTH suppression, nor any difference in metabolic markers 
including glucose, glycerol, free fatty acids or insulin. However, there was an increase 
in expression of acutely responsive glucocorticoid transcripts period circadian protein 
homolog 1 (PER1) and lipoprotein lipase (LPL) in the cortisol group compared to 
corticosterone (Nixon et al. 2016).  While there was no evidence of improved 
metabolic markers, this was a short-term study and any effect may be limited as a 
result. This raises the question of whether corticosterone might be a superior choice as 
a replacement therapy in patients with impaired glucocorticoid synthesis.  
1.4.3 Associations of the cortisol: corticosterone ratio with the metabolic 
syndrome 
The metabolic syndrome is strongly associated with increased morbidity and mortality 
related to cardiovascular disease (Reaven 1988). While lifestyle factors are associated 
with the development of these conditions, there is also a substantial heritable 
component. Genome-wide association studies have consistently reported associations 
between variants in CYP17A1 gene expression and both obesity and hypertension (Yan 
et al. 2012; Newton-Cheh et al. 2009). CYP17A1 encodes the enzyme 17-hydroxylase 
in the steroidogenesis pathway and is therefore integral in the synthesis of cortisol and 
any variation in expression will affect the ratio of cortisol to corticosterone (Figure 1-
2).  
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The mechanism underlying this association is not well defined. Deficiency of 17-
hydroxlyase results in low renin hypertension due to the accumulation of 
mineralocorticoids deoxycorticosterone and aldosterone (Goldsmith et al. 1967). It 
could be assumed therefore that such polymorphisms result in reduced production of 
this enzyme.  
While hypertension is a key component of the metabolic syndrome, genetic risk factors 
for increased blood pressure are not associated with all other features of this syndrome. 
In fact, variations in CYP17A1 are associated with a reduction in both subcutaneous 
and visceral fat and these polymorphisms which predict obesity are associated with 
insulin resistance (Hotta et al. 2012; Echiburú et al. 2008). This presents a paradox of 
CYP17A1 polymorphisms causing a reduction in 17-hydroxylase and increased 
corticosterone to cortisol ratio being associated with an increase in blood pressure but 
lower BMI and improved insulin sensitivity.  
This may be explained by the evidence presented above regarding differential control 
of the HPA axis centrally. Cortisol is exported from the CNS by ABCB1 whereas 
corticosterone is not. Therefore it appears to be changes in corticosterone 
concentration which influence the drive of the HPA axis and effect the circulating 
cortisol concentration. A relative excess of corticosterone would reduce HPA 
activation and consequently cortisol production whereas relative deficiency would 
drive HPA axis activation and cause cortisol excess. The metabolic syndrome is 
associated with increased activation of the HPA axis and resultant cortisol excess.  
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There is good evidence that raised early morning cortisol is associated with many 
features of the metabolic syndrome, such as hypertension, dyslipidaemia and insulin 
resistance (Phillips et al. 1998; Reynolds et al. 2003; Reynolds et al. 2010). There is 
limited evidence however of the associations of raised morning corticosterone 
although we would hypothesise that raised corticosterone would be associated with a 
favourable metabolic profile compared to cortisol.  
There are no published data regarding the association of corticosterone and metabolic 
parameters however this was addressed in a recent thesis (Mackenzie 2015). A number 
of UK based population cohorts were investigated: the Orkney Complex Disease Study 
(ORCADES); the Edinburgh Type 2 Diabetes Study (ET2DS) and the East 
Hertfordshire Study (EHERTS).  
In the ORCADES study, a genetic epidemiological study based in the Orkney islands, 
both raised morning plasma cortisol and corticosterone were associated with lower 
body mass index (BMI), raised fasting glucose and raised triglycerides although the 
magnitude of effect was greater with cortisol. Neither cortisol nor corticosterone was 
associated with total cholesterol or low density lipoprotein (LDL) cholesterol however 
raised morning corticosterone was associated with HDL cholesterol. In patients with 
established T2DM in ET2DS, raised plasma cortisol and corticosterone was associated 
with lower BMI and an increase in fasting glucose. After dexamethasone suppression 
in EHERTS, higher corticosterone was associated with lower BMI but also a lower 
fasting insulin and HOMA-IR. After ACTH stimulation, higher corticosterone was 
associated with lower glucose before and after glucose load and a lower HOMA-IR. 
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Associations from the ORCADES and ET2DS confirmed previous findings of cortisol 
associations with features of metabolic disease and corticosterone largely mimics these 
associations.  Data from EHERTS is intriguing due to the effective normalisation of 
the HPA axis with dexamethasone induced suppression followed by ACTH activation. 
There was an inverse association with glucose and HOMA-IR. If corticosterone does 
make a disproportionate contribution to HPA axis suppression, these results provide a 
key observation into the regulation of the HPA axis in humans. 
1.4.4 Alternative HPA axis 
Drawing together the evidence presented above, we propose an alternative HPA axis 
(Figure 1-6). We hypothesise that while cortisol circulates in higher concentration than 
corticosterone in plasma, differential tissue specific regulation of ABCB1 and ABCC1 
allows corticosterone to exert a more significant role in HPA negative feedback. The 
greater expression of ABCB1 in brain excluding cortisol but not corticosterone is 
supported by relatively higher concentrations of corticosterone in brain tissue and CSF 
(Karssen et al. 2001; Raubenheimer et al. 2006). With ABCC1 highly expressed in 
skeletal muscle and adipose tissue, cortisol appears to be the principal glucocorticoid 
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Figure 1-6: Alternative negative feedback of the HPA axis  
 
With this hypothesis in mind, the association of variants in CYP17A1 with 
hypertension and obesity may be explained by an increasein 17-hydroxylase activity 
and therefore relative corticosterone deficiency. This would drive up-regulation in 
negative feedback of HPA axis and as a result, relative cortisol excess. This would 
account for higher morning plasma cortisol values in metabolic syndrome, an 
association not reflected in morning corticosterone concentrations. 
Implications of this alternative axis are particularly relevant in glucocorticoid 
replacement therapy. Current cortisol-based and synthetic glucocorticoids require 
relatively high doses to suppress ACTH and accumulation within adipose tissue may 
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result in over-activation of corticosteroid receptors. This, in turn, may lead to the 
development of glucocorticoid induced features of the metabolic syndrome. If 
corticosterone were the basis for glucocorticoid replacement therapy, relatively lower 
doses would be required for ACTH suppression and accumulation in adipose tissue 
and skeletal muscle would be less due to the presence of ABCC1.  
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1.5 Glucocorticoid replacement therapy 
1.5.1 Current glucocorticoid replacement therapy 
Current glucocorticoid replacement therapies are based on cortisol and the most 
commonly used replacement is hydrocortisone (Forss et al. 2012). Hydrocortisone is 
rapidly absorbed in the gut when taken orally and has a bioavailability of over 90%. 
Time to maximum concentration is only 1-2 hours and the half-life is short at 1.8-2 
hours (Thomson et al. 2007; Buning et al. 2017).  
Prednisolone has an intermediate duration of action and has more anti-inflammatory 
action than hydrocortisone (Meikle & Tyler 1977). Dexamethasone is a selective GR 
agonist and therefore has no mineralocorticoid activity. Prednisolone has a longer half-
life than hydrocortisone of 2-4 hours while dexamethasone is longer acting at 4-5 hours 
(Johannsson et al. 2007; Williams et al. 2016). Cortisone acetate is used more 
frequently in Europe and North America and has a slightly delayed onset of action 
compared to hydrocortisone as it needs to be activated by hepatic 11β-HSD1 (Oelkers 
et al. 2001; Laureti et al. 2003). The biological half-life of cortisone acetate is longer 
than hydrocortisone however (Feek et al. 1981). 
There are no randomised controlled drug trials in Addison’s disease or CAH and 
current guidelines for optimal treatment are based on low quality evidence. In 
Addison’s disease, hydrocortisone at doses of 15-25 mg or cortisone acetate 20-35 mg 
in two to three daily doses are suggested with prednisolone 3-5 mg daily as an 
alternative (Bornstein et al. 2016). It is suggested to avoid the use of dexamethasone 
due to difficulties in dose titration leading to increased risk of Cushingoid side effects. 
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In adults with CAH, Endocrine Society guidelines suggest treatment with 
hydrocortisone or long-acting glucocorticoids (Speiser et al. 2010). In a UK cohort 
study of 203 patients with CAH, glucocorticoid therapies were varied: hydrocortisone 
(26%), prednisolone (43%), dexamethasone (19%) or a combination (10%). Timing of 
dosing was also varied with reverse circadian administration in 41% (Arlt et al. 2010). 
In an association study of health outcomes, increasing glucocorticoid dose was 
associated with increased blood pressure although without significant improvement in 
markers of disease control. Any combination of treatment including dexamethasone 
resulted in improved disease control but at the expense of increased association with 
insulin resistance (Han, Stimson, et al. 2013). This study suggests that increasing the 
dose of glucocorticoid does not necessarily result in better disease control and may 
result in more side effects. It also highlighted the wide variety of treatments in use, 
underlining the lack of consensus on optimal glucocorticoid treatment. 
In a survey of patient-perceived health outcomes in 1245 patients with adrenal 
insufficiency, a majority reported significant impact of their disease or treatment on 
subjective health. Most patients took hydrocortisone (75%) either twice (42%) or 
thrice (32%) daily. 76% of respondents were concerned about long term side effects 
including osteoporosis, obesity and cardiovascular disease (Forss et al. 2012).     
1.5.1.1 Modified and sustained release glucocorticoids 
The increased morbidity and mortality in both Addison’s disease and CAH has been 
hypothesised to be secondary to a combination of lack of natural glucocorticoid 
circadian rhythm and supra-physiological dosing. In an attempt to mirror natural 
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circadian release of glucocorticoids, modified release and delayed release preparations 
of hydrocortisone have been developed and tested in patients with adrenal 
insufficiency.  
Various attempts have been made to more accurately reflect physiological 
glucocorticoid release with three times daily dosing and a continuous subcutaneous 
infusion which resulted in improved subjective quality of life and reduced overall daily 
dose (Groves et al. 1988; Løvås & Husebye 2007). Pilot studies were also carried out 
comparing conventional replacement regimens with two to three times daily 
hydrocortisone and varied intravenous infusion rates. It was demonstrated that variable 
infusion of hydrocortisone resulted in better control of ACTH and 17-OHP in patients 
with Addison’s and CAH (Merza et al. 2006). This lead to the development of two 
modified release preparations of hydrocortisone: Chronocort® (Diurnal Ltd, Cardiff, 
UK) and Plenadren® (Shire International, Jersey, UK).  
Chronocort®, a modified and delayed release preparation of hydrocortisone, was tested 
in healthy individuals to determine pharmacokinetic profile. The initial study in 6 
healthy individuals identified a formulation of hydrocortisone with delayed drug 
release of 4 hours and median peak cortisol concentration of 10 hours (Newell-Price 
et al. 2008). This formulation was then tested in healthy volunteers to compare cortisol 
profiles with conventional immediate release hydrocortisone. This suggested modified 
release hydrocortisone 15-20mg at 11pm and 10mg at 7am could reproduce 
physiological cortisol levels (Debono et al. 2009). In comparison with conventional 
hydrocortisone therapy in patients with CAH, better control of early morning 
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elevations in ACTH and 17-OHP were demonstrated however daytime cover was 
inadequate on once daily dosing (Verma et al. 2010). A further phase 2 study with 6 
months of treatment continued to show more effective control of ACTH and adrenal 
androgens but there was a significant fall in bone mineral density and rise in 
osteocalcin and HOMA-IR (Mallappa et al. 2015).  
Plenadren®, a dual release, once daily hydrocortisone tablet, comprising an immediate-
release coating and extended release core was developed to attempt to reproduce the 
physiological profile of cortisol release. Studies in healthy individuals established the 
plasma pharmacokinetic profile was similar to the physiological release of cortisol 
(Johannsson et al. 2009). In comparison with three times daily immediate release 
hydrocortisone, modified release hydrocortisone was associated with a 20% lower 
bioavailability with higher concentration in the morning and lower in the evening. 
There was a significant reduction in HbA1c, weight and both systolic and diastolic 
blood pressure (Johannsson et al. 2012). This study was limited by its short follow up 
time of 12 weeks and lack of effective blinding to interventions. Comparisons with 
immediate release hydrocortisone were invalid due to the differences in 
bioavailability. The average daily dose of hydrocortisone of at least 30mg was higher 
than recommended by Endocrine Society guidelines (Bornstein et al. 2016).  
While extended release preparations have been associated with higher quality of life 
scores, most studies are of too short follow up to allow assessment of cardiovascular 
outcomes or effect on bone mineral density. As a result, none of these preparations 
have been adopted into routine clinical practice until evidence of their improved 
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effectiveness compared to current standard therapy is more robust. A randomised 
controlled trial comparing Plenadren® with standard hydrocortisone over a longer 
period is due to be reported soon (Clinical Trials identifier NCT 02277587). 
1.5.1.2 Continuous subcutaneous hydrocortisone infusion (CSHI) 
There has been further development in delivering glucocorticoid replacement therapy 
as a continuous subcutaneous infusion. A prospective randomised crossover study in 
Norway and Sweden compared three times daily hydrocortisone with a 24-hour 
variable subcutaneous infusion over a 12 week period (Øksnes et al. 2014). Morning 
ACTH and salivary cortisol profiles were improved in the infusion phase however an 
overall higher dose of hydrocortisone was infused and this was associated with higher 
morning glucose with a trend for higher BMI and HOMA-IR. A similar study 
comparing CSHI with standard oral hydrocortisone in Addison’s disease was carried 
out in Australia although blinded and over a shorter follow up of 4 weeks (Gagliardi 
et al. 2014). Doses of infused and oral hydrocortisone were effectively matched but 
the primary outcome of subjective health status was no different between groups. 
A more recent study has studied the use of CSHI in a small number of CAH patients 
in an open label design over a 6 month period (Nella et al. 2016). Markers of CAH 
control were improved compared with baseline but remained above target levels.  
Metabolic outcomes were relatively unchanged and positive effects on quality of life 
and fatigue were reported. 
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Further studies are required to establish whether CSHI is an effective alternative form 
of glucocorticoid replacement therapy with larger cohorts of patients over a longer 
follow up.  
1.5.1.3 Adjuncts to glucocorticoid treatment 
Alternative approaches to treatment have been suggested for CAH with different levels 
of the steroidogenesis pathway targeted. Among glucocorticoid dose sparing 
strategies, CRH antagonists and ACTH inhibitors have been proposed with some early 
clinical trials conducted (Holsboer & Ising 2008; Schteingart 2009).  
Limiting androgen secretion is traditionally done through negative feedback loops but 
other strategies include targeting synthesis, conversion of testosterone, aromatisation 
and receptor activity. Ketoconazole is the most widely studied adrenal androgen 
inhibitor but is limited in use by side effects and poor oral absorption (Hsieh & Ryan 
2008).  
Abiraterone acetate is a prodrug which is metabolised to abiraterone, a potent inhibitor 
of CYP17A1. In prostate cancer, this treatment is given to induce chemical castration 
by inhibiting testosterone production and has been shown to improve survival in 
castration-resistant cases (de Bono et al. 2011; Ryan et al. 2013). Pharmacological 
inhibition results in the same phenotype as in 17 hydroxylase deficiency with low renin 
hypertension due to high circulating DOC and aldosterone. In order to manage this, 
abiraterone treatment is combined with prednisolone to suppress ACTH driven HPA 
axis overactivity. The mineralocorticoid excess experienced in these patients due to 
excess production of DOC is absent in CAH and therefore abiraterone added to 
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physiological glucocorticoid and mineralocorticoid replacement is hypothesised to 
control androgen excess. Early phase 1 clinical studies in patient with CAH have been 
promising and further studies are in progress (Auchus et al. 2014).   
1.5.2 Corticosterone as an alternative glucocorticoid replacement therapy 
To date, innovations in glucocorticoid replacement therapy have focussed on 
improving pharmacokinetic profile. All currently available glucocorticoids contain 
either cortisol (hydrocortisone), cortisone (converted to cortisol) or a synthetic 
glucocorticoid and comprise immediate, delayed and modified release preparations.  
Corticosterone is an endogenous human glucocorticoid with similar and possibly 
enhanced binding affinity to GR and MR respectively, compared to cortisol (Mani et 
al. 2016). There is evidence for tissue-specific responses to cortisol and corticosterone 
depending on expression of ABC transporters. In the CNS, corticosterone is present in 
disproportionately high concentrations suggesting HPA negative feedback may be 
more sensitive to changes in corticosterone (Karssen et al. 2001; Raubenheimer et al. 
2006). In metabolic tissues such as adipose tissue and skeletal muscle, ABCC1 actively 
exports corticosterone but not cortisol and may act in a protective manner to limit 
adverse metabolic effects of corticosterone (Nixon et al. 2016). We hypothesise that 
corticosterone would be a superior glucocorticoid than hydrocortisone for replacement 
therapy due to a reduction in adverse metabolic effects. Concerns regarding the effect 
of sustained release cortisol on bone mineral density may also be mitigated by the 
relatively high expression of ABCC1 in bones as well as adipose tissue and skeletal 
muscle.   
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This thesis aims to characterise the physiological differences between cortisol and 
corticosterone and define the role of ABCC1 in adipose tissue and skeletal muscle. We 
will also investigate the short-term outcomes in direct comparison of corticosterone 
and cortisol replacement in patients with CAH.   
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1.6 Hypotheses 
• Corticosterone concentrations in plasma, saliva and hair do not simply mimic 
those of cortisol in normal physiology. 
 
• In adipose tissue and skeletal muscle, cortisol is the principal glucocorticoid 
acting on GR and MR due to export of corticosterone by ABCC1. 
 
• In congenital adrenal hyperplasia, glucocorticoid replacement with 
corticosterone results in less adverse metabolic sequelae than cortisol for 
equally effective suppression of ACTH. 
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1.7 Aims 
1. To determine the characteristics of corticosterone concentrations in plasma, 
saliva and hair compared with cortisol in healthy individuals 
 
2. To determine whether cortisol and corticosterone are differentially bound to 
GR and/or MR in adipose tissue and skeletal muscle 
 
3. To determine whether the ABCC1 transporter is responsible for differential 
binding of cortisol and corticosterone to GR/MR in adipose tissue and skeletal 
muscle 
 
4. To determine whether corticosterone suppresses ACTH and adrenal androgen 
production to a similar degree as cortisol in congenital adrenal hyperplasia 
 
5. To compare the metabolic effects of corticosterone and cortisol replacement 
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2.1 Equipment 
2.1.1 Laboratory-based 
2.1.1.1 β-scintillation counter 
• Berthold LB509 detector (Berthold, Hertfordshire, UK). 
2.1.1.2 Balance 
• Mettler HK 60 microbalance (Mettler Instrumente Ag, Zürich, Switzerland). 
2.1.1.3 Centrifuge 
• General Laboratory use: Eppendorf centrifuge 5810R (Cambridge, UK). 
• Clinical sample processing (Chapter 3, 4 and 5): Sigma laboratory centrifuge 
4K15 (Osterode am Harz, Germany). 
• Real Time qPCR (Chapter 4): Eppendorf centrifuge 5415R (Cambridge, UK). 
2.1.1.4 Incubator 
• Grant-bio PHMP-4 Thermoshaker (Grant Instruments, Cambridge, UK). 
2.1.1.5 Liquid chromatography 
• Shimadzu Nexera LC-30AD ultra high performance liquid chromatograph 
(UHPLC) pump with Nexera SIL-30 AC autosampler (Shimadzu, Kyoto, 
Japan). 
2.1.1.6 Mass spectrometer 
• Linear ion trap QTRAP® 6500 triple quadrupole mass spectrometer 
configured with an ESI Turbo V source (Ab Sciex, Framingham, MA, USA). 
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2.1.1.7 Microplate shaker 
• GFL Orbital Shaker 3005 (GFL, Burgwedel, Germany). 
2.1.1.8 Microplate reader 
• Optimax tuneable microplate reader (Molecular Devices, Sunnyvale, Ca). 
2.1.1.9 Nitrogen dry-block 
• Dri-Block® DB3A sample concentrator (Techne, Staffordshire, UK). 
• Argonaut SPE Dry 96 Dual (Biotage, Uppsala, Sweden). 
2.1.1.10 Real-Time PCR System 
• LightCycler® 480 (Roche Diagnostics Ltd, Burgess Hill, UK), operated with 
LightCycler® 480 software version 1.5. 
2.1.1.11 Spectrophotometer 
• Nanodrop Spectrophotometer (Thermo Scientific Inc., Waltham, MA, USA). 
2.1.1.12 Thermal cycler 
• TC-512 Gradient Thermal Cycler (Techne, Staffordshire, UK). 
2.1.1.13 Vortex mixer 
• Rotamixer (Hook and Tucker Instruments, Longfield, UK). 
2.1.1.14 Water purification 
• Milli-Q® Advantage A10 Water Purification System (Merck Millipore 
Corporation, Darmstadt, Germany). 
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2.1.1.15 96-well vacuum manifold 
• IST VacMaster®-96 (Biotage, Uppsala, Sweden). 
2.1.2 Clinical-based 
2.1.2.1 Bioelectrical impedence 
• OMRON BF302, OMRON Healthcare (UK) Ltd, Henfield, UK 
2.1.2.2 Blood pressure and pulse measurement 
• OMRON 705IT BP monitor, OMRON Healthcare (UK) Ltd, Henfield, UK 
2.1.2.3 Electronic scales 
• SECA 704, SECA Electronic Scales, Hamburg, Germany 
2.1.2.4 Gamma counter 
• GMS411 Mediscint gamma counter (John Caunt Scientific Ltd, Bury, UK)  
• GMS411 Data Manager Version 12.0 
2.1.2.5 Warm air box 
• Manufactured in-house, calibrated to 60°C  
2.1.2.6 Pulse wave analysis 
• SphygmoCor System (AtCor Medical, Inc, USA) using AtCor Medical 
SCOR-2000 software, version 7.0. 
2.1.2.7 Plethysmography 
• AG101 Cuff Inflator source (Hokanson, WA, USA) 
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• E20 Rapid Cuff inflator (Hokanson, WA, USA) 
• EC4 plethysmograph (Hokanson, WA, USA) 
• Data displayed and analysed using Powerlab 4120 and LabChart® Reader 
(version 8) (AD Instruments, Oxford, UK) 
2.1.2.8 Red light probe 
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2.2 Materials 
2.2.1 Radioactive substances 
• 133Xenon gas (USP grade: >99.5% purity) (Nordion, Ottawa, Canada). 
Specific activity 0.00667 mCi per μL 
2.2.2 Solutions and solvents for clinical studies  
• Saline (NaCl):  
Sodium chloride (0.9% weight/volume(w/v)) (Baxter, Newbury, UK), 
containing 77 mmol/500 ml (154 mM) sodium and 77 mmol/500 ml (154 mM) 
chloride 
• Dextrose:  
Glucose 20% w/v containing 20g glucose per 100ml 
• 0.1% (v/v) Diethylpyrocarbonate (DEPC) water:  
DEPC (1mL) was added to distilled water (1L).  This was mixed and allowed 
to stand (room temperature) for 24 hours before autoclaving.  Storage was at 
room temperature. 
 




Chapter 2: Methods 
2.2.3 Drugs for clinical studies 
2.2.3.1 Stable isotopically labelled tracers 
2.2.3.1.1 D2-cortisone 
1,2-[2H]2-cortisone; >96.3% purity and 98% isotopic enrichment as determined by thin 
layer chromatography (Cambridge Isotope Laboratories, Andover, MA, USA). 
2.2.3.1.2 D8-corticosterone 
2,2,4,6,6,17α,21,21-[2H]8-corticosterone; ≥98% purity and 98.5% isotopic enrichment 
as determined by thin layer chromatography (Cambridge Isotope Laboratories, 
Andover, MA, USA). 
2.2.3.1.3 D2-glucose 
6,6-[2H]2-glucose; 99.3% purity and 99% isotopic enrichment as determined by thin 
layer chromatography (Euriso-top, Saint-Aubin, France) 
2.2.3.1.4 D5-glycerol 
1,1,2,3,3-[2H]5-glycerol; 99.5% purity and >99% isotopic enrichment as determined 
by thin layer chromatography (Euriso-top, Saint-Aubin, France) 
2.2.3.2 Unlabelled steroids 
2.2.3.2.1 Hydrocortisone 
Hydrocortisone sodium phosphate (Concordia, Ontario, Canada), 100mg/1mL. 
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2.2.3.3 Other drugs 
2.2.3.3.1 Potassium canrenoate 
Aldactone (Boehringer Ingelheim, Ingelheim am Rhein, Germany), 200 mg/10mL. 
2.2.3.3.2 Mifepristone 
Mifegyne (Exelgyn, Paris, France), 200mg tablets 
2.2.3.3.3 Probenecid capsules 
Probenecid (Arena Pharmaceuticals Ltd, Buckingham, UK), 500mg capsules.  
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2.3 Quantitation of glucocorticoids in plasma, saliva and hair 
2.3.1 Materials and reagents 
2.3.1.1 Reagents 
High performance liquid chromatography (HPLC) grade water and formic acid were 
from Fisher Scientific (Loughborough, UK). HPLC grade methanol was from VWR 
(Lutterworth, Leicestershire, UK). Acetonitrile, ethyl acetate and chloroform were 
obtained from Rathburn chemicals Ltd. (Walkerburn, Scottish Borders, UK). 
2.3.1.2 Glucocorticoids 
Unlabelled steroids cortisol (F), corticosterone (B), epi-corticosterone (epi-B), 
cortisone (E) and 11-dehydrocorticosterone (A) were supplied by Sigma Aldrich (St. 
Louis, MO, USA). Deuterium-labelled steroids deuterated cortisol (9,11,12,12-[2H]4-
cortisol, D4-cortisol), deuterated cortisone (1,2-[2H]2-cortisone, D2-cortisone) and 
deuterated corticosterone (2,2,4,6,6,17α,21,21-[2H]8-corticosterone, D8-
corticosterone) were supplied by Cambridge Isotopes (Tewksbury, MA, USA). Each 
of these steroids were weighed and dissolved in methanol (final concentration 1 
mg/mL) and stored at -20 C.  
2.3.1.3 Other analytes 
Mifepristone (RU486), canrenone, alfaxolone and deuterated canrenone (D6-
canrenone) were supplied by Sigma Aldrich (St. Louis, MO, USA).  
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2.3.2 Preparation of standard curves 
Stock solutions of the individual glucocorticoids (1 mg/mL) were diluted in methanol 
and mixed for serial dilution. Aliquots were pipetted into glass tubes producing a 
concentration range as specified in each section. Internal standards for each analyte 
were added. The volume of each standard was made up to 400 μL with water. The 
standards were then extracted according to the extraction protocol for the biological 
fluid of interest. 
2.3.3 Extraction of glucocorticoids from plasma 
Plasma samples were defrosted at room temperature. Samples (200 μL) enriched with 
internal standard (specified in the relevant section) were extracted by supported liquid 
extraction (SLE). Enriched samples were added to a disposable glass tube along with 
190 μL HPLC grade water and mixed thoroughly using a vortex. Samples were then 
transferred to an SLE 400+ 96-well plate (Biotage, Uppsala, Sweden) using a glass 
Pasteur pipette. The plate was placed in a 96-well vacuum manifold and a vacuum was 
applied for 5 minutes. Samples were eluted with 0.9 mL of dichloromethane and 
isopropanol (98:2) twice into a 96-well collection plate (Waters, Hertfordshire, UK). 
Each sample was allowed to elute under gravity for 5 minutes then the vacuum was 
applied for 2 minutes. Samples were dried down under nitrogen at 60 °C using a 96 
well nitrogen dry block (Biotage, Uppsala, Sweden) and stored at -20 °C until analysis. 
Prior to analysis, samples were re-suspended in HPLC grade water and acetonitrile 
(70:30, 70 μL) and mixed on a plate shaker.  
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2.3.4 Extraction of glucocorticoids from saliva 
The extraction method was optimised for extraction efficiency and ion suppression of 
internal standards by comparing unextracted and extracted samples with 3 replicates 
(Table 2-1).  
Table 2-1: Extraction efficiency and ion suppression of internal standards 
Internal Standard % Recovery % Ion Suppression 




Intra-assay analysis was assessed using 6 replicates at low (0.005 ng), medium (0.01 
ng) and high (0.025 ng) concentration. Lower limit of quantitation (LLOQ) was 
determined when relative standard deviation (%RSD) was 20% or less. Accuracy was 
accepted when less than 10 (Table 2-2). 
Saliva samples (200 μL) enriched with internal standard (D4-F, epi-B, 10 ng of each) 
were extracted by supported liquid extraction. Enriched samples were added to a 
disposable glass tube along with 200 μL zinc sulphate and were subject to 
centrifugation (10 minutes, 32 869 g, 4 °C). Samples were then transferred to SLE 
400+ 96-well plate (Biotage, Uppsala, Sweden) using a glass Pasteur pipette. The plate 
was placed in a 96-well vacuum manifold and a vacuum was applied for 5 minutes. 
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Samples were eluted with 0.9 mL of dichloromethane and isopropanol (98:2) twice 
into a 96 well collection plate (Waters, Hertfordshire, UK). 
Table 2-2: Limits of quantitation and expected ranges (400 μL saliva) 
LLOQ: Lower limit of quantitation; %RSD: % relative standard deviation. 
Analyte 
 
Expected range in 
saliva (am) 
Results from 6 replicate 
extracts 
 



















0.005 15.72 6.67 
Cortisone 
5-40* 4-20 0.025 13.8 0.17 
Cortisol 
2-15* 1-5 0.025 20.03 3.33 
* (Perogamvros et al. 2009; Perogamvros, Keevil, et al. 2010; Gao et al. 2015) 
Each sample was allowed to elute under gravity for 5 minutes then the vacuum was 
applied for 2 minutes. Samples were dried down under nitrogen at 60 °C using a 96 
well nitrogen dry block (Biotage, Uppsala, Sweden). A further identical extraction was 
carried out using another 200 μL of saliva sample and added to the initial sample on 
re-suspension.  
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Samples were stored at -20 °C until analysis. Prior to analysis, samples were re-
suspended in HPLC grade water and acetonitrile (70:30, 70 μL) and mixed on a plate 
shaker.  
2.3.5 Extraction of glucocorticoids from hair 
Hair samples were washed gently with 2 mL LC-MS grade isopropanol at room 
temperature and left to dry in the fume hood. Each segment was weighed and 
transferred to a fresh glass tube. 1.4 mL LC-MS grade methanol was added to each 
tube along with internal standard (1 ng). Tubes were incubated at 25 °C for 18 hours. 
Samples were subject to centrifugation at 4302 g for 5 minutes at 4 °C. 1 mL of the 
clear supernatant from each sample was transferred to fresh glass tube and dried down 
under nitrogen at 50 °C. The samples were re-suspended in 1 mL of 2% HPLC grade 
methanol and vortexed for 1 minute. Hair extracts were then cleaned by solid phase 
extraction using Oasis HLB 10 μm cartridges (Waters, MA, USA). Cartridges were 
conditioned with 1 mL of methanol followed by 1 mL of HPLC grade water. Samples 
were loaded (1 mL) into the cartridges, washed with 1 mL 30% methanol and eluted 
twice with 300 μL methanol. Extracts were dried down under nitrogen at 50 °C and 
stored at 4 °C until analysis.  
2.3.6 Liquid chromatography tandem mass spectrometry (LC-MS/MS) 
Two methods were used for LC-MS/MS analysis in this thesis. In chapters 3 and 4, the 
glucocorticoid assay was used and in chapter 5, the combined glucocorticoid and 
androgen assay was used. 
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2.3.6.1 Instrument 
The Shimadzu liquid chromatograph coupled with a QTRAP® 6500 mass spectrometer 
(Ab Sciex, Framingham, MA, USA) was used for all experiments. 
2.3.6.2 Glucocorticoid assay  
2.3.6.2.1 Chromatography conditions  
Steroids were separated on an ACE Excel C18 AR column (150 x 2.1 mm, 2 μm) at 
40 °C, at a flow rate of 5 mL/min with a total run time of 9 minutes. A gradient solvent 
system was used as shown in Table 2-3. 
Table 2-3: Solvent gradient   
Time (mins) Water with 0.1% formic acid 
(FA) 
Acetonitrile with 0.1% FA 
0.01 70 30 
4 70 30 
6 10 90 
7 10 90 
7.1 70 30 
9 Stop  
 
2.3.6.2.2 Mass spectrometry conditions 
Ionisation was performed in positive electrospray mode with curtain gas 40 psi, 
collision gas medium, spray voltage 5500 V, source temperature 700 °C, source gases 
40 psi. Mass transitions, retention times and collision energies of the analytes are 
displayed in Table 2-4. Typical chromatography is shown in Figure 2-1. 
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Cortisol 363.1→121.1 3.09 141 101 14 
Cortisone 361.2→77.2 3.53 166 99 36 
Corticosterone 347.1→121.1 5.48 66 69 8 
11-
dehydrocorticosterone 
345.1→121.1 5.36 57 33 8 
D4-cortisol 366.9→121 3.46 166 41 54 
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Figure 2-1: Typical chromatography for glucocorticoid assay 
m/z: mass to charge ratio; RT: retention time 
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2.3.6.3 Glucocorticoid and androgen method 
2.3.6.3.1 Chromatography conditions  
Steroids were separated on a Kinetex C18 column (150 x 3 mm, 2.6 μm) at 40 °C, at 
a flow rate of 5 mL/min with a total run time of 14 minutes. A gradient solvent system 
was used as shown in Table 2-5.  
Table 2-5: Solvent gradient 
Time (mins) Water with 0.1% FA 
(%) 
MeOH with 0.1% FA 
(%) 
0.01 45 55 
4 45 55 
10 0 100 
12 0 100 
12.1 45 55 
14 Stop  
 
2.3.6.3.2 Mass spectrometry conditions 
Ionisation was performed in positive electrospray mode with curtain gas 40 psi, 
collision gas medium, spray voltage 5500 V, source temperature 500 °C and source 
gases 40 psi. Typical chromatography is shown in Figure 2-2. 
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Cortisol 363.1→121.1 4.04 141 101 14 
Cortisone 361.2→77.2 3.39 166 99 36 
D8-corticosterone 355.1→79 5.87 56 97 12 
Corticosterone 347.1→121.1 5.41 66 69 8 
11-
dehydrocorticosterone 
345.1→121.1 3.97 57 33 8 
Testosterone 289.1→109.2 7.74 101 31 6 
Androstenedione 287→97 7.15 61 27 14 
17-OH progesterone 331→109.1 7.96 66 31 12 
D4-cortisol 366.9→121 3.99 166 41 54 
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Figure 2-2: Typical chromatography for glucocorticoid and androgen assay 
m/z: mass to charge ratio; RT: retention time 
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2.3.7 Data analysis 
MultiQuant® software was utilised to integrate area under the peak for each analyte 
and internal standard. The ratio of analyte peak area against its corresponding internal 
standard was used for quantification against a standard curve. A line of best fit (y = 
mx + c) was drawn after plotting known steroid concentrations (x axis) against 
corresponding analyte to internal standard peak area ratio (y axis) with a weighting of 
(1/x). A regression coefficient (r2) of >0.9 was accepted for each standard curve.  
 
2.4 Quantitation of salivary corticosterone by enzyme-linked 
immunosorbent assay (ELISA) 
Salivary corticosterone was measured using enzyme linked immunosorbent assay 
(ELISA) (Enzo Life Sciences, Exeter, UK). All reagents were stored at 2-8°C and 
allowed to come to room temperature before each assay. Assay and wash buffers were 
prepared with deionised water at 1:10 and 1:100 dilutions respectively. Standards were 
prepared by serial dilution to 20000, 4000, 800, 160 and 32 pg/ml concentrations and 
used within 60 minutes of preparation. Samples were extracted before analysis using 
liquid-liquid extraction with ethyl acetate. 100 μL of saliva was added to 400 μL of 
deionised water which was extracted twice with 4 mL of ethyl acetate before drying 
down with nitrogen at 60 °C. Samples were reconstituted using the sample diluent 
provided. Samples and standards (200μl) were added to a 96-well plate coated with 
donkey antibody specific to sheep IgG.  Alkaline phosphatase conjugated with 
corticosterone (50μl) was added to each well along with 50μl of a sheep polyclonal 
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antibody to corticosterone. The plate was incubated at room temperature on a plate 
shaker for 2 hours. The contents of the wells were emptied and washed 3 times with 
wash buffer. After the final wash, 200μl of substrate p-nitrophenyl phosphate buffer 
solution was added to each well and left for 1 hour at room temperature without 
shaking. The enzyme reaction was stopped with 50μl of stop solution and the 
absorbance was read (405 nm; correction between 570 and 590nm) in a 
spectrophotometric microtiter plate reader. A standard curve was generated by plotting 
absorbance against corticosterone concentration for each standard by fitting to a 
4-parameter curve (SoftMax Pro, Sunnyvale, Ca). Sensitivity was determined at 26.99 
pg/mL. Intra-assay precision for low, medium and high concentration with n=16 was 
determined with %CV 8.0, 8.4 and 6.6% respectively. Inter-assay precision was 
measured in low, medium and high concentration with n=8 with %CV 13.1, 8.2 and 
7.8% respectively. Samples were measured in duplicate and accepted if %CV was 
<15%.  
2.5 Quantitation of plasma ACTH by ELISA 
Plasma ACTH was measured using a two-site ELISA (Biomerica, Irvine, California). 
All reagents were stored at 2-8°C and allowed to come to room temperature before 
each assay. Assay calibrators and controls were reconstituted with deionised water (2 
mL) and mixed gently. Reconstituted calibrators and controls were stored (-20°C) for 
6 weeks with up to 3 freeze thaw cycles. Wash buffer concentrate (30 mL) was diluted 
1:20 in deionised water. The diluted wash buffer was stable for up to 90 days at room 
temperature. 
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For each patient, samples from both study visits were assayed together. Assay 
standards (0-541 pg/ml), controls and samples (200 μL) were added in duplicate to a 
96-well microtitre plate coated with streptavidin. Biotinylated ACTH antibody (25 μL) 
was added to each well followed by horseradish peroxidase (HRP) enzyme labelled 
ACTH antibody (25 μL). The plate was covered in aluminium foil to avoid light 
exposure and placed on a plate shaker for incubation (at room temperature for 4 hours). 
Unbound antibodies and buffer matrix were then removed by washing 5 times with 
wash solution (350 μL). For the detection of the immunocomplex, 
tetramethylbenzidine (TMB) substrate solution (150 μL) was added to each well and 
incubated for a further 30 minutes on a plate shaker (covered with aluminium foil).  
The HRP/TMB reaction was terminated with acidic stopping solution (100μL) and 
mixed gently. The absorbance was read within 10 minutes in a spectrophotometric 
microtitre plate reader at both 405 and 450nm. A standard curve was generated by 
plotting absorbance against plasma ACTH concentration for each calibrator by fitting 
to a 4-parameter curve (SoftMax Pro, Sunnyvale, Ca). 
Intra-assay CV, as assessed by measurement of ACTH concentration at low and high 
concentration in n=25 assays was 6.71% at 42.2 pmol/L and 2.27% at 269.9 pmol/L. 
Inter-assay CV was determined from two samples on 21 different days and was 7.1% 
and 6.9% at 42.3 pmol/L and 287.8 pmol/L respectively.  
2.6 Quantitation of serum insulin by ELISA 
Serum insulin was measured using a solid phase two-site enzyme immunoassay (DRG 
Diagnostics, Marburg, Germany). All reagents were stored at 2-8 °C and allowed to 
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come to room temperature before each assay. Wash buffer concentrate (50 mL) was 
diluted in 1000 mL deionised water. Peroxidase conjugated mouse monoclonal anti-
insulin antibody was diluted 1:11 in supplied diluent. Standards containing 
recombinant human insulin (0-20 mU/L) and samples (25 μL) were added in duplicate 
to wells of a microtiter plate coated with mouse monoclonal anti-insulin antibody. 
Diluted peroxidase antibody (100 μL) was added. The plate was sealed, covered and 
incubated on a plate shaker (900 rpm) for 1 hour at room temperature. Unbound 
enzyme labelled antibody and buffer matrix were removed by washing 6 times with 
dilute wash solution (350 μL). TMB substrate solution (200 μL) was added to each 
well and the plate sealed, covered and incubated for 30 minutes at room temperature. 
TMB stop solution (0.5M H2SO4, 50 μL) was added and mixed before measuring 
absorbance at 450 nm in a spectrophotometric microtiter plate reader. A standard curve 
was generated by plotting absorbance against serum insulin concentration for each 
standard and using cubic spline regression (SoftMax Pro, Sunnyvale, Ca). Intra-assay 
precision was determined with 6 replicates for low, medium and high concentration 
with %CV 5.3, 4.2 and 5.1% respectively. Inter-assay precision for the same 
concentrations had %CV of 2.7, 3.9 and 1.8% respectively. The limit of detection was 
0.15 mU/L. 
2.7 Quantitation of serum non-esterified fatty acids by enzymatic 
colorimetric assay 
Serum non-esterified fatty acids (NEFAs) were quantified by colorimetric assay 
(Wako Chemicals, Germany). Standards (0-1000 μM) were prepared by serial dilution 
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in deionized water and stored at 4 °C. Standards and samples (10 μL) were added to 
the wells of a 96-well plate, cooled on ice. Reconstituted reagent A (160 μL), 
containing acyl-CoA synthetase, was added to each well. The plate was incubated (37 
°C, 5 minutes) and mixed gently while NEFAs were converted to fatty acyl-CoA thiol 
esters, which react with oxygen in the presence of acyl-CoA oxidase to produce 
hydrogen peroxide. The optical density of each well was measured at 550 nm and 660 
nm to obtain a blank reading to allow for colour differences in the plasma samples. 
Reconstituted reagent B (80 μL), containing acyl-CoA and peroxidase, was then added 
to each well, allowing the oxidative condensation of 3-methyl-N-ethyl-N-(β-
hydroxyethyl)-aniline with 4-aminoantipyrine to form a purple pigment. The plate was 
incubated again (37 °C, 5 minutes) with gentle mixing.  The optical density of each 
well was again measured at 550 nm and 660 nm to give an actual reading. For both 
blank and actual reading, 660 nm was subtracted from 550 nm before blank was 
subtracted from actual readings. Serum NEFA concentration was calculated from a 
standard curve generated by linear regression analysis of absorbance plotted against 
NEFA concentration in standards. Precision was determined for 5 replicates at <1.5%. 
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2.8 Quantification of mRNA abundance in subcutaneous adipose 
tissue 
2.8.1 Materials and reagents 
RNA was extracted from adipose tissue using QIAGEN® RNeasy Mini Kit 
(QIAGEN®, Hilden, Germany). RLT, RPE and RW1 buffers were provided in the kit. 
Qiazol was obtained separately from QIAGEN® (Hilden, Germany). 
Tris/Borate/EDTA buffer (TBE): Tris base (0.89 M), boric acid (0.89 M) and EDTA 
(0.5 M, 40 mL) were dissolved in distilled water (800 mL). pH was adjusted to 8.0 
with the addition of NaOH (1 M), the volume was adjusted to 1 L with distilled water. 
Storage was at room temperature. 
2.8.2 Tissue collection 
A biopsy of subcutaneous adipose tissue was taken with informed written consent, as 
per the clinical study protocols (Chapter 4.2.5 and Chapter 5.2.5). Samples were 
cleaned with DEPC water and frozen immediately on dry ice and stored at -80 °C until 
analysis.  
2.8.3 RNA extraction from subcutaneous adipose 
Adipose tissue (~100 mg) was homogenised in Qiazol Lysis Reagent (1 mL, Qiagen) 
using ball bearings and a shaker. Chloroform (200 μL) was added, mixed and subject 
to centrifugation (12, 000 g for 15 minutes at 4 °C). The supernatant (approximately 
600 μL) was transferred to a 1.5 mL Eppendorf and an equal volume of ethanol (70%, 
v/v) was added and mixed. The solution was transferred to an RNase spin column and 
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the eluate discarded after centrifugation (12,000 g for 30 seconds at room temperature). 
The column was washed with Buffer RW1 (700 μL) and Buffer RPE (500 μL) 
sequentially and eluate was discarded after centrifugation (12,000 g for 30 seconds at 
room temperature). A further wash of the membrane with Buffer RPE (500 μL) was 
subject to centrifugation again (12,000 g for 2 minutes at room temperature). The 
RNeasy spin column was placed in a fresh collection tube and subject to centrifugation 
until dry (12,000 g for 1 minute at room temperature). The RNase spin column was 
placed in a fresh Eppendorf (1.5 mL). RNase-free water (30 μL) was added to the spin 
column, incubated for 1 minute and eluted by centrifugation (12,000 g for 1 minute at 
room temperature). The eluate was then added back to the RNeasy spin column, 
incubated for 1 minute and subject to centrifugation again (12,000 g for 1 minute at 
room temperature). RNA was stored at -80°C. 
2.8.4 RNA quantification 
RNA was quantified using a Nanodrop Spectrophotometer (Thermo Fisher, West 
Sussex, UK). Concentration was determined by the absorbance at 260 nm wavelength 
and the purity assessed by the ratio of RNA/DNA (260/280), which was deemed 
acceptable if between 1.8 and 2.0.  
2.8.5 RNA quality 
RNA quality was assessed by electrophoresis on a denaturing agarose gel (1.2% w/v 
in 1 x TBE). Samples (2 μL) were prepared by adding loading dye (Promega, WI, 
USA; 1 in 5 dilution in RNase free water; 10 μL). Prepared samples were 
electrophoresed on the gel (100 V, 45 minutes) and RNA integrity was deemed 
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satisfactory if clear 28S and 18S bands were present without smearing, and if the 28S 
rRNA band was approximately twice the intensity of the 18S rRNA band. 
2.8.6 Reverse transcription polymerase chain reaction 
RNA was reverse transcribed using the Quantitect Reverse Transcription kit (Qiagen, 
UK). 500 ng of RNA was used and made up to 12 μL with RNase free water. RNA 
was added to genomic DNA (gDNA) wipeout buffer (2 μL) and incubated (at 42 °C 
for 2 minutes) to eliminate any contaminating gDNA. Quantiscript Reverse 
Transcriptase (1 μL), Quantiscript RT buffer (4 μL) and RT primer mix (1 μL) were 
added to each sample. A negative control was prepared as above except replacing 
reverse transcriptase with water (denoted “–RT control”). Samples were incubated (at 
42 °C for 15 minutes, then 95 °C for 3 minutes) in PCR thermal cycler, before being 
cooled to 4°C. Resultant cDNA was stored at -20 °C. 
2.8.7 Real-time polymerase chain reaction (RT-PCR) 
2.8.7.1 Materials and reagents 
Primers were obtained from Invitrogen Life Technologies (Thermo Fisher Scientific 
Co, Waltham, MA, USA). Universal Probe Library (UPL®) Probes, Probe Mastermix 
and Lightcycler RNase free water were obtained from Roche Diagnostics Ltd (Burgess 
Hill, UK). Primers were designed to match intro-spanning probes within the UPL using 
online software (Universal Probe Library Assay Design Centre). 
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2.8.7.2 RT-PCR 
For each gene, a standard curve was made up from pooling all samples and prepared 
by serial dilution in RNase free water at concentrations of: 1:8; 1:16; 1:32; 1:64; 1:128; 
1:256; 1:512. cDNA samples were diluted (1:10) with RNase free water. A Mastermix 
of UPL Fastmix (5 μL), RNase free water (2.7 μL), forward primer (0.1 μL), reverse 
primer (0.1 μL) and probe (0.1 μL) was prepared for each sample. One gene was 
analysed with SYBR green master mix (Table 2-8) where mastermix (5 μL), RNase 
free water (2 μL), forward primer (0.5 μL) and reverse primer (0.5 μL) were prepared 
for each sample. A –RT control was analysed with each gene. Diluted cDNA (2 μL) 
was added to each well along with 8 μL of master mix. All samples and standards were 
assessed in triplicate. The plate was covered and subject to centrifugation (1500 g for 
2 minutes) before being run on the Light Cycler.  
Samples were denatured by heating (95 °C, 5 minutes), then amplified for 50 cycles 
of consisting of denaturation (10 secs, 95 °C), annealing (30 secs, 60 °C) and 
elongation (1 sec, 72 °C) and cooling (30 secs, 40 °C). 
All samples were analysed in triplicate. Amplification curves were plotted for each 
sample (y = fluorescence, x = cycle number). Triplicates were deemed acceptable if 
the standard deviation of the crossing point was <0.3 cycles. The standard curve 
generated for each gene (y = crossing point, x = log concentration) was deemed 
acceptable if the reaction efficiency was between 1.7 and 2.1. 
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2.8.7.3 Data analysis 
The abundance of each gene was expressed relative to the mean of housekeeping genes 
(18S and Cyclophillin A, Table 2-7) (e.g. abundance of gene of interest in sample 
X/mean abundance of 18S and Cyclophillin A in sample X) and expressed as arbitrary 
units. Tables 2-8 and 2-9 give details of the primers and UPL probes used.  
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Table 2-8: Primer sequence for qPCR and corresponding probe number for genes of 








Forward  GGTGAGAAGGGTGAGAAAGGA 85 




Forward  CTCCACCAACATCCACGAG 89 
Reverse CCCTGCTTGCACATCTCTC 
PER1: Period Circadian  
NM_002616.2 











Forward CGAAAGCTCCCCAAGTACAA 20 
Reverse GCTCTCTACTCGTGCCACATC 
ABHD5: Abhydrolase 
domain containing 5 
NM_016006.5 
Forward GGACAAAATGATCTTGCTTGG 66 
Reverse CCCAAGGCTCCACTAAAATG 
NR3C1: Nuclear 
receptor subfamily 3, 
group C, member 1 (α 
GR)        NM_000176.2 
Forward TTTTCTTCAAAAGAGCAGTGGA 11 
Reverse GCATGCTGGGCAGTTTTT 
NR3C2: Nuclear 
receptor subfamily 3, 
group C, member 2 
(MR)      NM_000901.4 
Forward CATCATGAAAGTTTTGCTGCTACT 64 
Reverse TCTTTGATGTAATTTGTCCTCATTTC 
SGK1: Serum and 
glucocorticoid-regulated 
kinase 1 
NM_001143676.1            
Forward GACAGGACTGTGGACTGGTG 24 
Reverse TTTCAGCTGTGTTTCGGCTA 
FKBP5: FK506 binding 
protein 5 
NM_001145775.2 
Forward GGATATACGCCAACATGTTCAA 15 
Reverse CCATTGCTTTATTGGCCTCT 
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Table 2-9: Primer sequence for qPCR using SYBR® Green master mix 
Gene: Name 
Gene accession number 
Primer Sequence 
LIPE: Hormone Sensitive 






2.9 Routine laboratory tests 
Routine laboratory blood tests for screening in clinical studies were sent for processing 
by the NHS Lothian clinical biochemistry and haematology laboratories at the Western 
General Hospital and Royal Infirmary of Edinburgh (Edinburgh, UK). The laboratory 
participates in the UK National External Quality Assessment Service to ensure quality 
control. Sample collection is described in Chapters 3, 4 and 5.  
Full blood count was measured by a XE-5000 automated flow cytometer (Sysmex UK, 
Milton Keynes, UK). Thyroid function was measured using Architect i2000 
immunoassay (Abbott Diagnostics Ltd, Maidenhead, UK). All other analytes were 
measured on an Architect c16000 analyser (Abbott Diagnostics Ltd, Maidenhead, UK) 


























Chapter 3: Physiology of corticosterone in healthy individuals 
3.1 Introduction 
Cortisol is routinely measured in human biological samples and physiology in healthy 
individuals is well established. In contrast, corticosterone is not routinely measured 
and although physiology is assumed to be similar to cortisol, the evidence for this is 
limited.  
Cortisol is released in a constant and reproducible circadian pattern characterised by a 
peak in the morning beginning prior to waking at 3am, peaking at 9am with a nadir in 
the evening around midnight (Selmaoui & Touitou 2003; Dickmeis 2009; Chan & 
Debono 2010). In plasma, cortisol circulates bound to CBG and albumin with 5-10% 
free and unbound (Lin et al. 2010). Clinically, adequacy of adrenal glucocorticoid 
secretion can be determined as part of a dynamic test measuring stimulated plasma 
cortisol concentrations (Wood et al. 1965; Bornstein et al. 2016). Plasma cortisol 
generally reflects total cortisol which includes both bound and un-bound portions. Free 
cortisol is seldom measured clinically as assays are time consuming and unsuitable for 
routine use (Turpeinen & Hämäläinen 2013). 
Salivary cortisol is a useful non-invasive method of measuring cortisol. This reflects 
the free unbound portion of circulating plasma cortisol which freely diffuses across 
salivary ducts (Hawley & Keevil 2016). Measurements correlate well with circulating 
plasma values and late night salivary cortisol is a validated screening test for Cushing’s 
syndrome (Vining et al. 1983; Nieman et al. 2008).  
An alternative non-invasive method for monitoring cortisol is through scalp hair 
measurement. A number of studies have validated hair cortisol measurement, showing 
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a time line of cortisol exposure over several months (Kirschbaum et al. 2009; 
Manenschijn et al. 2011; D’Anna-Hernandez et al. 2011). Given the circadian and 
ultradian variations in cortisol, this technique is unique in reflecting long term 
exposures to cortisol rather than single point in time measurements.  
As discussed previously, corticosterone has been measured in human clinical plasma 
samples from the early days of glucocorticoid research (Sweat 1955; Peterson 1957; 
Ely et al. 1958; Peterson & Pierce 1960). The assays in use at that time had poor 
specificity and more recent studies suggest plasma corticosterone circulates in 
concentrations approximately 10-20 fold lower than cortisol (Seckl et al. 1990; 
Karssen et al. 2001). Most studies measured early morning samples however some 
also measured day curves which suggest corticosterone too has a diurnal rhythm 
(Martin & Martin 1968; Hamanaka et al. 1970; West et al. 1973). Again, the assays 
used in these studies lacked specificity and there is a high chance of cross-reactivity.  
Salivary corticosterone is less well studied and although paired plasma and saliva 
concentrations have been studied, correlation has not yet been established (McVie et 
al. 1979). As might be expected given the difference in circulating plasma 
concentrations, salivary corticosterone concentrations were lower than cortisol. Again, 
this study used radioimmunoassay which lacks the specificity of tandem mass 
spectrometry. A literature review revealed no published evidence of either salivary day 
curves of corticosterone in healthy individuals or measurements of corticosterone in 
hair.   
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ABC transporter expression in salivary glands is low compared to adipose tissue and 
brain (Nishimura & Naito 2005) however it is reported that ABCB1 is expressed more 
highly than ABCC1 (Uematsu et al. 2003). This could result in relative corticosterone 
excess in saliva, similar to the hypothesised excess in brain due to export of cortisol 
by ABCB1. In contrast, ABCC1 expression in hair follicles is reported to be higher 
than ABCB1 and might suggest corticosterone will be difficult to measure in hair 
(Haslam et al. 2013). Given the uncertainty of how glucocorticoids are incorporated 
into hair however, the exact location of ABCC1 expression within the hair follicle is 
significant and as yet undefined. If ABCC1 is expressed in luminal epithelial cells for 
example, this could lead to higher corticosterone concentrations in hair.    
While historic data suggests corticosterone has a similar diurnal rhythm to cortisol in 
plasma, this has not been tested using a specific mass spectrometry assay and there is 
very limited data investigating corticosterone concentrations in saliva and none, to our 
knowledge, in hair. With differential ABC transporter expression resulting in tissue 
specific differences between cortisol and corticosterone, it cannot be assumed that 
corticosterone simply mimics cortisol within these biological fluids and tissues. 
Independent analysis of corticosterone using modern techniques is necessary to define 
the physiology of corticosterone in humans.   
We hypothesised that corticosterone physiology differs from cortisol in humans and 
that salivary and hair corticosterone concentrations are not directly comparable to 
cortisol. This chapter aimed to measure and explore the relationship between 
corticosterone and cortisol in human plasma, saliva and hair in healthy individuals.   
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3.2 Hair corticosterone 
Corticosterone has never to our knowledge been measured in hair and we aimed to 
achieve this by adapting a validated LC-MS/MS technique for cortisol (Noppe et al. 
2015). 
3.2.1 Methods 
3.2.1.1 Hair sample preparation 
A hair sample was obtained from one healthy female volunteer (age 31, BMI 22). 
Approximately 100-200 hairs were cut from the posterior vertex, as close to the scalp 
as possible.  
The initial analysis used the proximal 5 cm of hair, reflecting the most recent 5 months. 
The sample was cut into 1 cm segments each weighing 10-25 mg and transferred to 
disposable glass tubes.  
A further assay was performed with the remaining hair sample analysed as one sample 
weighing 247 mg. 
3.2.1.2 Preparation of standard curve 
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Table 3-1: Standard curve analytes and internal standards for hair 







Cortisol 0.01-5 D4-cortisol 1 
Cortisone 0.01-5 D4-cortisol 1 
Corticosterone 0.01-5 Epi-corticosterone 1 
11-
dehydrocorticosterone 
0.01-5 Epi-corticosterone 1 
 
3.2.1.3 Extraction of samples 
Samples were extracted using method described in section 2.3.5.  
3.2.1.4 LC-MS/MS analysis 
Samples were analysed using the method described in section 2.3.6.2.  
3.2.2 Results 
3.2.2.1 Glucocorticoid concentrations in 5 hair samples 
Cortisol and cortisone were detected in all 5 samples at varying concentrations (Figure 
3-1). Corticosterone and 11-dehydrocorticosterone were not detectable in any of the 
samples. 
3.2.2.2 Glucocorticoid measurements in large hair sample 
Cortisol, corticosterone and their inactive metabolites cortisone and 11-
dehydrocorticosterone were detectable in this sample and are shown in Figure 3-2. The 
ratio of corticosterone: cortisol was 0.025.  
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Figure 3-1: Hair cortisol and cortisone concentrations in one individual 
Data are for individual samples over five consecutive months for hair cortisol (blue fill) and cortisone 
(purple fill) concentrations in one individual. 
 
Figure 3-2: Glucocorticoid concentrations in 250 mg hair sample 
Data are for concentrations of 11-dehydrocorticosterone (orange fill), corticosterone (red fill), cortisone 
(purple fill) and cortisol (blue fill) in hair sample from one healthy female individual. 
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3.2.3 Discussion 
In this study of glucocorticoid measurement in human hair, we have detected cortisol 
and cortisone at similar concentrations to those published in healthy individuals. 
Corticosterone was not detectable in the standard hair sample but we have 
demonstrated it was present when a larger sample was analysed.  
There can be wide variability in glucocorticoid measurements in hair. In a study of 
cortisol and cortisone measurements in 17 male and 27 female participants aged 2-90 
years, cortisol and cortisone concentrations ranged from 5-91 pg/mg (mean 18 pg/mg) 
and 12-163 pg /mg (mean 70 pg/mg) respectively (Raul et al. 2004). Cortisone is 
generally reported at higher concentration than cortisol in hair (Stalder et al. 2013; 
Noppe et al. 2015). This is largely reflected in the 5 hair segments representing 
monthly exposure which is comparable with these results. The larger sample did not 
reflect this but is not representative of a one month hair segment and is therefore 
difficult to compare effectively. 
Corticosterone was not detected using the initial method with the recommended 
amount of hair per sample (10-30 mg) (Manenschijn et al. 2011; Noppe et al. 2015). It 
had been anticipated that it may be difficult to detect corticosterone in hair considering 
the already low values for cortisol, the limits of detection of our analytical method and 
the relative expression of ABCC1 and ABCB1 in hair follicles. The limit of detection 
of corticosterone for this assay was 0.1 ng and assuming corticosterone might be 
present in hair at 10-fold lower concentration than cortisol, we estimated a sample of 
approximately 250 mg would be required. In combining the remaining hair sample, 
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we were able to analyse for glucocorticoids, but this was not representative of any 
relevant period of time as the full length of the lock of hair was used. Corticosterone 
was detectable in this large sample but at very low levels. The cortisol: corticosterone 
ratio was much lower than in plasma.  
The reported relatively high expression of ABCC1 compared to ABCB1 in the hair 
follicle may play a role in the relatively low concentration of corticosterone in hair 
(Haslam et al. 2013). The mechanism of cortisol absorption in hair is not well 
understood although it is thought to come primarily from the blood supply along with 
some incorporation from sebum and sweat (Meyer & Novak 2012). Unlike plasma and 
saliva, there does not appear to be metabolism of glucocorticoids once incorporated 
into the hair shaft. This suggests hair glucocorticoid concentration is determined at the 
follicle and if ABCC1 is present, this would account for lower concentrations of 
corticosterone than in plasma.  
Of note, 5α reductase (type 1 and 2) is present in hair follicles and has been targeted 
to prevent male pattern baldness (Batrinos 2014). Clearance of glucocorticoids via the 
5α-reductase pathway is therefore likely to occur at this site however both cortisol and 
corticosterone would be metabolised through the same pathway. 
A clear limitation in drawing conclusions from these data is that only one individual’s 
hair has been analysed. This may not be representative and further analysis with 
multiple samples would be required to confirm our findings. 
In practical terms, if our results are representative, in order to reliably detect 
corticosterone for monthly exposure in 1cm segments of hair, the volume required 
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would be over 250 mg. This represents a significant portion of hair and would not be 
feasible or acceptable as a clinical tool for measuring long term corticosterone 
exposure.     
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3.3 Salivary corticosterone 
We hypothesised that salivary corticosterone would differ from cortisol in 
concentration due to ABC transporter expression. In this section, we aimed to measure 
corticosterone in saliva from healthy volunteers over a 14-hour period.  
3.3.1 Methods 
Saliva samples from a previous clinical study were obtained. This study investigated 
the association of 5α-reductase inhibition and metabolic dysfunction in males (Upreti 
et al. 2014). Six healthy male participants provided five salivary samples over the 
course of one day: on waking; 30 minutes after waking; at midday; at 6pm and at 
bedtime. Samples were taken from the placebo phase of this study. 
3.3.1.1 Saliva collection 
Participants were asked to collect each saliva sample using Salivette collection tubes 
(Sarstedt, Sarstedt, Germany). They were advised to avoid eating, drinking coffee/tea, 
brushing teeth and smoking cigarettes prior to sampling. On collection, saliva was 
subject to centrifugation (at 1912 g for 5 minutes at 4 °C) and frozen at -40 °C until 
analysis. Samples had already been through one freeze-thaw process prior to analysis 
for corticosterone.    
3.3.1.2 Sample analysis 
Saliva samples were analysed using immunoassay to measure corticosterone as 
described in section 2.4. Cortisol concentrations had been measured previously (Upreti 
2013). 
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3.3.1.3 Statistical analysis 
Data are mean ± SEM unless otherwise stated. Cortisol and corticosterone 
concentrations and corticosterone: cortisol ratio over the 14-hour period were 
compared using repeated measures analysis of variance (ANOVA) with post-hoc least 
square difference (LSD) testing. Data were analysed using SPSS version 23. P<0.05 
was considered significant. 
3.3.2 Results 
Participant demographics are shown in Table 3-2.  
Table 3-2: Participant demographic data 
 Mean ± standard 
deviation 
Range 
Age (years) 32.8±12.0 22.0-53.0 











There was diurnal variation of salivary cortisol with a peak at 30 minutes after waking 
and values thereafter significantly different to waking (p<0.05) (Figure 3-3). 
Corticosterone concentrations were not significantly different at any time point 
compared to waking values. The salivary corticosterone: cortisol ratio was high at 
baseline compared to usual circulating plasma ratio of approximately 0.05-0.1 and 
increased significantly over the course of the day (p<0.05). 
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Figure 3-3: Salivary cortisol and corticosterone by ELISA 
Data are mean ± SEM for A) salivary cortisol (blue line) and corticosterone (red line) and B) corticosterone: 
cortisol ratio at 5 different time points (n=6). Salivary cortisol but not corticosterone decreased from 
baseline (cortisol: p<0.05 v time, * significant on post hoc testing, corticosterone: p=0.38). The 
corticosterone: cortisol ratio increased from baseline (p<0.05 v time, * significant on post hoc testing).  
 
3.3.3 Discussion 
In this small group of healthy individuals, we have shown salivary cortisol has a 
circadian rhythm over a 14-hour period but corticosterone is unchanged.  
The salivary corticosterone concentrations in our study were higher than the few 
published studies which found early morning concentrations of 0.5 nmol/L (McVie et 
al. 1979) or indeed undetectable (Saracino et al. 2014). The reasons for this 
discrepancy are unclear but one reason may be the assays used in each study. It is 
possible that by measuring corticosterone by immunoassay, we have over-estimated 
the true value due to interference of other glucocorticoid metabolites. Cross reactivity 
in our assay was reported as 28.6% with deoxycorticosterone, 1.7% with progesterone 
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measured at 0.23 nmol/L (Al-Dujaili et al. 2011) and progesterone in healthy males 
were reported at 0.26 nmol/L (Leisegang et al. 2014) suggesting they are unlikely to 
be causing significant interference with our results. The assay does not mention cross 
reactivity with 11-dehydrocorticosterone and the concentration of this in human saliva 
is as yet unknown.  
The higher corticosterone concentrations may also be a reflection of the action of ABC 
transporters in salivary glands. A study of ABC expression in various tissues suggested 
that both ABCB1 and ABCC1 expression were relatively low in salivary glands 
compared to other tissues (Nishimura & Naito 2005) however a study of salivary 
glands alone found expression of both, with ABCB1 more highly expressed than 
ABCC1 in striated and excretory duct cells (Uematsu et al. 2003). With higher ABCB1 
expression, there may be a relative excess of corticosterone due to export of cortisol.  
The integrity of the samples is another possible confounder as they have all previously 
been used in other assays and had therefore been through the freeze- thaw process at 
least once. It may be expected that this would lead to degradation of the sample and 
under-estimation of the concentration however. 
The lack of diurnal variation of corticosterone was unexpected. We are unaware of any 
previously published data of salivary corticosterone throughout a wake/sleep cycle so 
we have no comparisons for this finding. This raises the question of whether salivary 
corticosterone truly reflects plasma concentrations or whether plasma corticosterone 
has a less defined circadian rhythm.  
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With limited published data on salivary corticosterone, it was difficult to be certain 
whether our results were reproducible. Further investigation of these findings with 
paired plasma and saliva samples and LC-MS/MS analysis was therefore performed 
to improve our understanding of corticosterone physiology.  
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3.4 Paired plasma and saliva cortisol and corticosterone 
measurements in healthy individuals 
3.4.1 Introduction 
The results from section 3.3 suggest that salivary corticosterone does not have a diurnal 
rhythm unlike cortisol. We hypothesised that salivary corticosterone does not correlate 
with plasma corticosterone and that only plasma corticosterone has a circadian rhythm.  
We aimed to investigate the relationship between salivary and plasma corticosterone 
in healthy individuals by measuring paired plasma and saliva samples over a 14-hour 
period. To improve detection and specificity, we optimised a new LC-MS/MS method 
to measure both cortisol and corticosterone.  
3.4.2 Methods 
3.4.2.1 Ethical and research governance approvals 
This study was approved by the ACCORD Medical Research Ethics Committee 
(AMREC) (16-HV-029) and NHS Lothian Research and Development committee 
(2017/0004). Research support approvals were secured with the Wellcome Trust 
Clinical Research Facility (WTCRF) and NHS Lothian laboratories at the Royal 
Infirmary of Edinburgh (RIE). 
3.4.2.2 Study design 
A healthy volunteer study was performed to measure glucocorticoid concentrations in 
plasma and saliva over a 14-hour period (from 8am to 10pm). Participants attended for 
one study day and paired plasma and saliva samples were taken at regular intervals.  
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3.4.2.3 Participants 
10 participants were recruited via advertisement on social noticeboards and from 
contacting individuals who had previously taken part in clinical studies. Subjects were 
then invited for a screening visit to discuss the study in detail and to obtain written 
informed consent. Eligibility was assessed through acquisition of relevant medical 
history, clinical examination and baseline blood tests.  
3.4.2.3.1 Inclusion criteria 
o Aged 18-60 years 
o Male or female 
3.4.2.3.2 Exclusion criteria 
o Current acute or chronic medical condition 
o Exogenous glucocorticoid use by any route in last 3 months 
o Any regular medication use 
o Abnormal screening bloods (full blood count (FBC), urea and electrolytes 
(U+E), thyroid function tests (TFTs), liver function tests (LFTs), random 
glucose) 
o Alcohol intake >14 units/week 
3.4.2.4 Measurements 
Height, weight (clothed), BMI, hip and waist circumference were measured as per 
standard operating procedure. A self-standing height measurement was used to 
measure height to the vertex of the head with their shoes off and back of heels and 
head against the measuring board (to one decimal place). Clothed weight was 
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measured before the first visit on calibrated electronic scales (SECA 704, SECA 
Electronic Scales, Hamburg, Germany). Waist circumference was measured mid-way 
between the costal margin and the iliac crest with the participant standing. Hip 
circumference was measured around the maximum circumference of the buttocks in 
the standing position (World Health Organisation 2008). Percentage body fat and lean 
body mass were measured using the mean of three recordings by bioelectrical 
impedance on the morning of each visit (OMRON BF302, OMRON Healthcare (UK) 
Ltd, Henfield, UK). Blood pressure and pulse (OMRON 705IT BP monitor, OMRON 
Healthcare (UK) Ltd, Henfield, UK) were recorded with the participant sitting.  
3.4.2.5 Sample size calculation 
Previous studies have shown correlation between plasma and salivary cortisol 
concentration with correlation coefficients of between 0.61-0.94 (Vining et al. 1983; 
Thomson et al. 2007). Assuming a moderate correlation between plasma and salivary 
corticosterone of 0.5, 10 subjects provides >0.9 power to be able to reject the null 
hypothesis that there was no correlation between plasma and saliva corticosterone 
concentrations. The Type 1 error probability associated with the test of this null 
hypothesis was 0.05. 
3.4.2.6 Clinical protocol 
3.4.2.6.1 Study visits 
Participants attended the WTCRF at 7.45am following an overnight fast. On arrival, 
participants had height, weight and blood pressure measured. Lean body mass and fat 
mass using bioelectrical impedance analysis was measured as in section 3.4.2.4. A 20 
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gauge (20G) (Braun, Sheffield, UK) cannula was inserted in the antecubital fossa 
under aseptic technique.  
Figure 3-4: Study protocol 
Paired blood and saliva sampling was carried out every 30 minutes (blue arrows) with more frequent 
sampling every 15 minutes after meals for 1 hour (red arrows). 
 
Study visits commenced at 8am (Time (t) = 0 mins) when the first paired plasma and 
saliva samples were taken. Sampling was every 30 minutes thereafter. Meals were 
given at 8.30am (t+30 mins), 12 noon (t+240 mins) and 6pm (t+600 mins) of set 
nutritional content (Figure 3-4). Paired blood and saliva sampling was performed every 
15 minutes after meals for 1 hour before reverting to 30 minute sampling again. Meals 
consisted of 55% carbohydrate, 15% protein and 30% fat. Calorie content was 350 
kcal, 500 kcal and 700 kcal for breakfast, lunch and dinner respectively. After the final 
sample at 10pm, the cannula was removed and subjects were allowed home. 
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3.4.2.6.2 Sample collection and processing 
Plasma samples were obtained in lithium heparin (2.9 mL) tubes (Monovette®, 
Sarstedt, Numbrecht, Germany) and immediately placed on ice. Samples were gently 
mixed by inverting several times. Blood samples were subject to centrifugation 
immediately after sampling (2000 g for 10 minutes at 4°C) and the plasma was 
removed and stored at -80°C prior to analysis.  
Saliva samples were obtained using the Salivette® saliva collection device (Sarstedt, 
Numbrecht, Germany). Subjects chewed on the Salivette® for 1 minute before placing 
it back in the collection tube. This was centrifuged immediately (2200 g for 10 minutes 
at 20 °C) after sampling, separated and stored at -80°C for analysis. 
3.4.2.7 Sample analysis 
3.4.2.7.1 Preparation of standard curves 
Standard curves were prepared for plasma and saliva analytes in Table 3-3 and Table 
3-4 as described in section 2.3.2.  
 
Table 3-3: Standard curve analytes and internal standards for plasma 







Cortisol 0.01-200 D4-cortisol 50 
Cortisone 0.01-200 D4-cortisol 50 
Corticosterone 0.001-20 Epi-corticosterone 10 
11-
dehydrocorticosterone 
0.001-20 Epi-corticosterone 10 
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Table 3-4: Standard curve analytes and internal standards for saliva 







Cortisol 0.0005-10 D4-cortisol 0.5 
Cortisone 0.0005-10 D4-cortisol 0.5 
Corticosterone 0.0005-10 Epi-corticosterone 0.5 
11-
dehydrocorticosterone 
0.0005-10 Epi-corticosterone 0.5 
 
3.4.2.7.2 Extraction of samples 
Plasma and saliva samples were extracted as described in sections 2.3.3 and 2.3.4 
respectively.  
3.4.2.7.3 LC-MS/MS analysis 
Both plasma and salivary samples were analysed as described in section 2.3.6.2. 
3.4.2.8 Statistical analysis 
All data presented are mean ± SEM unless otherwise stated. Data were analysed using 
SPSS (version 23, IBM SPSS Statistics, Portsmouth, UK). Plasma and salivary 
measurements were compared independently with time using repeated measures 
analysis of variance (ANOVA) and least squares difference (LSD) post-hoc testing. 
Samples below the limit of quantitation were assigned the value of that limit. Plasma 
and saliva measurements were analysed for correlation using Pearson’s correlation if 
normally distributed and Spearman’s Rank correlation if not normally distributed. 
Correlation plots presented show mean data for each time point. P<0.05 was 
considered significant. 
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3.4.3 Results 
3.4.3.1 Characteristics of study participants 
Anthropometric data from the ten healthy volunteers (n=5 female) are presented in 
Table 3-5. During the study visits, two participants (one female) fainted during 
insertion of the peripheral cannula. Although the study visit continued after they 
recovered, glucocorticoid measurements were up to 5-fold higher than expected and 
they were therefore excluded from analysis as outliers.  
Table 3-5: Participant demographic data 
 Mean ± standard 
deviation 
Range 
Age (years) 27.2±6.3 20.0-40.0 
BMI (kg/m2) 25.8±3.9 22.1-32.7 
Bioimpedance: 
% Fat 
















3.4.3.2 Plasma and saliva glucocorticoids 
3.4.3.2.1 Corticosterone 
Plasma corticosterone peaked in the morning and fell during the day with a second 
peak mid-afternoon (Figure 3-5). There was no increase in corticosterone following 
meals. Salivary corticosterone was very low and 42% of samples were at or below the 
limit of detection of the assay. Detectable concentrations of corticosterone did not 
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show any diurnal variation (p=0.44). Subject 10 had no salivary corticosterone values 
below the limit of detection and diurnal variation was not apparent compared with 
plasma concentration (Figure 3-5 B). Salivary and plasma concentrations did not 
correlate when compared with Spearman’s rank correlation.  
3.4.3.2.2 11-dehydrocorticosterone 
There was diurnal variation of 11-dehydrocorticosterone in plasma with a second peak 
in mid-afternoon with no increase following meals (Figure 3-6). Salivary 11-
dehydrocorticosterone also followed a diurnal rhythm and was present in higher 
concentrations than corticosterone (p<0.05 vs time, p=0.02 vs corticosterone). Only 
9.3% of samples were below the limit of quantitation of the assay. Salivary 11-
dehydrocorticosterone correlated significantly with plasma concentrations of both 11-
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Figure 3-5: Plasma and salivary corticosterone 
Data are mean ± SEM for A) plasma corticosterone (red unbroken line) on left axis and salivary 
corticosterone (red dashed line) on right axis (n=8). Comparison was tested using repeated measures 
ANOVA. Plasma corticosterone changed with time (p<0.0001 vs time) but salivary corticosterone was 
unchanged (p=0.44 vs time). Plasma (red unbroken line) on left axis and salivary (red dashed line) 
corticosterone on right axis for Subject 10 is shown in B. Correlation of salivary and plasma corticosterone 
is shown in C (n=8). Correlation was tested with Spearman’s rank correlation. There was no correlation 
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Figure 3-6: Plasma and salivary 11-dehydrocorticosterone 
Data are mean ± SEM for A) plasma 11-dehydrocorticosterone (orange unbroken line) on left axis and 
salivary 11-dehydrocorticosterone (orange dashed line) on right axis (n=8). Comparison was tested using 
repeated measures ANOVA. Both plasma and salivary 11-dehydrocorticosterone changed significantly 
with time (both p<0.05 vs time). Correlation of salivary and plasma 11-dehydrocorticosterone is shown 
in B (n=8). Correlation was tested with Spearman’s rank correlation. There was significant correlation of 
plasma and salivary 11-dehydrocorticosterone (r=0.6720, p<0.0001). Correlation of salivary 11-
dehydrocorticosterone and plasma corticosterone is shown in C (n=8).  There was significant correlation 
of salivary 11-dehydrocorticosterone and plasma corticosterone (r=0.7154, p<0.0001). 
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3.4.3.2.3 Cortisol 
Both plasma and salivary cortisol followed a classic circadian rhythm (Figure 3-7). 
There was a small peak after lunch and dinner. Correlation of plasma and salivary 
concentrations was significant (r=0.8812, p<0.0001) 
Figure 3-7: Plasma and salivary cortisol 
Data are mean ± SEM for A) plasma cortisol (blue unbroken line) on left axis and salivary cortisol (blue 
dashed line) on right axis (n=8). Comparison was tested using repeated measures ANOVA. Both plasma 
and salivary cortisol changed significantly with time (both p<0.05 vs time). Correlation of salivary and 
plasma cortisol is shown in B (n=8). Correlation was tested with Spearman’s rank correlation. There was 
significant correlation of plasma and salivary cortisol (r=0.8812, p<0.0001). 
 
3.4.3.2.4 Cortisone 
There was diurnal variation of cortisone in both plasma and saliva (Figure 3-8). 
Salivary concentrations were greater than measured cortisol concentrations (p=0.001 
vs cortisol). There was good correlation between plasma and salivary concentrations 
(r=0.8778, p<0.0001) and salivary cortisone correlated well with plasma cortisol 
(r=0.9650, p<0.0001). 
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Figure 3-8: Plasma and salivary cortisone 
Data are mean ± SEM for A) plasma cortisone (purple unbroken line) on left axis and salivary cortisone 
(purple dashed line) on right axis (n=8). Comparison was tested using repeated measures ANOVA. Both 
plasma and salivary cortisone changed significantly with time (both p<0.001 vs time). Correlation of 
salivary and plasma cortisone is shown in B (n=8). Correlation was tested with Pearson’s correlation. 
There was significant correlation of plasma and salivary cortisone (r=0.8778, p<0.0001). Correlation of 
salivary cortisone and plasma cortisol is shown in C (n=8). There was significant correlation of plasma 
cortisol and salivary cortisone (r=0.9650, p<0.0001). 
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3.4.3.3 Relationship between cortisol and corticosterone in plasma and saliva 
The plasma concentrations of cortisol and corticosterone followed a similar diurnal 
pattern and there was significant correlation (Figure 3-9).  
Figure 3-9: Correlation of plasma cortisol and corticosterone 
Correlation of plasma cortisol and corticosterone is shown (n=8). Correlation was tested with Spearman’s 
rank correlation. There was significant correlation of plasma cortisol and corticosterone (r=0.8182, 
p<0.0001).  
 
The corticosterone: cortisol ratio in saliva and plasma was similar at baseline and 
despite an apparent rise over the study period in saliva, there was no significant 
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Figure 3-10: Corticosterone: cortisol ratio in plasma and saliva 
Data are mean ± SEM for corticosterone: cortisol ratio in plasma (black unbroken line) and saliva (grey 
dashed line) (n=8). Comparison was tested using repeated measures ANOVA. There was no significant 
difference between salivary and plasma corticosterone: cortisol ratio although there was a trend for the 
salivary ratio to increase with time (p=0.07). 
 
3.4.4 Discussion 
This study of glucocorticoid concentrations in paired plasma and saliva of healthy 
volunteers has shown that corticosterone does have a diurnal variation in plasma but 
not in saliva, where salivary corticosterone is low in concentration. In contrast, both 
plasma and salivary concentrations of 11-dehydrocorticosterone, cortisol and cortisone 
have a diurnal rhythm and correlate significantly with each other.  
The concentration of corticosterone in saliva is much lower than our results in section 
3.2 but corroborate better with previously published data (McVie et al. 1979). 
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Interestingly, McVie et al used radioimmunoassay in their analysis and the main 
drawback of immunoassay use is over-estimation of steroid content due to cross-
reactivity with other substances (Keevil 2013). While this is likely to be the cause of 
the elevated values in the previous section, McVie et al appear to have a more specific 
assay which correlates with our current data using LC-MS/MS analysis.  
We chose to measure salivary corticosterone using LC-MS/MS which allows a more 
sensitive and specific method of detection and simultaneous measurement of several 
glucocorticoids (Turpeinen & Hämäläinen 2013). Our method was optimised to allow 
the analysis of 400 μL of saliva with a limit of quantitation (LOQ) of 0.005 ng. Other 
methods have been published using only 100 μL of saliva with LOQ < 0.005 ng (Gao 
et al. 2015). In addition to testing the validity of their method, they also measured 
steroid content of 16 saliva samples from a previous clinical study. Corticosterone 
measurements ranged from 0-1.5 nmol/L with a mean±SD of 0.184±0.39 nmol/L.  This 
range is similar to the results in this study. The sensitivity of our assay was variable 
and our LOQ ranged between 0.005-0.025 ng which meant a number of samples were 
at the very limits of detection.  
With 43% of the salivary corticosterone measurements below the limit of detection for 
our assay, this represents a significant limitation of this study. We were unable to 
detect any diurnal variation but this may simply be lost due to the lack of sensitivity. 
There was no significant correlation between salivary and plasma corticosterone but it 
is difficult to conclude there is no correlation at all without being able to quantify the 
true salivary concentrations. In one subject who had detectable salivary corticosterone 
 




Chapter 3: Physiology of corticosterone in healthy individuals 
throughout, there was no clear correlation with plasma concentrations. Although 
salivary corticosterone was low in concentration, the corticosterone: cortisol ratio was 
similar at baseline for plasma and saliva.  
While the salivary corticosterone concentrations may simply be proportional to the 
circulating plasma levels, there may be further metabolism of corticosterone in saliva 
which would account for the lack of observed diurnal rhythm.  There is significant 
activity of 11β-HSD2 in the parotid gland (Smith et al. 1996) and as a result cortisone 
is widely reported to be present in higher concentrations than cortisol in saliva 
(Perogamvros et al. 2009; Mezzullo et al. 2016). Corticosterone is also subject to 
inactivation by 11β-HSD2 and we can confirm this in our study with 11-
dehydrocorticosterone salivary concentrations significantly higher than 
corticosterone. It is possible that the conversion is sufficient to result in such low 
substrate levels that any diurnal variation is lost.  
The lack of correlation of plasma and salivary corticosterone suggests that without a 
more sensitive assay, saliva is not a useful marker of plasma corticosterone. Similar to 
cortisone and cortisol however, our data show 11-dehydrocorticosterone is an effective 
marker of plasma corticosterone. In fact, salivary cortisone rather than cortisol has 
been suggested as a better measure to reflect plasma cortisol and our data reflects this 
with better correlation of plasma cortisol with salivary cortisone (Perogamvros, 
Keevil, et al. 2010). The same appears to be true for corticosterone and 11-
dehydrocorticosterone. 
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In contrast, plasma corticosterone had a circadian rhythm similar to cortisol and 
mirrored the limited published data available for repeated daily measurements. Martin 
et al measured plasma corticosterone at 6 time points over a 24 hour period using a 
fluorometric method and concentrations ranged from 17.3 nmol/L at 9am to 5 nmol/L 
at midnight (Martin & Martin 1968). Our data adds to the published literature 
suggesting plasma corticosterone too has a circadian rhythm. The positive correlation 
of plasma cortisol and corticosterone suggest they are under similar regulation within 
the circulation. 
There is evidence that eating influences cortisol concentrations with peaks seen after 
meals (Quigley & Yen 1979; Follenius et al. 1982). More recent data suggests this is 
mediated by a combination of adrenal secretion and extra-adrenal regeneration 
depending on macronutrient meal content (Stimson et al. 2014). Protein and fat lead 
to a cortisol rise largely mediated by adrenal secretion whereas the contribution of 
adrenal and extra-adrenal regeneration was roughly equal after carbohydrate. There is 
no published evidence of the effect meals have on circulating corticosterone in 
humans. Our data support the literature with small peaks observed in plasma cortisol 
after lunch and dinner. The response of plasma corticosterone is less clear, with a small 
discernible peak after lunch but little change after dinner. There does appear to be a 
peak in the mid-afternoon around 3pm which is also seen in plasma 11-
dehydrocorticosterone and to a lesser extent in plasma cortisone levels. The reason for 
this delayed peak in plasma levels is unclear. The meals provided were of identical 
nutrient content with a set ratio of carbohydrate, protein and fat. A delayed secretion 
of adrenal corticosterone seems unlikely since cortisol would follow the same pattern. 
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A delay in regeneration of corticosterone via 11β-HSD1 is possible and this would 
require further investigation with in vivo tracer studies. 
In conclusion, we have shown corticosterone has a circadian rhythm in plasma similar 
to cortisol. In saliva, corticosterone concentrations were low and appeared to lack a 
diurnal rhythm. Until a more sensitive assay is available, salivary 11-
dehydrocorticosterone would be a suitable alternative as a non-invasive measure of 
plasma corticosterone. In scalp hair, corticosterone was only detectable in a very large 
sample and based on this preliminary work, clinical use is likely to be limited. 
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4.1 Introduction 
Intracellular glucocorticoid concentration is determined in a tissue specific manner by 
the expression of ABC transporters (Ueda et al. 1992; Karssen et al. 2001; Nixon et al. 
2016). ABCB1 is most highly expressed in brain, adrenals and small intestine and 
exports cortisol but not corticosterone (Karssen et al. 2001; Karssen et al. 2004; 
Nishimura & Naito 2005; Begley 2004). ABCC1 is more widely expressed although 
primarily in adipose tissue, skeletal muscle and thyroid and conversely exports 
corticosterone but not cortisol (Nixon et al. 2016; Nishimura & Naito 2005; Webster 
& Carlstedt-Duke 2002).  
Although circulating plasma corticosterone concentrations are relatively low 
compared to cortisol, the tissue-specific differential expression of these transporters 
allows corticosterone to have a more or less significant role in certain tissues. In brain, 
for example, the predominant expression of ABCB1 over ABCC1 at the blood brain 
barrier would suggest a more significant role for corticosterone in central 
hypothalamic negative feedback of the HPA axis (Karssen et al. 2001). This is 
supported by evidence of increased concentration of corticosterone in CSF and post-
mortem brain specimens compared to circulating levels (Raubenheimer et al. 2006). 
Negative feedback is mediated at the level of the pituitary, hypothalamus and higher 
limbic structures and only the pituitary is out with the blood brain barrier. This would 
suggest corticosterone plays more of a key role in these central areas of HPA negative 
feedback rather than in the pituitary itself. 
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Peripherally, selective ABCC1 rather than ABCB1 expression in skeletal muscle and 
adipose tissue may minimise the effects of corticosterone. Pharmacological inhibition 
and genetic knock out of ABCC1 increased corticosterone activation of corticosteroid 
receptors in vitro and in mice (Nixon et al. 2016). In a study of patients with Addison’s 
disease, corticosterone and cortisol infused to achieve similar circulating 
concentrations resulted in comparable suppression of ACTH but higher expression of 
the acutely responsive glucocorticoid-responsive transcript PER1 in adipose tissue in 
the cortisol phase (Nixon et al. 2016). This suggests that while cortisol and 
corticosterone induce equivalent suppression of the HPA axis, activation of 
intracellular receptors in adipose tissue is greater with cortisol. This may be due to 
export of corticosterone from adipose tissue cells by ABCC1 leading to reduced 
activation of corticosteroid receptors.  
The export of corticosterone by ABCC1 is significant when we consider those who 
require glucocorticoid replacement therapy with hydrocortisone, the most widely used 
treatment (Forss et al. 2012). Many are maintained on supra-physiological doses due, 
in part, to the complexity of accurately mimicking the natural circadian release of 
glucocorticoids (Peacey et al. 1997). These patients can develop Cushingoid features 
and have significant morbidity and mortality secondary to cardiovascular disease 
(Falhammar et al. 2014).  
If the actions of ABCB1 and ABCC1 in in vitro and murine models are similar in 
humans, this mechanism may be exploited to potentially improve outcomes in patients 
taking glucocorticoid replacement. ABCC1 expression in adipose tissue and skeletal 
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muscle is significant given the role these tissues play in development of metabolic 
syndrome (Morton 2010). Using corticosterone as an alternative replacement therapy 
may allow adequate glucocorticoid cover with less accumulation within adipose tissue 
and skeletal muscle and therefore potentially less metabolic side effects. 
The effects of ABCC1 inhibition in humans have not yet been tested directly. The 
clinical study presented in this chapter aimed to determine whether inhibition of 
ABCC1 would affect the central negative feedback of the HPA axis and occupancy of 
the corticosteroid receptors in the peripheral tissues, adipose and skeletal muscle. We 
hypothesised that ABCC1 inhibition would not affect the HPA axis but would increase 
occupancy (and activation) of corticosteroid receptors by corticosterone, but not 
cortisol, in adipose and skeletal muscle.  
In order to test this hypothesis, central negative feedback of the HPA axis had to be 
demonstrated and in addition, occupancy of GR and MR in adipose tissue and skeletal 
muscle measured. The GR and MR antagonists mifepristone (RU486) and potassium 
canrenoate were given to activate the HPA axis centrally and displace bound 
glucocorticoids peripherally. This technique has been used previously to measure 
occupancy of MR by cortisol in the myocardium (Iqbal et al. 2014). ABCC1 inhibition 
was achieved using the uricosuric agent probenecid which inhibits renal excretion of 
organic anions and reduces tubular reabsorption of urate. Historically used as treatment 
for chronic gout in humans, it has also been used as a synergistic treatment with 
antimicrobials (Cunningham et al. 1981; Robbins et al. 2012). Probenecid has been 
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used experimentally to inhibit ABCC1 both in vitro and in vivo (Webster & Carlstedt-
Duke 2002; Nixon et al. 2016).  
4.2 Methods 
4.2.1 Ethical and research governance approvals 
This study was approved by the Scotland A Research Ethics Committee (15/SS/0034) 
and by NHS Lothian Research and Development (2015/0200). Research support 
approvals were secured with the Royal Infirmary of Edinburgh Clinical Research 
Facility (RIECRF), NHS Lothian laboratories and radiopharmacy at the Royal 
Infirmary of Edinburgh (RIE). 
4.2.2 Study design 
A double blind randomised crossover study was performed in healthy men comparing 
the displacement of cortisol and corticosterone by corticosteroid receptor antagonists 
with simultaneous arterio-venous sampling from adipose tissue and skeletal muscle in 
the presence and absence of the ABCC1 inhibitor, probenecid. Participants attended 
on two occasions and were given either placebo or probenecid for 5 days prior to each 
visit (Figure 4-1). Displacement of cortisol and corticosterone was achieved using the 
MR antagonist potassium canrenoate and GR antagonist mifepristone (RU486). 1,2-
[2H]2-cortisone (D2-cortisone) was infused to allow in vivo kinetic calculations of 
whole body and tissue glucocorticoid appearance rates. Blood flow was measured in 
adipose tissue and skeletal muscle by 133Xenon gas washout and venous occlusion 
plethysmography respectively. Adipose tissue biopsies were taken before and after 
displacement to compare mRNA expression of known glucocorticoid-regulated genes. 
 




Chapter 4: The role of ABCC1 in glucocorticoid transport in vivo 
Figure 4-1: Study design 
 
4.2.3 Participants 
Participants (n=14) were recruited through advertisement in a local newspaper and 
with posters. Subjects initially attended the RIECRF for a screening visit to discuss 
the study in detail and to obtain written informed consent. Eligibility was assessed 
through acquisition of relevant medical history, clinical examination and baseline 
blood tests.  
4.2.3.1 Inclusion criteria 
o Males aged 18-60 years old 
o BMI 20-30 kg/m2 
4.2.3.2 Exclusion criteria 
o Current acute or chronic medical condition (including history of kidney 
stones) 
o Exogenous glucocorticoid use by any route in the past 3 months 
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o Abnormal screening bloods (full blood count (FBC), urea and electrolytes 
(U+E), thyroid function tests (TFTs), liver function tests (LFTs), random 
glucose) 
o Any regular medication 
o Alcohol intake >21units/week 
o Venous anatomy that precludes adipose vein cannulation 
4.2.4 Sample size calculation 
We planned a study of a continuous response variable from within-subject pairs of 
measurements. Prior data from a myocardial release study was used to power this 
current protocol, in which cortisol release from the myocardium was measured after 
MR blockade (Iqbal et al. 2014). The mean change in cortisol concentration from 
steady state to maximal release (which occurred 25 minutes following canrenoate) was 
normally distributed at 55.3 with a standard deviation of 69.1. Based on this, 14 pairs 
of subjects were required in order to reject the null hypothesis that this response 
difference was zero with probability (power) 0.8. The Type 1 error probability 
associated with this test of this null hypothesis was 0.05. 
4.2.5 Clinical protocol 
4.2.5.1 Study visits 
Participants attended on two occasions at least three weeks apart to allow washout 
between visits. They took either placebo or probenecid (Arena Pharmaceuticals Ltd, 
Buckingham, UK) 1g twice daily for 5 days prior to each study visit. Capsules were 
manufactured by Tayside Pharmaceuticals in sterile conditions. Participants were 
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given written instructions to take 2 x 500mg capsules twice daily (8am and 8pm) for 
5 days before each study visit, with the last 2 capsules taken on the morning of the 
visit. Participants were given placebo and probenecid in random order. Randomisation 
was undertaken by Tayside Pharmaceuticals and kept securely in a sealed envelope 
until all measurements were complete. 
Participants attended the RIECRF at 8am having fasted from 10pm the night before. 
On arrival, measurements were taken of clothed height, weight, waist and hip 
circumference. Blood pressure, lean body mass and fat mass were also measured as 
described in section 3.4.2.4. A standardised breakfast was supplied consisting of 55% 
carbohydrate, 30% fat and 15% protein totalling 350 kcal.  
The participant was cannulated using an aseptic technique at three sites for blood 
sampling and one further site for infusions (Figure 4-2). A retrograde 20G intravenous 
cannula (Braun, Sheffield, UK) was inserted in the deep branch of the medial cubital 
vein in the antecubital fossa of one arm for forearm skeletal muscle sampling. An 
inflatable cuff was placed at the wrist and inflated to 200 mmHg for 2 minutes prior to 
sampling to minimise contamination of blood from the hand. A further retrograde 
cannula was inserted in the dorsum of the hand on the contralateral side. The hand was 
placed in a hot box (manufactured in house) heated to 60C for 5 minutes prior to 
sampling in order to obtain arterialised samples. This technique has been shown to 
mimic arterial blood and has been used in previous clinical studies to avoid the need 
for invasive arterial cannulation (Roddie et al. 1956; Stimson et al. 2009; Hughes et 
al. 2012). A branch of the superficial epigastric vein on the anterior abdominal wall 
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was cannulated for adipose tissue sampling (Karpe et al. 2002). A 20G single lumen 
paediatric central venous catheter (Careflow single lumen catheter, Argon Medical, 
London, UK) was inserted using the Seldinger technique with the aid of a filtered red 
light (Frayn et al. 1989; Hughes et al. 2012). Sampling cannulae were kept patent with 
a slow infusion of 0.9% Saline. Infusions were stopped and a dead space was discarded 
before blood samples were obtained. A final anterograde 20G cannula was positioned 
in the opposite antecubital fossa for the intravenous infusion of D2-cortisone and bolus 
of potassium canrenoate.  
Figure 4-2: Participant set up 
 
At t=0 minutes, an intravenous bolus of 0.076mg D2-cortisone diluted in 20 mL 
sodium chloride 0.9% w/v was given over 5 minutes followed by an infusion at 0.1053 
mg/hr for 355 minutes (Figure 4-3). At t+15 minutes, 133Xenon gas was injected 
subcutaneously lateral to the umbilicus in the abdomen and a gamma counter 
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(GMS411 Mediscint gamma counter, John Caunt Scientific Ltd, Bury, UK) secured 
over the area to measure gamma radiation emission (see section 4.2.5.4.1). At t+30 
minutes, an abdominal adipose tissue biopsy was performed (see section 4.2.5.5). At 
t+60 minutes, participants were given an intravenous bolus of MR antagonist 
potassium canrenoate (Aldactone, Boehringer Ingelheim, Ingelheim, Germany) 
200mg over 5 minutes. At t+105 minutes, GR antagonist mifepristone/RU486 
(Mifegyne, Exelgyn, Paris, France) 400mg was taken orally with 100 mL of water. A 
further abdominal fat biopsy was taken at t+330 minutes. At t+360 minutes following 
the adipose tissue biopsy, the D2-cortisone infusion was stopped, all cannulae 
removed, participants were given lunch and allowed home.  
Figure 4-3: Study diagram 
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4.2.5.2 Blood sampling protocol 
Plasma lithium heparin samples were taken from 3 sites: arterialised (4.9mL), skeletal 
muscle (4.9mL) and adipose tissue (2.7mL) to measure cortisol, corticosterone, 
cortisone, 11-dehydrocorticosterone and D2-cortisone. Samples were collected at 
baseline and every 20 minutes until potassium canrenoate was given at 60 minutes. 
Thereafter sampling was every 10 minutes for 60 minutes, then every 15 minutes for 
the next 60 minutes and finally every 20 minutes until the study finished at 360 minutes 
(Figure 4-3). In addition, canrenoate and mifepristone levels were measured every 
hour in the arterialised samples. Potassium EDTA samples were obtained to measure 
ACTH from the arterialised cannula at baseline then every 60 minutes. 
4.2.5.3 Sample collection and processing 
Samples were obtained in plasma lithium heparin (2.7 and 4.9mL) and potassium 
EDTA tubes (2.6mL, both Monovette®, Starstedt, Numbrecht, Germany). Samples 
were gently mixed by inverting several times. Plasma samples were kept on wet ice 
and subject to centrifugation at 2000 g for 10 minutes at 4 °C within 60 minutes of 
sampling. Potassium EDTA samples were subject to centrifugation at 2500 g for 10 
minutes at 4 °C immediately after sampling. All samples were separated and stored at 
-80°C until analysis.  
4.2.5.4 Blood flow measurements 
Blood flow was measured in adipose tissue and skeletal muscle to allow tissue specific 
in vivo kinetic calculations.  
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4.2.5.4.1 Adipose tissue blood flow 
133Xenon wash out was used to measure blood flow in abdominal subcutaneous 
adipose tissue (Karpe et al. 2002). A dose of 2 MBq was injected subcutaneously 
approximately 5 cm lateral to the umbilicus and a gamma counter (GMS411 Mediscint 
gamma counter, John Caunt Scientific Ltd, Bury, UK) was secured in place at the 
injection site. Measurements of activity were recorded every 20 seconds throughout 
the study. 
Adipose tissue blood flow (ATBF) is calculated from the semilog plot of 
disappearance of counts versus time in 20 second intervals. For the calculation of 
ATBF, the relative solubility of 133Xenon between tissue and blood (partition 
coefficient or λ) is assumed to be 10 ml/g (Goossens & Karpe 2008). ATBF was 
calculated using the following equation: 
Equation 4-1: ATBF (ml/100g tissue/min) =  
slope of semilog plot (ln counts/s) x λ (ml/g) x 100 (g) x 60 (s) 
4.2.5.4.2 Skeletal muscle blood flow 
Skeletal muscle forearm blood flow (FBF) was measured using venous occlusion 
plethysmography (Hokanson et al. 1975; Rojek et al. 2007; Wilkinson & Webb 2001). 
For all blood flow measurements, the arm was supported on foam blocks at the elbow 
and wrist. A mercury-in-silastic strain gauge was applied across the mid forearm and 
blood flow was obstructed at the wrist using a cuff inflated to 200 mmHg. A further 
cuff was placed around the upper arm and rapidly inflated to 50 mmHg. Intermittent 
inflation every 10 seconds for 10 seconds followed by release of venous outflow above 
 




Chapter 4: The role of ABCC1 in glucocorticoid transport in vivo 
the forearm resulted in dilation of the forearm which was detected by the strain gauge. 
This corresponds to arterial blood flow rate.  
Calibration of the strain gauge was performed prior to each study visit so that 1% 
change in length of the gauge was equal to 1% change in limb volume. FBF (ml/100 
mL tissue/min) was calculated from the slope of the voltage-time curve from the strain 
gauge using LabChart Reader (Version 8) software (AD Instruments, Oxford, UK). At 
least 3 measurements were taken hourly and mean flow rate calculated. 
4.2.5.5 Biopsy of subcutaneous abdominal fat 
Two biopsies of subcutaneous abdominal adipose tissue were obtained at t+30 and 
t+330 minutes using an aseptic technique from a site lateral to the umbilicus. Local 
anaesthetic was injected (5mL of 2% lignocaine, Hameln Pharmaceuticals, Gloucester, 
UK) and a 14G 2.1x80mm needle (Braun, Sheffield, UK) with a 30mL syringe 
attached was inserted subcutaneously, directed towards the umbilicus. The plunger 
was withdrawn to create a vacuum and held in place with a 13 x 100 mm glass test 
tube. The sample of adipose tissue was collected in the syringe and placed on 
autoclaved aluminium mesh before washing with 0.1% DEPC treated water (section 
2.2.2). The sample was then placed in a 2 mL Eppendorf on dry ice before storage at -
80°C prior to analysis for glucocorticoid responsive gene expression by qRT-PCR 
(section 2.8). Up to 3 passes were attempted on each occasion. Samples were not 
obtained from one subject in whom the procedure was deemed unsafe due to low 
adiposity. 
 




Chapter 4: The role of ABCC1 in glucocorticoid transport in vivo 
4.2.6 Sample analysis 
4.2.6.1 Preparation of standard curves 
Standard curves were prepared for analytes in Table 4-1 as described in section 2.3.2. 
Table 4-1: Standard curve analytes and internal standards 






Cortisol 0.01-400 D4-cortisol 50 
Cortisone 0.01-400 D4-cortisol 50 
Corticosterone 0.001-40 Epi-corticosterone 10 
11-
dehydrocorticosterone 
0.001-40 Epi-corticosterone 10 
D2-cortisone 0.001-40 D4-cortisol 50 
Canrenone 0.01-400 D6-canrenone 50 
RU486 0.01-400 Alfaxolone 50 
 
Three standard curves were prepared for each analysis. An aqueous curve was used to 
quantify endogenous glucocorticoids. A separate aqueous D2-cortisone standard curve 
was prepared to avoid interference between endogenous and deuterated cortisone. A 
plasma standard curve was prepared for the drug analysis. Standards were made up to 
400 μL with stock plasma instead of water.  
4.2.6.2 Extraction of plasma samples  
Plasma samples were extracted as described in section 2.3.3.  
4.2.6.3 LC-MS/MS analysis 
Samples were analysed as described in section 2.3.6.2. In addition to the analytes in 
Table 2-4, the mass transitions, retention times and collision energies were assessed 
for the following analytes (Table 4-2). 
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D2-Cortisone 363.1→165.1 3.75 166 31 22 
Canrenone 341.1→107 6.42 130 47 10 
RU486 430.2→134 5.56 130 47 10 
D6-Canrenone 347.2→107 6.42 126 43 8 
Alfaxolone 333→297 6.29 136 18 10 
4.2.7 Data analysis 
4.2.7.1 Tracer kinetics 
The tracer D2-cortisone was used to allow measurement of flux of endogenous 
glucocorticoids (or ‘tracees’) cortisol and corticosterone. The tracer: tracee ratio (TTR) 
(Equation 4-2) was used for compartmental modelling calculations and allowed 
assessment of whether endogenous tracees were in steady state. The clearance of both 
tracer and tracee should be similar in order to calculate whole body rate of appearance.  
This was calculated for D2-cortisone using Equation 4-3 and compared to previously 
published clearance data for cortisol and corticosterone. 
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Equation 4-3: Clearance of D2 Cortisone 
𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =
𝑅𝑎𝑡𝑒 𝑜𝑓 𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛 (𝑛𝑚𝑜𝑙 min )⁄
𝑆𝑡𝑒𝑎𝑑𝑦 𝑆𝑡𝑎𝑡𝑒 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑚𝑜𝑙 𝐿)⁄
 
Rate of appearance (Ra) of cortisol and corticosterone were calculated by dividing the 
rate of infusion of tracer by the corresponding TTR (Wolfe & Chinkes 2005). Whole 
body rate of appearance of glucocorticoids were calculated using both steady state 
(Equation 4-4 and Equation 4-5) and non-steady state (Equation 4-6 and Equation 4-7) 
equations as potassium canrenoate and RU486 were given prior to this.  
In order to calculate steady state rate of appearance, tracer and tracee clearance must 
be similar as these are usually cancelled out. Any differences in clearance between 
tracees, cortisol and corticosterone, and D2 cortisone were therefore corrected. 
Clearance of D2 cortisone has been reported as 1.04±0.80 L/min (Hughes et al. 2012) 
and clearance of cortisol has been relatively consistently reported at 0.28-0.33 L/min 
(Andrew et al. 2002; Stimson et al. 2007). Clearance of corticosterone in humans has 
not been formally assessed using tracers however clearance of D8 corticosterone in 
healthy volunteers was determined by our group in both bolus and steady state 
infusions (1.46±0.36 and 1.11±0.20 L/min respectively) (Mackenzie 2015). Cortisol 
clearance is approximately 4-fold slower than D2 cortisone and this was corrected 
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using Equation 4-4. The clearance rates of corticosterone and D2 cortisone were 
similar therefore the rate of appearance of corticosterone was calculated without any 
correction in Equation 4-5.  
Equation 4-4: Whole body Ra of Cortisol (Steady State) 
𝑅𝑎 𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙 (𝑛𝑚𝑜𝑙 min ) =  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝐷2 𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑛𝑒 𝑖𝑛𝑓𝑢𝑠𝑖𝑜𝑛 (𝑛𝑚𝑜𝑙 min )⁄
𝑇𝑇𝑅 𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙 ∗ 4
⁄  
 
Equation 4-5: Whole Body Rate of Appearance of Corticosterone (Steady State) 
𝑅𝑎 𝐶𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 𝑛𝑚𝑜𝑙 𝑚𝑖𝑛 =  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝐷2 𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑛𝑒 𝑖𝑛𝑓𝑢𝑠𝑖𝑜𝑛 (𝑛𝑚𝑜𝑙 min )⁄
𝑇𝑇𝑅 𝑐𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒
⁄  
     
Non-steady state calculations are derived from the Steele equation first published in 
1959 to address the effect of insulin on glucose (Steele 1959). This was applied using 
Equation 4-6 and Equation 4-7, where F = tracer infusion rate, pV = fractional volume 
of distribution, t = time, [Cortisolt] = arterialised cortisol concentration at time = t and 
TTRt = tracer:tracee ratio at time = t. F was 4.84 nmol/min and pV was assumed to be 
12 litres, as has been widely used for glucose (Gastaldelli et al. 1999). This value has 
also been used in calculating non-steady state rate of appearance of cortisol (Andrew 
et al. 2005).    
Equation 4-6: Whole Body Rate of Appearance of Cortisol (Non-Steady State) 
𝑅𝑎 𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙 (𝑛𝑚𝑜𝑙 min ) =
𝐹 − 𝑝𝑉 𝑥 ([𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑡1] + [𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑡2] 2) × (𝑇𝑇𝑅𝑡2 −  𝑇𝑇𝑅𝑡1/(𝑇2 − 𝑇1)⁄
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Equation 4-7: Whole Body Rate of Appearance of Corticosterone (Non-Steady 
State) 
𝑅𝑎 𝐶𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 (𝑛𝑚𝑜𝑙 min ) =
𝐹−𝑝𝑉 𝑥 ([𝐶𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒𝑡1]+[𝐶𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒𝑡2] 2)×(𝑇𝑇𝑅𝑡2− 𝑇𝑇𝑅𝑡1/(𝑇2−𝑇1)⁄
(𝑇𝑇𝑅𝑡1+𝑇𝑇𝑅𝑡2 2)⁄
⁄   
 
The rate of appearance of cortisol and corticosterone across tissues (skeletal muscle 
and adipose tissue) was calculated using arteriovenous differences in TTR whilst 
factoring in blood flow rate through the tissue (Equation 4-8 and Equation 4-9).  
Equation 4-8: Ra Cortisol across tissue 
𝑅𝑎 𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙 𝑎𝑐𝑟𝑜𝑠𝑠 𝑡𝑖𝑠𝑠𝑢𝑒 (𝑝𝑚𝑜𝑙 100𝑔 𝑡𝑖𝑠𝑠𝑢𝑒 𝑚𝑖𝑛⁄⁄ )
= (𝐵𝑙𝑜𝑜𝑑 𝐹𝑙𝑜𝑤 (𝐵𝐹)𝑥[𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝐴𝑟𝑡𝑒𝑟𝑦]𝑥
𝑇𝑇𝑅𝐴𝑟𝑡𝑒𝑟𝑦
𝑇𝑇𝑅𝑇𝑖𝑠𝑠𝑢𝑒
) − 𝐵𝐹𝑥[𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝐴𝑟𝑡𝑒𝑟𝑦] 
Equation 4-9: Ra Corticosterone across tissue 




) − 𝐵𝐹𝑥[𝐶𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒𝐴𝑟𝑡𝑒𝑟𝑦] 
Net balance was calculated for each glucocorticoid across adipose tissue and skeletal 
muscle to demonstrate either net release or uptake within the tissue. This was 
demonstrated by calculating the difference in arterial and tissue glucocorticoid 
concentration and controlling for blood flow (Equation 4-10 and Equation 4-11). 
Equation 4-10: Net Balance of Cortisol across tissue 
𝑁𝑒𝑡 𝐵𝑎𝑙𝑎𝑛𝑐𝑒 (𝑝𝑚𝑜𝑙 100𝑚𝑙 𝑡𝑖𝑠𝑠𝑢𝑒/𝑚𝑖𝑛⁄ )
= [[𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑇𝑖𝑠𝑠𝑢𝑒] − [𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝐴𝑟𝑡𝑒𝑟𝑦]] 𝑥 𝐵𝑙𝑜𝑜𝑑 𝐹𝑙𝑜𝑤(𝐵𝐹) 
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Equation 4-11: Net Balance of Corticosterone across tissue 
𝑁𝑒𝑡 𝐵𝑎𝑙𝑎𝑛𝑐𝑒 (𝑝𝑚𝑜𝑙 100𝑚𝑙 𝑡𝑖𝑠𝑠𝑢𝑒/min )⁄  
= [[𝐶𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒𝑇𝑖𝑠𝑠𝑢𝑒] − [𝐶𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒𝐴𝑟𝑡𝑒𝑟𝑦]] 𝑥 𝐵𝐹 
4.2.7.2 Statistical analysis 
All data are mean ± SEM unless otherwise stated. Data were analysed using Graph 
Pad Prism® (version 6.01) and checked for normality of distribution using the 
Kolmogorov-Smirnov test. If not normally distributed, data were log transformed to 
achieve this before analysis. Differences between placebo and probenecid groups were 
assessed using repeated measures analysis of variance (ANOVA) with post-hoc 
Bonferroni testing. Due to difficulties with sampling from the multiple sampling sites, 
there were a number of individuals with missing data points. Where these were 
minimal, specific time points were excluded in the analyses. When multiple data points 
were missing, data were combined by calculated average values for each subject in 
three time periods before statistical analysis: 1) pre-drug (t=0-60 min); 2) following 
potassium canrenoate (t=70-105 min); 3) following potassium canrenoate plus RU486 
(t=110-360 min). P<0.05 was considered significant. 
mRNA transcript levels in adipose tissue were expressed in relation to the abundance 
of two housekeeping genes (see section 2.8.7.3). Data were compared using two-way 
ANOVA.  
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4.3 Results 
4.3.1 Characteristics of study participants 
Characteristics of all participants are summarised in Table 4-3 below. 
Abdominal adipose vein cannulation was technically challenging and was 
unsuccessful on a number of study visits. In total, 7 patients had adipose tissue data 
available from both study visits. Arterialised and skeletal muscle data are presented 
from all 14 participants while adipose tissue data are presented from those 7 
participants with data from both visits.  
Table 4-3: Participant demographic data 
Data are mean ± standard deviation and range for n=14 participants (all male). 
 Mean ± standard 
deviation 
Range 
Age (years) 28.7 ± 13.5 18.0-61.0 





13.9 ± 6.3 








136.5 ± 6.5 
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4.3.2 Whole body glucocorticoid measurements 
4.3.2.1 Arterialised glucocorticoid measurements 
Arterialised plasma cortisol and corticosterone concentrations are presented in Figure 
4-4. During the placebo phase, both cortisol and corticosterone concentrations 
increased after potassium canrenoate administration and fell steadily thereafter, 
including after the addition of RU486. Probenecid potentiated the increase in cortisol 
after canrenoate and after RU486 administration (p=0.01). Probenecid tended to 
increase corticosterone levels following RU486 (p=0.08).  
4.3.2.2 Whole body rate of appearance of glucocorticoids 
Plasma D2 cortisone concentrations and calculated clearance (using Equation 4-3) are 
shown in Figure 4-5. D2 cortisone reached steady state at 165 minutes. Clearance was 
unchanged over time once steady state was achieved and there was no difference 
between drug phases at any point (p=0.40).   
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Figure 4-4: Arterialised cortisol and corticosterone concentrations 
Data are mean ± SEM for A) plasma cortisol (blue lines) and B) corticosterone (red lines) concentrations 
in arterialised samples at time points 0-360 minutes during placebo (unbroken lines) and probenecid 
phases (dashed lines) (n=14). Comparison was tested by repeated measures ANOVA. Canrenoate (K Can) 
and mifepristone (RU486) increased cortisol concentrations (p<0.001 vs time) and probenecid 
significantly increased cortisol compared to placebo (p=0.05 vs placebo, p=0.01 interaction of drug and 
time). Canrenoate and RU486 increased corticosterone concentrations (log transformed, p<0.001 vs 
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Figure 4-5: Arterialised D2 cortisone plasma concentration and clearance 
Data are mean ± SEM for A) plasma D2-cortisone concentration and B) clearance of D2-cortisone in 
placebo (black unbroken line) and probenecid (black dashed line) phases (n=14). Comparison was tested 
by repeated measures ANOVA. Steady state plasma concentration was achieved from 165 minutes with 
no significant difference thereafter against time (p=0.08 vs time) and no difference between placebo and 
probenecid phases (p=0.59 vs placebo). Clearance was unchanged with time or drug at steady state 
(p=0.11 vs time, p=0.40 vs placebo). 
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Whole body rate of appearance of glucocorticoids were calculated using both steady 
state (Equation 4-4 and Equation 4-5) and non-steady state (Equation 4-6 and Equation 
4-7) equations as potassium canrenoate and RU486 were given prior to steady state of 
D2 cortisone being achieved. There was no difference between steady state and non-
steady state results and the steady state data is presented in Figure 4-6. There was 
significant appearance of both cortisol and corticosterone in the placebo phase with 
peaks after potassium canrenoate infusion (p<0.0001 vs zero). Probenecid 
significantly increased the rate of appearance of cortisol after RU486 administration 
at t=200 minutes (p=0.005).  Probenecid did not affect the rate of appearance of 
corticosterone (p=0.12).  
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Figure 4-6: Whole body rate of appearance of cortisol and corticosterone 
Data are mean ± SEM for whole body rate of appearance of A) cortisol (blue lines) and B) corticosterone 
(red lines) for placebo (unbroken line) and probenecid (dashed line) at time points 0-360 minutes (n=14). 
Comparison was tested by repeated measures ANOVA. There was significant release of both cortisol and 
corticosterone (log transformed) during the placebo phase after potassium canrenoate (K Can) (both 
p<0.001 vs time).  In the probenecid phase, there was significantly increased release of cortisol (p=0.005 
interaction of drug and time, t=200mins on post hoc Bonferroni testing) but not corticosterone (p=0.12 
vs placebo) compared to placebo.  
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4.3.2.3 ACTH 
Plasma ACTH in both placebo and probenecid phases is shown in Figure 4-7. In the 
placebo phase, there was no significant change in ACTH with time (p=0.22). 
Probenecid did not significantly alter ACTH concentration but there was a trend for 
increased ACTH release (p=0.06). 
Figure 4-7: Plasma ACTH concentration  
Data are mean ± SEM for plasma ACTH concentrations in placebo (green unbroken line) and probenecid 
phase (green dashed line) (n=14). Comparison was made with repeated measures ANOVA. There was no 
significant change in ACTH with time but there was a trend for increased ACTH release in the probenecid 
phase (log-transformed, p=0.22 vs time, p=0.11 vs placebo, p=0.05 interaction of drug and time). 
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4.3.3 Adipose tissue 
4.3.3.1 Adipose tissue blood flow 
Due to difficulties with adipose vein cannulation, data presented are for n=7 subjects. 
Adipose blood flow (calculated as described in section 4.2.5.4.1) is shown at individual 
time points and was also averaged for each subject for time periods after MR and GR 
antagonist administration: i.e. pre-drug (0-60 minutes); after potassium canrenoate 
(70-105 minutes); and after addition of RU486 (110-360 minutes) (Figure 4-8). Data 
were analysed using groups due to missing data for individual time points. Mean blood 
flow over the whole study period was 6.1±0.5 and 7.8±0.8 mL/100g tissue/min in the 
placebo and probenecid phase respectively. There was no significant change in blood 
flow over time (p=0.12). Probenecid increased adipose tissue blood flow after 
combined receptor antagonism.   
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Figure 4-8: Adipose tissue blood flow  
Data are mean ± SEM for adipose tissue blood flow at A) individual time points and B) grouped data: 
before drugs given (before 60 mins), after potassium canrenoate (70-105 mins) and after RU486 (110-
360 mins) during placebo (purple solid line/fill) and probenecid (purple dashed line/striped fill) phases 
(n=7). Comparison was made using grouped data with repeated measures ANOVA. There was no 
significant difference over time (p=0.12 vs time) however blood flow significantly increased after 
combined receptor antagonism in the probenecid phase (p=0.03 interaction of drug and time, 
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4.3.3.2 Rate of appearance of glucocorticoids in adipose tissue 
Tissue specific rate of appearance of glucocorticoids was measured using the D2-
cortisone tracer (using Equation 4-8 and Equation 4-9). There was net uptake of D2-
cortisone in adipose tissue in both drug phases and this was not significantly altered 
by time (Figure 4-9). 
Rate of appearance of cortisol and corticosterone in adipose tissue are presented in 
Figure 4-10. During the placebo phase, there was detectable cortisol production across 
adipose tissue before, but not after, canrenoate and RU486 were given (p=0.04 vs 
zero).  Probenecid did not alter the appearance of cortisol across the tissue.  
In the placebo phase, the rate of appearance of corticosterone in adipose was not 
significantly different to zero either before or after GR and MR antagonism. 
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Figure 4-9: Net balance of D2 cortisone in adipose tissue 
Data are mean ± SEM for net balance of D2-cortisone in adipose tissue with A) individual time points and 
B) grouped data during placebo (black unbroken line) and probenecid (grey dashed line) phase (n=14). 
Comparison was made with repeated measures ANOVA using grouped data. There was significant 
uptake of D2-cortisone during both placebo and probenecid phases (p=0.002 and p=0.006 vs zero 
respectively) There was no significant change in uptake after administration of canrenoate or RU486 
(p=0.31 v time). 
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Figure 4-10: Rate of appearance of cortisol and corticosterone in adipose tissue 
Data are mean ± SEM for rate of appearance of cortisol (blue) in adipose tissue using A) individual time 
points and B) grouped data (before GR/MR antagonism: 0-60mins, after MR antagonism: 60-105mins 
and after combined receptor antagonism: 110-360mins). Rate of appearance of corticosterone (red) in 
adipose tissue is shown using C) individual time points and D) grouped data (as above) for placebo 
(unbroken line/solid fill) and probenecid phase (dashed line/striped fill) (n=7). Comparison was made with 
repeated measures ANOVA using grouped data. There was significant appearance of cortisol in both 
placebo and probenecid phases in the pre-drug period compared to zero but not after potassium 
canrenoate or RU486 (placebo: p=0.05 vs zero, *pre-drug significant on post-hoc Bonferroni testing and 
probenecid: p=0.04 vs zero, *pre-drug significant on post-hoc Bonferroni testing). There was no 
significant appearance of corticosterone before or after receptor antagonism in either placebo or 
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4.3.3.1 Net balance of glucocorticoids within adipose tissue 
Net balance of glucocorticoids in adipose was calculated by measuring the 
arteriovenous difference across the tissue controlled for blood flow and is shown in 
Figure 4-11 (using Equation 4-10 and Equation 4-11). In the placebo phase, there was 
detectable uptake of cortisol but not corticosterone in adipose tissue compared with 
zero (p=0.01 and p=0.13 v zero respectively). There was no change in uptake of 
cortisol or corticosterone over time (p=0.98 and p=0.11 v time respectively). 
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Figure 4-11: Net balance of cortisol and corticosterone in adipose tissue 
Data are mean ± SEM for net balance of cortisol (blue) in adipose tissue using A) individual time points 
and B) grouped data (before GR/MR antagonism: 0-60mins, after MR antagonism: 60-105mins and after 
combined receptor antagonism: 105-360mins). Net balance of corticosterone (red) in adipose tissue is 
shown using C) individual time points and D) grouped data (as above) for placebo (unbroken line/solid 
fill) and probenecid phase (dashed line/striped fill) (n=7). Comparison was made with repeated measures 
ANOVA. There was significant uptake of cortisol throughout both placebo and probenecid phases 
compared to zero but not corticosterone (cortisol: placebo p=0.01 vs zero, and probenecid p=0.02 vs zero, 
corticosterone: placebo p=0.13 vs zero, and probenecid p=0.14 vs zero). There was no effect over time or 
when probenecid was compared to placebo for either cortisol or corticosterone (cortisol: p=0.98 vs time, 
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4.3.4 Skeletal muscle 
4.3.4.1 Skeletal muscle blood flow 
Skeletal muscle blood flow was measured hourly over the study period and is 
presented in Figure 4-12. In the placebo phase, skeletal muscle blood flow did not 
change with time (p=0.68). Probenecid increased mean blood flow compared with 
placebo (5.15±0.48 vs 4.16±0.43 mL/100mL tissue/min respectively, p=0.03).  
Figure 4-12: Skeletal muscle blood flow 
Data are mean ± SEM for skeletal muscle blood flow at individual time points during placebo (green solid 
line) and probenecid (green dashed line) phases (n=14). Comparison was made using repeated measures 
ANOVA. Blood flow was significantly increased during the probenecid phase (p=0.03 vs placebo) and 
there was no change with time (p=0.68 vs time).  
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4.3.4.2 Rate of appearance of glucocorticoids in skeletal muscle 
There was uptake of D2-cortisone within skeletal muscle which was unaltered by time 
or drug phase (Figure 4-13).  
Figure 4-13: Net balance of D2 cortisone in skeletal muscle 
Data are mean ± SEM for net balance of D2-cortisone in placebo (black unbroken line) and probenecid 
(grey dashed line) phase (n=14). There was significant uptake of D2-cortisone in the placebo phase 
compared to zero (p=0.005 vs zero) and there was no difference compared with probenecid at any point 
in the study period (p=0.42 vs time, p=0.64 vs placebo). 
 
Rate of appearance of cortisol and corticosterone are shown in Figure 4-14. In the 
placebo phase, there was significant detectable appearance of cortisol and 
corticosterone in skeletal muscle (p<0.0001 and p=0.04 v zero respectively). There 
was no significant change in rate of appearance over time (p=0.09 and p=0.07 vs time 
respectively). Probenecid did not alter the appearance of cortisol or corticosterone 
(p=0.15 and p=0.81 vs placebo respectively).  
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Figure 4-14: Rate of appearance of cortisol and corticosterone in skeletal muscle 
Data are mean ± SEM for rate of appearance of cortisol (blue) in skeletal muscle using A) individual time 
points and B) grouped data (before GR/MR antagonism: 0-60mins, after MR antagonism: 60-105mins 
and after combined receptor antagonism: 105-360mins). Rate of appearance of corticosterone (red) in 
skeletal muscle is shown using C) individual time points and D) grouped data (as above) for placebo 
(unbroken line/solid fill) and probenecid phase (dashed line/striped fill) (n=14). Comparison was made 
with repeated measures ANOVA. There was significant appearance of cortisol vs zero in both placebo 
and probenecid phases throughout the study period (placebo: p<0.0001 vs zero and probenecid: 
p=0.0002 vs zero) Rate of appearance of corticosterone was also significant compared to zero (placebo: 
p=0.04 at t=80 and 110 on post-hoc Bonferroni testing, probenecid: p=0.01 at t=20 and 120 on post-hoc 
Bonferroni testing). There was no significant effect over time or when probenecid was compared to 
placebo for cortisol or corticosterone (cortisol: p=0.09 vs time, p=0.15 vs placebo and corticosterone: 
p=0.07 vs time, p=0.81 vs placebo). 
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4.3.4.3 Net balance of glucocorticoids in skeletal muscle 
Net balance of glucocorticoids in skeletal muscle is shown in Figure 4-15. In the 
placebo phase, there was no significant detectable uptake or release of cortisol or 
corticosterone across skeletal muscle (p=0.40 and p=0.39 vs zero respectively). There 
was no change in net balance over time. Probenecid had no significant effect on net 
balance of cortisol or corticosterone within skeletal muscle (p=0.53 and p=0.91 vs 
placebo respectively).  
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Figure 4-15: Net balance of cortisol and corticosterone in skeletal muscle 
Data are mean ± SEM for net balance of cortisol (blue) in skeletal muscle using A) individual time points 
and B) grouped data (before GR/MR antagonism: 0-60mins, after MR antagonism: 60-105mins and after 
combined receptor antagonism: 105-360mins). Net balance of corticosterone (red) in skeletal muscle is 
shown using C) individual time points and D) grouped data (as above) for placebo (unbroken line/solid 
fill) and probenecid phase (dashed line/striped fill) (n=14). Comparison was made with repeated 
measures ANOVA. There was no significant difference in net balance of cortisol or corticosterone when 
compared to zero (cortisol: placebo p=0.40 vs zero, and probenecid p=0.27 vs zero, corticosterone: 
placebo p=0.40 vs zero, and probenecid p=0.79 vs zero). There was no effect over time or when 
probenecid was compared to placebo for either cortisol or corticosterone (cortisol: p=0.15 vs time, p=0.53 
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4.3.5 Summary of Glucocorticoid Actions 
In summary, arterialised cortisol concentration and rate of appearance increased as 
expected after corticosteroid receptor inhibition and probenecid significantly 
potentiated this effect. Corticosterone concentration and rate of appearance were 
similarly increased and there was a trend for probenecid to enhance this effect. 
In adipose tissue, there was increased rate of appearance of cortisol and relative uptake 
within the tissue. Corticosterone showed no increase in rate of appearance or any 
uptake or release compared to zero. In skeletal muscle, there was an increase in rate of 
appearance of both cortisol and corticosterone but no significant uptake or release of 
either. Probenecid had no significant effect on either glucocorticoid. 
Table 4-4: Glucocorticoid Summary Table 
* Denotes significant change compared to placebo (p<0.05) 
 Cortisol Corticosterone 





        *   
Whole Body Rate 
of Appearance 





 No effect No change No effect 







 No effect  No effect 
Net Balance No uptake 
or release 
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4.3.6 Plasma canrenoate and RU486 concentrations 
There was no difference in plasma concentrations of potassium canrenoate and RU486 
during placebo and probenecid phases (Figure 4-16).  
Figure 4-16: Plasma drug concentrations 
Data are mean ± SEM for plasma arterialised concentrations of A) canrenoate and B) RU486 during 
placebo (unbroken line) and probenecid (dashed line) phases (n=14). Comparison was made using 
repeated measures ANOVA. There was no difference in either canrenoate or RU486 concentration 
between placebo and probenecid phases (canrenoate: p=0.36 vs placebo, RU486: p=0.28 vs placebo). 
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4.3.7 Glucocorticoid-responsive gene expression in subcutaneous adipose tissue 
Expression of glucocorticoid responsive genes in subcutaneous adipose tissue are 
shown inFigure 4-17. Comparison was made between the sample taken at baseline and 
after combined receptor antagonism in the placebo and probenecid phase. Data for 
placebo at baseline were normalised to 1 and results are presented as fold of change 
from baseline. PER1 mRNA transcript levels fell over time (p<0.001 and p<0.05 
respectively). Gene transcripts for ABHD5, GR and SGK1 increased with time 
(p<0.05). Probenecid did not alter mRNA transcript levels. 
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Figure 4-17: mRNA transcript levels of glucocorticoid responsive genes in 
subcutaneous adipose tissue 
Data are mean ± SEM for mRNA transcript levels of glucocorticoid responsive genes adiponectin 
(ADIPOQ), adipose triglyceride lipase (ATGL), period circadian clock (PER1), lipoprotein lipase (LPL), 
phosphoenolpyruvate carboxykinase (PEPCK), abhydrolase domain containing protein 5 (ABHD5), 
glucocorticoid receptor (GR), mineralocorticoid receptor (MR), FK506 binding protein 5 (FKBP5), serum 
and glucocorticoid-regulated kinase (SGK1) and hormone sensitive lipase (HSL) (n=12). Data are 
expressed as a ratio to the mean of 2 housekeeping genes. Comparisons between first (solid fill) and 
second (striped fill) biopsy and between placebo (red fill) and probenecid (blue fill) phases were made 
with two -way ANOVA. PER1 transcripts fell significantly over the study period while ABHD5, GR and SGK1 
transcript levels increased. *p<0.05 **p<0.01 ***p<0.001 vs time. 
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4.4 Discussion 
In a randomised placebo-controlled crossover study of the effects of ABCC1 inhibition 
on central negative feedback and glucocorticoid occupancy of corticosteroid receptors 
in adipose tissue and skeletal muscle, we have demonstrated a central effect of 
probenecid on the HPA axis.  
This study is the first to our knowledge to measure the direct effects of ABCC1 
inhibition on glucocorticoid flux in vivo in humans. In order to achieve ABCC1 
inhibition, participants were given probenecid 1 g BID for five days prior to the study 
visits. Probenecid has historically been used as a synergistic agent to improve the 
efficacy of some antibiotics and subsequently as a uricosuric agent in the treatment of 
gout (Cunningham et al. 1981; Robbins et al. 2012). The half-life of probenecid is 
between 3-8 hours and therapeutic doses range from 0.5-3 g (Selen et al. 1982; 
Cunningham et al. 1981; Robbins et al. 2012). It has been demonstrated as an ABCC1 
inhibitor with no effect on ABCB1 and used in in vitro and in vivo studies for this 
purpose (Feller et al. 1995; Gollapudi et al. 1997; Webster & Carlstedt-Duke 2002). 
We used a dose of 1g twice daily which was taken on the morning of each study visit 
to ensure ABCC1 inhibition was maintained.  
We hypothesised that inhibition of ABCC1 would have no effect on central negative 
feedback of the HPA axis given the relative abundance of ABCB1 at the blood brain 
barrier (Reul & de Kloet 1985; Karssen et al. 2001; Raubenheimer et al. 2006).  In 
fact, our results suggest ABCC1 is significant in negative feedback with an enhanced 
activation of the HPA axis to MR and GR antagonism during ABCC1 inhibition. This 
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effect appears to be centrally mediated with a trend for increased ACTH release with 
probenecid. This suggests an increased drive of ACTH induced adrenal production 
rather than any primary effect on the adrenal or peripheral clearance of 
glucocorticoids. This may reflect increased occupancy of corticosteroid receptors in 
the pituitary during probenecid therapy and suggests ABCC1 expression is significant 
in pituitary driven HPA negative feedback.  
The significance of ABCB1 in glucocorticoid transport at the blood brain barrier was 
highlighted by Karssen et al in 2001 who demonstrated that ABCB1 limited access of 
cortisol and cortisone to the brain suggesting corticosterone played a more significant 
role in negative feedback (Karssen et al. 2001). The corticosterone: cortisol ratio was 
significantly higher in post mortem brain samples compared to plasma however they 
did not examine specific areas within the brain. It should be noted that there is ABCC1 
expression at the blood brain barrier which has been shown to have effects on drug 
efflux although expression is relatively lower than ABCB1 (Huai-Yun et al. 1998; Tan 
et al. 2000; Rao et al. 1999).   
Expression of ABCB1 and ABCC1 in the pituitary, out with the blood brain barrier, is 
less well defined. Bernstein et al investigated the vascular and extravascular 
distribution of ABC transporters in post mortem human brain samples and showed 
both ABCB1 and ABCC1 were highly expressed in the anterior pituitary (Bernstein et 
al. 2014). Given that ABCC1 exports drug conjugates of glutathione, leukotrienes and 
other organic anions, it is not unexpected that it may play a role in protecting the brain 
from exposure to these toxins (Dean et al. 2001).  
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Our data has highlighted that ABCC1 likely plays a significant role in regulating 
access of corticosterone to the pituitary. The data from Karssen et al suggests the 
higher relative expression of ABCB1 at the blood brain barrier is significant in 
regulating glucocorticoid access to the hypothalamus and higher limbic structures. The 
same does not appear to be true of the pituitary where ABCC1 appears to play a more 
significant role. It should be noted that we have not tested the effects of ABCB1 
inhibition on HPA negative feedback and without this data, we cannot conclude which 
glucocorticoid has the more proportionate effect. If ABCB1 inhibition lead to even 
greater activation of the axis, our hypothesis of the disproportionate effects of cortisol 
and corticosterone on negative feedback would still be valid. 
We cannot exclude that probenecid may also have inhibitory effects on ABCB1 
although this seems less likely. The main body of literature describing probenecid 
effects on ABC transporters would refute this but one group showed that probenecid 
reduced both mRNA and protein levels of ABCB1 in human neuroblastoma cells 
(Campos-Arroyo et al. 2016). This is an isolated report in a human tumour cell line 
which may not be true of normal human tissues. Our own data from in vitro and murine 
experiments support probenecid as an inhibitor of ABCC1 and not ABCB1 (Nixon et 
al. 2016).  
This study was designed to determine the occupancy of corticosteroid receptors by 
cortisol and corticosterone in adipose tissue and skeletal muscle in the presence and 
absence of ABCC1 inhibition. MR and GR antagonists potassium canrenoate and 
RU486 were given to block respective receptors and displace bound glucocorticoids. 
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We expected to demonstrate release of glucocorticoids from each tissue in response to 
these antagonists but in fact, we have evidence of uptake within both tissues. Our 
adipose tissue data was limited to n=7 due to technical difficulties and was therefore 
under powered so may have missed any small corticosteroid release. Our skeletal 
muscle data however was fully powered and displacement was still not demonstrated.  
Displacement of glucocorticoids across tissue can be measured, for example, in heart 
(Iqbal et al. 2014), but the increments were very small in this study and may be difficult 
to demonstrate in other tissues. We included the infusion of the tracer D2-cortisone to 
enhance sensitivity however there was no difference with either net balance or rate of 
appearance data. Detecting displacement from corticosteroid receptors requires those 
displaced glucocorticoids to exit the cell and enter the local circulation. It is, of course, 
possible that there has been displacement from GR and MR but these glucocorticoids 
remained within the cell. It is also feasible that the enhanced central effect on the HPA 
axis stimulating adrenal release of cortisol and corticosterone may have masked any 
effect of displacement due to the change in circulating concentrations.  
Another factor in the calculation of release and rate of appearance in these tissues was 
blood flow.  Skeletal muscle blood flow was higher than measured in a previous 
clinical study in healthy individuals (2.8±0.2 mL/min/100g tissue) (Hughes et al. 2012) 
but similar to a more recent study of lean and obese individuals (Anderson 2017). 
Probenecid significantly increased skeletal muscle blood flow throughout the study 
period. In addition to inhibiting ABCC1, probenecid is a potent transient receptor 
potential vanilloid 2 (TRPV2) agonist, which has a significant role in cardiac function. 
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Probenecid has been shown to be a positive inotrope and cause increased contractility 
in a murine model and may therefore affect peripheral blood flow through this 
mechanism (Rubinstein et al. 2014). In a direct comparison of the effect of probenecid 
on endothelial function however, forearm blood flow was unaltered compared to 
placebo after 7 days of 500mg BID (George et al. 2006). Our data would support the 
increased inotropic effect of probenecid leading to increased skeletal muscle blood 
flow throughout the probenecid phase.  
In adipose tissue, calculated blood flow was similar to the previous clinical study in 
healthy individuals which was reported as 5.7±1.3 mL/min/100g tissue (Hughes et al. 
2012).  Probenecid also increased adipose blood flow but not from baseline and only 
after combined receptor antagonism. This suggests a glucocorticoid-mediated 
mechanism rather than a direct effect on cardiac output. 
Although the difference in blood flow between placebo and probenecid was 
significant, the calculation for glucocorticoid rate of appearance takes blood flow into 
account for this reason and therefore is unlikely to be a major confounding factor. 
Data from subcutaneous adipose tissue biopsies were somewhat contradictory. 
Expression of GR levels increased 1.5-fold in adipose tissue at the end of the study 
period which suggests we were successful in antagonising adipose GR. The inverse 
has been shown recently with reduced GR and MR transcript levels in adipose tissue 
in the presence of high glucocorticoid concentrations (Stimson et al. 2017).  There was 
no similar effect seen with MR but potassium canrenoate was given first and any 
compensatory increase may have been transient. The glucocorticoid sensitive gene 
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PER1 fell significantly with time in both phases. PER1 encodes period circadian 
homolog 1, a vital component of the circadian clock in peripheral tissues which is 
acutely sensitive to glucocorticoids (Stavreva et al. 2009). This may be interpreted as 
successful inhibition of GR but given its circadian nature, we would need to have had 
placebo controls for canrenoate and RU486 administration to confirm this; 
unfortunately, this was considered impractical due to the invasive nature of the 
protocol. The rise in ABHD5 and SGK1 transcript levels following receptor 
antagonism are unexpected as both are glucocorticoid sensitive, the former a co-factor 
of key lipase ATGL and the latter an early transcriptional glucocorticoid target 
activated by insulin (Lord & Brown 2012; Ullrich et al. 2005). Although SGK1 is 
regulated by glucocorticoids, both acute and chronic inflammation are also able to 
induce expression (Schernthaner-Reiter et al. 2015). Both biopsies were taken from 
the same area of adipose tissue and inflammation from the initial biopsy may have 
influenced expression in the subsequent sample. Although we showed no significant 
effect of probenecid on transcript expression at baseline, there was a trend for 
expression to be higher in the probenecid phase for all genes tested.  These data 
represent n=12 as one participant had low adiposity and biopsies were not attempted 
and another had a poor yield from one sample and was therefore excluded from 
analysis. This study was powered on the basis of measuring differences in 
glucocorticoid rates of appearance rather than changes in adipose transcript levels and 
may therefore be under powered to detect any significant difference in the probenecid 
phase. 
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Our data represents the first evidence of ABCC1 regulating pituitary driven HPA 
negative feedback in vivo in humans. While we were unable to detect effects in 
peripheral tissues, our data further highlights the discrete roles of cortisol and 
corticosterone in humans.  
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5.1 Introduction 
The transmembrane transporter ABCC1 transports corticosterone but not cortisol and 
is highly expressed in adipose tissue and skeletal muscle which are important 
metabolic tissues (Webster & Carlstedt-Duke 2002; Nixon et al. 2016). Conversely, 
the transporter ABCB1 exports cortisol but not corticosterone and is expressed at the 
blood brain barrier, leading to accumulation of corticosterone in the brain and CSF 
(Karssen et al. 2004; Raubenheimer et al. 2006). We have shown in the previous 
chapter that acute HPA axis feedback may be modulated by ABCC1 at the pituitary. 
This may have implications in patients requiring glucocorticoid replacement therapy 
and suppression of the HPA axis drive such as in CAH. 
CAH is a common genetic endocrine condition of impaired steroidogenesis most 
frequently caused by mutation in the CYP21A2 gene encoding the enzyme 21-
hydroxylase (Han et al. 2014). Deficiency in 21-hydroxylase causes disrupted cortisol 
synthesis and impaired negative feedback of the HPA axis leading to subsequent over-
production of 17-OHP and adrenal androgens. Glucocorticoid replacement therapy is 
given to replace glucocorticoid and suppress androgen over-production. Many patients 
also have mineralocorticoid deficiency due to 21-hydroxylase playing a key role in 
aldosterone production. Observational studies have shown significant morbidity and 
mortality in this patient cohort with high prevalence of cardiovascular disease and 
osteoporosis (Arlt et al. 2010). Mortality is higher than matched controls and quality 
of life is poor (Han, Krone, et al. 2013; Falhammar et al. 2014). There is a lack of 
consensus on optimal management of this condition and current therapies with 
synthetic glucocorticoids such as dexamethasone are associated with poor health 
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outcomes without necessarily improving markers of disease control (Han, Stimson, et 
al. 2013). The most commonly used glucocorticoid treatment is hydrocortisone (Forss 
et al. 2012) and newer modified release preparations have been developed to try and 
address these issues however metabolic side effects on insulin resistance and bone are 
still observed (Mallappa et al. 2015). 
The clinical study presented in this chapter aimed to test the hypothesis that 
corticosterone replacement is equally effective as cortisol at suppressing ACTH and 
adrenal androgens and has less adverse metabolic side effects in individuals with CAH. 
We therefore compared the effects of placebo, corticosterone and hydrocortisone 
infusions on biochemical markers of disease control and circulating metabolic 
biomarkers in vivo in a randomised crossover study. Assessment of the dose-response 
effect was performed using 2-step ramped steady state infusions of placebo, 
hydrocortisone and the previously validated stable isotope tracer, 2,2,4,6,6,17α,21,21-
[2H]8-corticosterone (D8-corticosterone) (Mackenzie 2015).  
Unfortunately, as is often the case in clinical studies, unavoidable delays lead to the 
late start of this study. Due to time limitations, I was unable to complete the study 
before the end of my research period. While at the time of writing this study is ongoing, 
I present interim data of the 8 participants who have completed the full protocol. 
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5.2 Methods 
5.2.1 Ethical and research governance approvals 
This study was approved by the South-East Scotland Research Ethics Committee 02 
(16/SS/0045) and NHS Lothian Research and Development committee (2016/0069). 
Approval was also secured from NHS Greater Glasgow and Clyde Research and 
Development committee (GN16ME098) to allow recruitment from both health boards 
due to the small number of patients in Lothian. Research support approvals were 
secured with the Royal Infirmary of Edinburgh Clinical Research Facility (RIECRF) 
and NHS Lothian laboratories at the Royal Infirmary of Edinburgh (RIE). 
5.2.2 Study design 
A double blind randomised crossover study was performed in patients with CAH 
comparing the biochemical and metabolic effects of corticosterone, cortisol and 
placebo infusion over 5.5 hours. Participants attended on three occasions after 
overnight fast, receiving each drug or placebo in random order. Cortisol 
(hydrocortisone) and D8-corticosterone were infused to achieve 400 then 800 nmol/L 
to reflect the typical plasma concentration after 5 and 10mg of hydrocortisone 
replacement (Debono et al. 2009). 6,6-[2H]2-glucose (D2-glucose) and 1,1,2,3,3-[
2H]5-
glycerol (D5-glycerol) were infused to measure glucose metabolism and lipolysis 
respectively. Blood pressure was measured regularly and pulse wave analysis and 
velocity were measured during low and high glucocorticoid concentrations. An 
adipose tissue biopsy was taken at the end of each visit to compare glucocorticoid 
specific transcripts. 
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5.2.3 Participants 
Participants (n=8, 6 female) were identified from patient databases in Glasgow and 
Edinburgh and were approached at their clinic appointment by a member of the direct 
care team or contacted by post and sent the participation information sheet along with 
a cover letter. Subjects were then invited for a screening visit to discuss the study in 
detail and to obtain written informed consent. Eligibility was assessed through 
acquisition of relevant medical history, clinical examination and baseline blood tests.  
5.2.3.1 Inclusion criteria 
o Aged 18-80 years 
o Male or female 
o Diagnosed with classic CAH secondary to 21-hydroxylase deficiency 
o On glucocorticoid replacement therapy for CAH 
o Blood pressure greater than 90/50 mmHg at screening 
5.2.3.2 Exclusion criteria 
o On additional oral, inhaled or topical glucocorticoids for an unrelated 
condition 
o Abnormal screening bloods (full blood count (FBC), urea and electrolytes 
(U+E), thyroid function tests (TFTs), liver function tests (LFTs), random 
glucose) 
o Recent admission with adrenal crisis in preceding 6 months 
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5.2.4 Sample size calculation 
Data from a study involving 10 patients with Addison’s disease were used to calculate 
sample size for this study (Nixon et al. 2016). In that study, patients were given either 
D8-corticosterone or 9,11,12,12-[2H]4-cortisol (D4-cortisol) and ACTH levels were 
measured at frequent intervals. Adipose tissue biopsies were obtained to look at 
downstream glucocorticoid signalling.  Using these results, 16 patients provides 
greater than 85% power with a significance value of 0.05 to detect a difference of 15% 
in suppression of ACTH (this was observed in the pilot study) and over 90% power to 
detect a 30% increase in adipose tissue PER1 expression (this was increased by 60% 
in the previous work). 
5.2.5 Clinical protocol 
5.2.5.1 Study visits 
Participants attended for three study visits and received placebo, cortisol and D8-
corticosterone infusions in random order at least three weeks apart to allow washout 
between treatments, resolution of abdominal bruising and recovery of blood loss 
(Figure 5-1). Randomisation was undertaken by an independent researcher at the 
University of Edinburgh and both patient and study researcher were blinded until 
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Figure 5-1: Study design 
 
Participants attended the RIECRF at 8am having fasted from 10pm the night before. 
On the previous evening, usual evening glucocorticoid treatment was taken before 
6pm. Normal morning glucocorticoid medication was omitted but all other medication 
including fludrocortisone was continued as usual. On arrival, participants had height, 
weight and blood pressure measured. Lean body mass and fat mass using bioelectrical 
impedance analysis was also measured as described in section 3.4.2.4.  
Each participant was cannulated using an aseptic technique at two sites. A 20G cannula 
(Braun, Sheffield, UK) was inserted in the antecubital fossa of one arm for infusion of 
placebo/cortisol/corticosterone and tracers and a further retrograde 20G cannula 
(Braun, Sheffield, UK) was inserted in the dorsum of the contralateral hand for 
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sampling (Figure 5-2). The hand was placed in a hot box (manufactured in-house) 
heated to 55-60C for 5 minutes prior to sampling in order to obtain arterialised 
samples. The sampling cannula was kept patent with a slow infusion of 0.9% Saline. 
Blood samples were taken from the retrograde cannula to measure glucocorticoids, 
androgens, 17-hydroxyprogesterone, ACTH, endogenous and tracer glucose and 
glycerol, insulin, non-esterified fatty acids and bone markers. 
Figure 5-2: Anatomical placement of cannulas and sphygmomanometer cuff 
 
At t-30 minutes, D2-glucose and D5-glycerol were given as a bolus of 1.66 
μmol/kg/min and 17.6 μmol/kg/min respectively over 5 minutes followed by a 
constant infusion at 0.22 μmol/kg/min and 0.11 μmol/kg/min respectively for 355 
minutes (Figure 5-3). At t=0 minutes, either placebo, hydrocortisone (0.94 mg) or D8-
corticosterone (2.55 mg) was given as a bolus over 5 minutes then an infusion 
(hydrocortisone 2.71 mg at 44.8 ml/hr and D8-corticosterone 17.3 mg at 47.1 ml/hr) 
to achieve a concentration of 400nM for 145 minutes. A further identical bolus was 
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given at t+150 minutes followed by an infusion (hydrocortisone 6.53 mg at 89.6 ml/hr 
and D8-corticosterone 41.77 mg at 94.2 ml/hr) to achieve a steady state concentration 
of 800nM until the end of the study. Blood sampling was every 30 minutes from t-30 
minutes until t+120 minutes when the frequency increased to every 7.5 minutes until 
t+150 minutes. Sampling returned to 30 minute intervals thereafter. At t+270 minutes, 
7.5 minute sampling resumed until the final sample at t+300 minutes. Blood pressure 
was measured hourly using an average of two readings. Pulse wave analysis and 
velocity were measured at t+100 minutes and t+250 minutes. An abdominal fat biopsy 
was taken at t+300 minutes as described in section 4.2.5.5. At t+330 minutes, the 
infusions were discontinued, all cannulae removed, participants were given lunch and 
allowed home.  
5.2.5.2 Sample collection and processing 
Samples were obtained in plasma lithium heparin (7.5 mL), serum gel (4.9 or 7.5 mL) 
and potassium EDTA tubes (2.7 or 4.9 mL, all Monovette®, Starstedt, Numbrecht, 
Germany). Samples were gently mixed by inverting several times. All samples were 
subject to centrifugation immediately after sampling, separated and stored at -80°C for 
analysis. Lithium heparin and serum samples were subject to centrifugation at 2000 g 
for 10 minutes at 4 °C and EDTA samples at 2500 g for 10 minutes at 4 °C. 
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Figure 5-3: Study diagram 
Blood pressure (BP) was measured hourly at time points indicated with X. Pulse wave analysis (PWA) and 
pulse wave velocity (PWV) were measured at the end of the low and high glucocorticoid concentration 
period. Blood samples were taken at 30 minute intervals (blue arrows) and at 7.5 minute intervals (red 
arrows) at the end of the low and high glucocorticoid concentration period. 
 
5.2.5.3 Preparation of stable isotope tracers  
D2-glucose and D5-glycerol (Euroisotop, Saint-Aubin, France) were prepared in water 
for injection, filtered by Tayside Pharmaceuticals to produce sterile stock solution and 
stored at -20°C for maximum 12 months. Solutions were prepared in the RIECRF on 
the morning of each study visit.  
D8-corticosterone (Cambridge Isotope Laboratories, Andover, MA) was prepared in 
pharmaceutical grade ethanol/water (90/10%) and filtered by Tayside Pharmaceuticals 
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to produce sterile stock solution. This was stored at -20°C for maximum 12 months.  
Solutions were prepared in the RIECRF on the morning of each study visit.  
5.2.5.4 D2-glucose and D5-glycerol infusion protocol 
The deuterated glucose and glycerol infusions were infused on a weight dependent 
basis. If the participant was under 73 kg, the infusion was made up in 500 mL sodium 
chloride 0.9% w/v while those who weighed over 73 kg had infusions made up in 1000 
mL sodium chloride 0.9% w/v.  
D5-glycerol stock solution contained 330 mg in 33 mL (10mg/mL) of water for 
injection. D2-glucose stock solution contained 1.76 g in 22 mL (80mg/mL) of water 
for injection.  
The bolus dose was prepared with 2 mL of 10 mg/mL D5-glycerol stock solution added 
to 13 mL sodium chloride 0.9% w/v followed by 5 mL of 80 mg/mL D2-glucose stock 
solution. A final concentration of 1 mg/mL of D5-glycerol and 20 mg/mL of D2-
glucose was achieved. An intravenous bolus of 17.6 μmol/kg/min and 1.66 
μmol/kg/min for glycerol and glucose respectively was given over 5 minutes. 
The 500 mL infusion was prepared with 30 mL of 10 mg/mL D5-glycerol and 14 mL 
of 80 mg/mL D2-glucose added to 456 mL of sodium chloride 0.9% w/v to give a final 
concentration of 0.6 and 2.24 mg/mL respectively.  
The 1000 mL infusion was prepared with 60 mL of 10 mg/mL D5-glycerol and 28 mL 
of 80 mg/mL D2-glucose added to 912 mL of sodium chloride 0.9% w/v to give the 
same final concentration of 0.6 and 2.24 mg/mL respectively.  
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5.2.5.5 D8-corticosterone infusion protocol 
D8-corticosterone stock solution (Cambridge Isotopes, Andover, MA) contained 83.6 
mg in 5.5 mL (15.2mg/mL) of ethanol/water (90/10%).  
The infusion was prepared with 5 mL of 15.2 mg/mL stock solution added to 495 mL 
sodium chloride 0.9% w/v to give a final concentration of 0.152 mg/mL. An 
intravenous bolus of 2.55 mg was given over 5 minutes at 30.6 mg/hr followed by 17.3 
mg over 145 minutes at 7.16 mg/hr. A further bolus of 2.55 mg over 5 minutes was 
given at 150 minutes followed by 41.77 mg over 175 minutes at 14.32 mg/hr.  
5.2.5.6 Hydrocortisone infusion protocol 
Hydrocortisone sodium phosphate (Concordia, Ontario, Canada) contained 100 mg in 
1 mL of sterile aqueous solution (100 mg/mL).  
The infusion was prepared with 1 mL of 100 mg/mL hydrocortisone added to 19 mL 
water for injection to give a final concentration of 5 mg/mL. 2.5 mL of this solution 
was added to 497.5 mL sodium chloride 0.9% w/v to give a final concentration of 0.025 
mg/mL. An intravenous bolus of 0.94 mg was given over 5 minutes at a rate of 11.28 
mg/hr followed by 2.71 mg over 145 minutes at 1.12 mg/hr. A further bolus of 0.94 
mg over 5 minutes was given at 150 minutes followed by 6.53 mg over 175 minutes 
at 2.24 mg/hr.  
5.2.5.7 Placebo infusion protocol 
A 500 mL bag of sodium chloride 0.9% w/v (Baxter, Newbury, UK) was infused at 
200 mL/hr for 5 minutes then 45 mL/hr for 145 minutes. At 150 minutes, a further 
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bolus of 200 mL/hr over 5 minutes was given and the infusion continued at 90 mL/hr 
until the end of the study. 
5.2.5.8 Pulse wave analysis 
Pulse wave analysis (PWA) was performed at the radial artery by applanation 
tonometry using a SphygmoCor device (AtCor Medical Inc, Illinois, USA). The radial 
pulse waveform was recorded and central aortic pressure was derived using an 
automated generalised transfer function (O’Rourke & Gallagher 1996). The 
augmentation index was calculated as the increment in pressure from the shoulder of 
the ascending pressure wave to the peak of the reflected wave (Figure 5-4). To correct 
for the effect of pulse rate, augmentation index results were normalised for a heart rate 
of 75 bpm.  
5.2.5.9 Pulse wave velocity 
Carotid-femoral pulse wave velocity (PWV) was quantified using the SphygmoCor 
device (AtCor Medical Inc, Illinois, USA). The distance between the carotid and 
femoral arterial capture sites and the sternal notch were measured. Applanation 
tonometry was performed at each site and the arterial waveform was recorded. 
Simultaneous electrocardiogram monitoring was performed and the R-wave was used 
as a reference point for PWV calculations. PWV was calculated from the difference in 
transit time of the pulse wave to the carotid and femoral arteries. 
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Figure 5-4: Aortic pressure wave 
The aortic pressure wave is derived from the radial pulse wave using a validated algorithm and is the sum 
of all forward and backward waves. P1 represents the first wave and P2 is the reflected second wave. The 
augmentation pressure (AP) is the contribution of the reflected wave to pulse pressure (PP). 
Augmentation index (AIx) represents the relationship between augmentation pressure and pulse 
pressure.  
 
5.2.5.10 Biopsy of subcutaneous abdominal fat 
A biopsy of subcutaneous fat was undertaken at t+300 minutes. This was carried out 
as described in section 4.2.5.5. Up to three aliquots were taken. 
5.2.6 Sample analysis 
5.2.6.1 Analytes 
In addition to the labelled and unlabelled steroids in section 2.3.1.2, testosterone, 
androstenedione, 17-OH progesterone and D8-corticosterone were analysed. The 
above standards were supplied by Cambridge Isotopes. 
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5.2.6.2 Preparation of standard curves 
Standard curves were prepared for all analytes across a range of 0.01-100 ng with D4-
cortisol and epi-corticosterone added as internal standards (10 ng) (Figure 5-1). 1% 
bovine serum albumin (BSA) was used instead of water as a diluent and 0.5M 
ammonium hydroxide was used to make up each standard to 400 μL.  
Table 5-1: Standard curve analytes and internal standards  







Cortisol 0.01-100 D4-cortisol 10 
Cortisone 0.01-100 D4-cortisol 10 
Corticosterone 0.01-100 Epi-corticosterone 10 
11-
dehydrocorticosterone 
0.01-100 Epi-corticosterone 10 
17-OHP 0.01-100 D4-cortisol 10 
Testosterone 0.01-100 D4-cortisol 10 
Androstenedione 0.01-100 D4-cortisol 10 
 
5.2.6.3 Extraction of plasma samples 
Plasma samples were extracted as described in section 2.3.3 using 0.5M ammonium 
hydroxide instead of water to make up the solution. Internal standards D4-cortisol and 
epi-corticosterone (10 ng) were added to each sample.  
5.2.6.4 LC-MS/MS analysis 
Samples were analysed using the glucocorticoid and androgen assay as described in 
section 2.3.6.3. 
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5.2.7 Data analysis 
LC-MS/MS data were analysed as described in section 2.3.7. Clearance of infused 
glucocorticoids cortisol and D8-corticosterone were calculated using Equation 5-1. 
The first period of steady state was t+30-150 minutes and the second period was t+180-
300 minutes. 
Equation 5-1 
𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 (𝐿 min ) =  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛 (𝑛𝑚𝑜𝑙 𝑚𝑖𝑛⁄ )
𝑆𝑡𝑒𝑎𝑑𝑦 𝑆𝑡𝑎𝑡𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑚𝑜𝑙 𝐿)⁄
⁄  
 
In order to compare glucocorticoid effect on disease control, percentage change in 
ACTH from baseline was calculated and plotted against detected glucocorticoid 
concentration. Linear regression was performed for each participant and validity was 
confirmed by comparison against zero.  For each participant, the dose of glucocorticoid 
required to suppress ACTH by 50% was calculated and mean ± SEM for cortisol and 
D8-corticosterone is presented. Data were analysed using GraphPad Prism® Version 
6.01.   
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5.3 Results 
We plan to recruit 16 participants to this study and both recruitment and study visits 
continue. The data presented in this chapter are for the 8 participants who have 
completed all three study visits to date. Analysis of D2-glucose and D5-glycerol is 
incomplete and has been omitted. The LC-MS/MS method included testosterone 
however this data was not robust and requires further analysis. We will complete 
plasma analysis with bone markers of resorption and formation, CTX and P1NP 
respectively. Adipose biopsy samples have not yet been analysed. 
5.3.1 Characteristics of study participants 
Characteristics of participants are presented in Table 5-2. Participants were taking a 
variety of glucocorticoid therapies at different doses and times of the day: 
hydrocortisone (37.5%), prednisolone (50%) or a combination (12.5%). Concomitant 
treatment with fludrocortisone was taken by 87.5% of participants.  
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Table 5-2: Participant demographic data 
Data are for n=8 (6 female). Daily equivalent hydrocortisone dose calculated using British National 
Formulary conversion chart where prednisolone 5mg = hydrocortisone 20mg. 
 Mean ± standard 
deviation 
Range 
Age (years) 39.1±13.0 25-59 
Height (m) 1.6±0.1 1.4-1.7 


























5.3.2 Plasma glucocorticoids 
Measurement of cortisol and corticosterone concentrations during the infusions 
indicated ramped steady state had been achieved (Figure 5-5). Baseline cortisol 
concentrations were low (mean ± SEM 35.71 ± 12.12 nmol/L) and D8-corticosterone 
was undetectable. Steady state concentrations of corticosterone were similar to those 
intended, however cortisol concentrations were substantially lower than planned. 
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Clearance of cortisol and D8-corticosterone were calculated using Equation 5-1 and 
are shown in Table 5-3. 
Figure 5-5: Plasma glucocorticoid concentrations 
Data are mean ± SEM for plasma cortisol (blue line) and corticosterone (red line) concentrations at time 
points -30-300 minutes (both n=8). Intended circulating concentration indicated with black dashed line.  
 
Table 5-3: Plasma glucocorticoid clearance 








30-150 0.19±0.01 0.72±0.04 
180-300 0.23±0.01 0.92±0.06 
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5.3.3 Plasma ACTH concentration 
Plasma ACTH for each phase is shown in Figure 5-6. ACTH at baseline was elevated 
above the normal range in all phases and fell with time during both cortisol and D8-
corticosterone phases. There appeared to be no clear change with time during the 
placebo phase. 
Figure 5-6: Plasma ACTH 
Data are mean ± SEM for plasma ACTH for placebo (green line), cortisol (blue line) and D8-corticosterone 
(red line) phases at time points -30-300 minutes (all n=8). The blue shaded area represents the first steady 
state glucocorticoid dose and the grey area is the second higher dose. 
 
 
The percentage change in ACTH from baseline was calculated and plotted against 
achieved plasma concentration of glucocorticoid (Figure 5-7). Linear regression was 
applied to each individual plot and the glucocorticoid concentration at which 50% 
suppression of ACTH was achieved is summarised in Table 5-4. 
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Figure 5-7:  Linear regression of % suppression ACTH from baseline and plasma 
glucocorticoid concentration. 
Data are for n=7 as subject 8 was an outlier. 
 
Table 5-4: Linear regression of percentage suppression ACTH from baseline and 
plasma glucocorticoid concentration. 
Slope of linear regression for cortisol (F) and D8-corticosterone (D8B) for each participant were calculated 
and goodness of fit is shown with R2 value. Those slopes starred (*) were significantly different from zero. 
50% ACTH suppression was calculated from slope equations using y= -50. This was calculated only for 
slopes significantly different to zero. 
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5.3.4 Plasma 17-OHP and androstenedione concentration 
Plasma 17-OHP and androstenedione were measured in arterialised plasma samples 
for each phase and are shown in Figure 5-8. Both were elevated above the normal 
range at baseline. 17-OHP appeared to be suppressed in both cortisol and D8-
corticosterone phases with time and remained elevated in placebo phase. 
Androstenedione concentrations followed a similar pattern.  
Figure 5-8: Plasma 17-OHP and androstenedione 
Data are mean ± SEM for A) plasma 17-OH progesterone (17OHP) and B) androstenedione in arterialised 
samples at time points -30-300 minutes during placebo (green line), cortisol (blue line) and D8-
corticosterone (red line) phases (all n=8). The blue shaded area represents the first steady state 
glucocorticoid dose and the grey area is the second higher dose. 
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5.3.5 Metabolic markers of glucocorticoid action 
5.3.5.1 Blood pressure 
Blood pressure was measured at regular intervals during the study visit and are 
presented in Figure 5-9. Both systolic and diastolic blood pressure appeared similar in 
each phase. 
5.3.5.2 Pulse wave assessment 
Both pulse wave analysis and velocity appeared unchanged over the study period and 
in each phase (Figure 5-10).  
Figure 5-9: Blood pressure 
Data are mean ± SEM for systolic (unbroken line) and diastolic (dashed line) blood pressure (mmHg) for 
placebo (green lines), cortisol (blue lines) and D8-corticosterone (red lines) (n=8). The blue shaded area 
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Figure 5-10: Pulse wave analysis and velocity 
Data are mean ± SEM for A) pulse wave analysis and B) pulse wave velocity during placebo (green fill), 
cortisol (blue fill) and D8-corticosterone (red fill) phases (all n=8). Pulse wave analysis was measured using 
augmentation index (normalised to HR 75) and pulse wave velocity using metres per second (m/s). 
 
5.3.5.3 Insulin 
Plasma insulin was measured at intervals throughout the study period (Figure 5-11). 
There was a suggestion that the corticosterone phase is associated with lower 
circulating insulin compared to placebo and cortisol phases.  
5.3.5.4 Non-esterified fatty acids 
Non-esterified fatty acids (NEFAs) were measured regularly throughout the study 
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Figure 5-11: Plasma insulin 
Data are mean ± SEM for plasma insulin during placebo (green line), cortisol (blue line) and D8-
corticosterone (red line) phases at time points -30-300 minutes (n=8). The blue shaded area represents 
the first steady state glucocorticoid dose and the grey area is the second higher dose. 
 
Figure 5-12: Plasma NEFAs 
Data are mean ± SEM for plasma NEFAs during placebo (green line), cortisol (blue line) and D8-
corticosterone (red line) phases at time points -30-300 minutes (n=8). The blue shaded area represents 
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5.4 Discussion 
This randomised placebo-controlled crossover study comparing the biochemical and 
metabolic effects of cortisol and corticosterone in CAH is ongoing and the data we 
present represents the midway point. We have chosen not to perform an interim 
statistical analysis as we are powered for 16 participants and as such the results would 
likely be misleading. Therefore, the data is presented without statistical analysis.  
We chose to study patients with CAH as they are the group who could benefit most 
from corticosterone therapy. Outcomes in patients with CAH are poor with current 
therapy and we hypothesised that corticosterone may provide adequate glucocorticoid 
replacement and adrenal androgen suppression with fewer metabolic side effects. In 
comparison with the UK cohort studied as part of the Congenital Adrenal Hyperplasia 
Adult Study Executive (CaHASE), our subjects are also on a variety of glucocorticoid 
replacement regimens, with prednisolone the most common. We had no patients taking 
dexamethasone in contrast to 24% of males and 17% of females in CaHASE (Arlt et 
al. 2010). This may reflect changing prescribing tendencies as more evidence suggests 
dexamethasone is associated with greater insulin resistance and poor metabolic 
outcomes (Han, Stimson, et al. 2013). Most of our patients also required 
mineralocorticoid replacement with 87.5% on fludrocortisone, compared to 72-82% 
of the CaHASE cohort. In addition, our patient group are similarly short in height with 
raised BMI in line with the UK cohort. 
It is striking from the analysis of infused glucocorticoid concentration that our 
intention of matching cortisol and corticosterone plasma concentrations was 
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unsuccessful. Cortisol reached a steady state of approximately 250 nmol/L initially 
and only rose to approximately 400 nmol/L during the second steady state period. In 
contrast, plasma D8-corticosterone concentrations were much closer to our intended 
steady state concentrations of 400 nmol/L and 800 nmol/L. The reasons for this 
discrepancy are unclear.  
We considered the possibility that this result may have been due to analytical error 
during the LC-MS/MS analysis. The analysis was revisited and repeated using freshly 
prepared standard curves and a selection of random samples. This confirmed the 
original results.  
A further possibility was that incorrect assumptions were made in calculating the rate 
of cortisol infusion.  This calculation was based on a previous in vivo study in patients 
with Addison’s disease (Nixon et al. 2016). In this study, D4-cortisol rather than 
hydrocortisone was infused to achieve three ramped steady state concentrations at 25, 
100 and 250 nmol/L. ACTH was only marginally suppressed at the end of the study 
period and these concentrations were relatively low when compared to physiological 
concentrations. Although D4-cortisol and hydrocortisone are similar, they are not 
interchangeable when considering pharmacokinetics as clearance of D4-cortisol is 
more rapid when compared to cortisol (0.46 vs 0.28 L/min respectively) (Andrew et 
al. 2002). This is due to regeneration of D3-cortisol rather than D4-cortisol from D3-
cortisone unlike the reversible interconversion of cortisol and cortisone via 11β-HSD. 
With this in mind, it might be expected that we would have given more hydrocortisone 
then necessary and achieved greater than planned steady state concentrations however 
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the opposite is true. It is not clear why this is the case and may suggest an alternative 
explanation for these findings. 
A final consideration is that patients with CAH have altered glucocorticoid 
metabolism. These patients have genetically disrupted steroidogenesis and it is 
possible that they handle glucocorticoids differently to healthy individuals. While 
cortisol pharmacokinetics have not been extensively investigated in CAH patients, 
there is considerable recent data comparing conventional and modified release 
preparations of hydrocortisone (Newell-Price et al. 2008; Verma et al. 2010; Mallappa 
et al. 2015). This is summarised by Mallappa et al and shows similar area under the 
curve concentrations over 24 hours for modified release hydrocortisone in CAH and 
healthy controls. There is limited literature directly measuring clearance in this group 
of patients but Charmandari et al have investigated cortisol pharmacokinetics in pre-
pubertal, pubertal and post-pubertal patients with CAH. In this study, cortisol 
clearance in pre- and post-pubertal participants (0.25 and 0.29 L/min) were similar to 
published values in healthy individuals. During puberty, there was an observed 
increase in cortisol clearance (0.43 L/min) which was hypothesised to be secondary to 
the other endocrine changes occurring during this period (Charmandari et al. 2001). 
The clearance of cortisol in healthy individuals is estimated at between 0.28 and 0.33 
L/min (Andrew et al. 2002; Stimson et al. 2007) and this is similar to that calculated 
by Charmandari et al in the post-pubescent phase. The calculated clearance of cortisol 
in our study is marginally reduced at 0.19-0.23 L/min and if anything, one might 
expect accumulation of cortisol. It seems likely therefore that we have under-estimated 
the hydrocortisone dose required to achieve our target plasma concentrations.    
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While the achieved glucocorticoid concentrations differ during each steady state 
period, a comparison can be made of the plasma concentration of cortisol and 
corticosterone required to suppress biochemical markers of CAH by 50%. This could 
be analysed with either ACTH or adrenal androgens however ACTH was used as a 
more direct marker of suppression of the HPA axis. Using linear regression, 
glucocorticoid concentration was plotted against percentage suppression of ACTH. 
One participant had very low concentration of ACTH from baseline and throughout 
each study visit. This may reflect a prolonged effect of glucocorticoid treatment 
despite taking their evening dose prior to 6pm the night before or simply non-
compliance with study instructions. As such, glucocorticoid concentrations for 50% 
reduction in ACTH in this participant could not be calculated. One further participant 
was an outlier in the cortisol phase and had a slower response with ACTH initially 
rising before falling. This meant the linear regression was not significant and could not 
be analysed. 
From the data available, the concentration of corticosterone required to suppress 
ACTH by 50% is higher than cortisol which may suggest corticosterone is less potent 
than cortisol. It is difficult to make any clear conclusions at this stage however as this 
represents only half the intended data. While this initial data suggests corticosterone 
may be less potent than cortisol, it does show corticosterone has a suppressive effect 
on the HPA axis which has not previously been demonstrated in CAH patients. This 
is supported by the adrenal androgen data where both glucocorticoid phases suppress 
17-OHP and androstenedione to normal values by the end of the study period. 
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At this stage, there does not appear to be any clear difference in metabolic markers 
between study visits although any difference is likely to be small and may not yet be 
apparent. There are some limitations in assessing this response, in particular, the time 
of exposure to glucocorticoid and the likelihood of seeing a difference in effect. The 
difference in our achieved glucocorticoid concentrations will also complicate analysis. 
While we can compare the dose achieved in the first phase of D8-corticosterone and 
the second phase of cortisol, there will also be a significant impact of time which will 
not be comparable. The placebo phase will be useful in controlling for the normal 
diurnal variation of these markers. 
The mechanism of glucocorticoid effect on blood pressure is likely to be multifactorial 
mediated by renal sodium retention, plasma volume expansion and increased 
peripheral resistance (Walker 2007). Most studies assessing impact of glucocorticoids 
on blood pressure look at outcomes over a much longer period of time with follow up 
assessed after months rather than hours (Mallappa et al. 2015; Giordano et al. 2016). 
It is therefore possible that we will not see any significant difference in blood pressure 
in this short 5.5 hour study period. 
Non-invasive measures of cardiovascular parameters are useful in assessing the 
mechanism of increased cardiovascular risk. PWV is a gold standard measure of 
arterial stiffness and is an independent predictor of cardiovascular events. A meta-
analysis of studies which evaluated PWV found an increase by 1 m/s was associated 
with 15% increase in total cardiovascular events (Vlachopolous et al. 2010). Similarly, 
PWA measured by the augmentation index is a measure of left ventricular systolic 
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loading and a surrogate marker of arterial stiffness. Another meta-analysis by the same 
authors demonstrated that a 10% increase in augmentation index was associated with 
a 30% increased risk of cardiovascular events (Vlachopoulos et al. 2010). Our results 
show no obvious difference between groups at present but this is a sensitive marker of 
cardiovascular risk and comparing the percentage change with glucocorticoid dose 
would be a clinically useful evaluation. A recent study investigated the effect of a short 
term (7 days) increase in glucocorticoid replacement dose on insulin sensitivity with 
change in pulse wave analysis as the primary outcome (Petersons et al. 2014). They 
reported no change in augmentation index which perhaps highlights the need for longer 
term studies before an effect will be observed. 
In the previous comparison of cortisol and corticosterone in Addison’s disease, 
circulating metabolic markers, insulin and NEFAs were unchanged during the study 
period. Our study benefits from the addition of a placebo phase to show baseline 
effects on these markers without circulating glucocorticoids.  
There is a trend for insulin to fall over the study period when exposed to corticosterone 
in comparison to cortisol. The placebo phase appears to fall with time too but to a 
lesser extent. Considering the corticosterone plasma exposure is almost double that of 
cortisol, this would be a significant outcome should the final results be similar.  
NEFAs appear to increase gradually over the study period but there is no clear 
divergence from either glucocorticoid phase. Previous studies have shown differing 
effects of glucocorticoids on lipolysis and insulin secretion with most effect seen after 
several hours of supra-physiological glucocorticoid exposure (Dinneen & et al. 1993; 
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Djurhuus et al. 2002). A recent study has shown short term exposure to cortisol at 
similar concentration to those achieved in this study had no effect on lipolysis (Stimson 
et al. 2017).  
In summary, our interim results demonstrate that corticosterone is a potential treatment 
for CAH with evidence it suppresses ACTH drive and subsequent adrenal androgen 
production. There does not appear to be any difference in metabolic markers between 
cortisol and corticosterone at this stage and it may be challenging to compare the 
metabolic effects with the difference in achieved glucocorticoid concentrations. Final 
analysis with a full data set will determine whether corticosterone is equipotent to 
cortisol and whether any difference in metabolic side effects can be detected. As 
discussed above, a number of the metabolic effects we are interested in preventing are 
best assessed after a longer term exposure to glucocorticoid therapy. The next step in 
our investigation of corticosterone as an alternative to cortisol would be to develop an 
oral formulation which could be taken over a period of months and compared to current 
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Chapter 6: Conclusions 
Despite being the first glucocorticoid identified by Hench, Kendall and Reichstein in 
1937, the role of corticosterone in humans remains poorly defined. Circulating at 
relatively low plasma concentration, it has long been assumed to have little role over 
and above cortisol, the more abundant glucocorticoid in humans. Increasingly, 
evidence is emerging of distinct tissue-specific regulation of these glucocorticoids, 
particularly by the differential expression of ABC transporters ABCB1 and ABCC1 
which selectively export cortisol and corticosterone respectively (Webster & 
Carlstedt-Duke 2002; Karssen et al. 2001; Raubenheimer et al. 2006). We propose an 
alternative HPA axis which accounts for the actions of both glucocorticoids in different 
tissues. The higher relative expression of ABCB1 at the blood brain barrier excluding 
cortisol but not corticosterone suggests corticosterone may have a more significant 
role in negative feedback of the HPA axis. Increased expression of ABCC1 in adipose 
tissue and skeletal muscle suggests cortisol is the principal glucocorticoid acting in 
these tissues with corticosterone actively exported. We hypothesise that corticosterone 
would therefore be a suitable alternative glucocorticoid replacement therapy in patients 
with Addison’s disease and CAH. Doses of corticosterone required to suppress the 
HPA axis may be relatively lower than current standard treatment with hydrocortisone. 
The presence of ABCC1 in tissues such as adipose and skeletal muscle may protect 
these tissues from accumulation of corticosterone and subsequently lead to fewer 
metabolic side effects. 
The studies presented in this thesis explore the differences between cortisol and 
corticosterone in different human biological samples and further characterise the role 
of ABCC1 in central negative feedback of the HPA axis and in corticosteroid receptor 
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occupancy of peripheral tissues. The first human data using corticosterone as a 
glucocorticoid replacement therapy in patients with CAH is also presented. 
Our data highlights differences in relative cortisol and corticosterone concentrations 
within different biological samples. Measuring glucocorticoids in hair is increasingly 
being used as an effective measure of long term glucocorticoid exposure. 
Corticosterone had never, to our knowledge, been measured in hair and we anticipated 
this may be difficult due to the already low concentration of cortisol in previous reports 
(Raul et al. 2004; Manenschijn et al. 2011). Preliminary data from a single individual 
suggest corticosterone concentration is very low in hair and routine measurement is 
unlikely to be feasible due to the large volume of sample required. Further 
measurements in more subjects would be necessary to confirm these findings.  
Our initial investigation of salivary corticosterone suggested a lack of diurnal rhythm 
in comparison to cortisol. In a clinical study obtaining paired plasma and saliva 
samples over a 14-hour period in healthy individuals, we were able to investigate the 
relationship between plasma and saliva corticosterone in humans for the first time 
using LC-MS/MS. Salivary corticosterone concentration is much lower than cortisol 
with no discernible circadian rhythm nor any correlation with plasma concentrations. 
Plasma corticosterone however has a similar circadian rhythm to cortisol and 
correlates well with salivary 11-dehydrocorticosterone which was present in higher 
concentration than corticosterone. Our results underline the role of 11β-HSD2 in the 
parotid gland with 11-dehydrocorticosterone a better measure of plasma 
corticosterone, similar to the relationship between salivary cortisone and plasma 
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cortisol (Perogamvros, Keevil, et al. 2010). We have demonstrated plasma 
corticosterone has a circadian rhythm similar to cortisol suggesting they are under 
similar regulation in the circulation. The differences in saliva and hair glucocorticoid 
concentrations may be secondary to differential local ABC transporter expression 
however this was not tested directly in this thesis.  
Our proposed alternative HPA axis highlights the importance of ABC transporters in 
regulating tissue specific glucocorticoid concentration and we aimed to further define 
the role of ABCC1 in HPA axis negative feedback and peripheral corticosteroid 
receptor occupancy. Our hypothesis that ABCC1 inhibition would not impact negative 
feedback of the HPA axis was based on literature supporting the greater relative 
expression of ABCB1 over ABCC1 in the brain (Karssen et al. 2001; Raubenheimer 
et al. 2006). The higher relative concentration of corticosterone in brain and CSF 
suggests cortisol is exported via ABCB1 and central negative feedback is 
disproportionately influenced by corticosterone. Our data in fact shows that ABCC1 
inhibition does influence HPA negative feedback with enhanced glucocorticoid 
secretion after combined corticosteroid receptor antagonism. This key finding suggests 
that ABCC1 is significant in negative feedback and given that ABCB1 expression is 
greater than ABCC1 at the blood brain barrier, this must be outside the brain itself. 
The pituitary gland lies out with the blood brain barrier and our study has highlighted 
the pituitary contribution to HPA negative feedback.  
We did not demonstrate that corticosteroid receptor occupancy in peripheral tissues is 
influenced by ABCC1 inhibition. We used MR and GR antagonists potassium 
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canrenoate and mifepristone (RU486) to displace the bound glucocorticoids and 
measure release or uptake within different tissues using arterio-venous sampling. 
Displacement of cortisol from MR across the myocardium has been demonstrated 
before (Iqbal et al. 2014) however the increment in this study was small and it may be 
difficult to measure such small changes in tissue glucocorticoid concentrations. While 
we have not managed to prove our hypothesis, this may be due to lack of sensitivity 
of the technique. The data from in vitro and murine models remains compelling that 
ABCC1 exports corticosterone from these cells and may provide a mechanism by 
which we can protect metabolic tissues from excess corticosteroid exposure. 
We present the first data in humans using corticosterone as glucocorticoid replacement 
therapy in patients with CAH. We hypothesised that corticosterone would provide a 
suitable glucocorticoid replacement therapy with potential for enhanced HPA axis 
negative feedback when compared to cortisol and that metabolic side effects would be 
minimised due to export of corticosterone from peripheral tissues such as adipose 
tissue and skeletal muscle. Our interim data shows that corticosterone is effective at 
suppressing the HPA axis with suppressed ACTH, 17-OHP and androstenedione. This 
has never been shown in patients with CAH before and is promising as an indication 
of the final results. The metabolic data shows no clear differences at present although 
the trend for lower circulating insulin in the corticosterone phase is interesting. As 
discussed previously, we may not see any significant changes in these metabolic 
markers over this short study period. We have yet to analyse the effects on glucose 
metabolism with in vivo deuterated glucose and glycerol measurements and the effect 
on bone markers P1NP and CTX. A final analysis of adipose biopsies to compare 
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glucocorticoid sensitive transcripts in each phase will give an indication of whether 
ABCC1 prevents accumulation of corticosterone and protects from over-activation of 
corticosteroid receptors. 
Overall, one of the strengths of these studies is the use of LC-MS/MS to measure 
corticosterone which is a sensitive and specific method of quantification. The historical 
data available regarding corticosterone, while relatively extensive, is limited by the 
variety of assays used which have now largely been superseded by more modern 
techniques. Conducting in vivo studies was another strength, allowing assessment of 
corticosterone and ABC transporter activity in humans where before only in vitro and 
mouse models have been used. Both interventional clinical studies benefitted from a 
crossover design which allowed each participant to act as their own control, a 
particular strength when assessing individual hormone profiles. The inclusion of a 
placebo arm in the final study in CAH patients was particularly important to 
distinguish between normal diurnal variation of circulating hormones and true effects 
of cortisol and corticosterone. 
As with many in vivo studies, these were not without their limitations. I have discussed 
already the difficulties in demonstrating displacement from individual tissues. This 
was further limited by the difficulties with abdominal vein cannulation which was a 
technically challenging procedure and restricted the analysis of adipose tissue 
displacement to half of the participating cohort. Consideration must always be made 
of off-target effects of study medication, particularly the use of probenecid, a drug with 
several therapeutic targets.  
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The findings of this thesis raise a number of important questions which ought to be 
addressed. Firstly, we have identified that corticosterone does not simply mimic 
cortisol in hair and saliva and is present in low concentration and lacks diurnal rhythm 
respectively. While we can speculate that these differences are related to differential 
ABC transporter expression, we have not directly tested this. Further investigation 
with ABCB1 and/or ABCC1 inhibition would clarify the influence these transporters 
have on glucocorticoid concentrations and add to our understanding of glucocorticoid 
metabolism in humans.  
Our study of the physiological relevance and importance of ABC transporters in 
normal glucocorticoid metabolism has highlighted the role of ABCC1 in HPA negative 
feedback. We have inferred that this is through pituitary driven negative feedback 
given the evidence of ABCB1 action at the blood brain barrier and this raises further 
intriguing questions regarding the differential influence of cortisol and corticosterone 
at pituitary and hypothalamic sites. We can speculate that rapid induction of negative 
feedback is influenced primarily by cortisol at the pituitary and corticosterone at the 
hypothalamus and slower feedback via GR and MR will be influenced by relative 
binding affinities. This has implications in dissecting out ultradian regulation of the 
HPA axis and would warrant consideration of corticosterone as well as cortisol 
pulsatility in further studies. 
In order to fully explore the relevance of both ABCB1 and ABCC1 in the regulation 
of the HPA axis, we would wish to examine the expression of ABC transporters in 
human pituitary and hypothalamus tissue samples in more detail. In addition, a further 
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parallel study assessing the effect of ABCB1 inhibition in vivo would be necessary. 
Using an ABCB1 inhibitor such as quinine, a similar displacement study may be 
undertaken with arteriovenous brain tissue sampling via jugular vein cannulation 
(Kilgour et al. 2015).  
Subject to the final results of our study of corticosterone in CAH, the logical next step 
in assessing corticosterone as a replacement therapy would be to carry out a longer-
term study. For this, we would require an oral formulation of corticosterone in a likely 
modified release form. A double-blind randomised cross over study design would be 
ideal and follow up ought to be at least 3 months for better assessment of metabolic 
outcomes.  
Further work to determine the regulation of corticosterone in normal physiology will 
add to the mounting evidence that cortisol and corticosterone are under distinct tissue 
specific regulation. The potential metabolic benefits of using corticosterone as an 
alternative glucocorticoid replacement therapy are yet to be seen however we now 
have evidence that it can provide effective HPA axis suppression. The prospect of 
corticosterone as a new glucocorticoid replacement therapy joins a number of other 
new developments in this field including continuous subcutaneous hydrocortisone 
infusion, modified release hydrocortisone and inhibitors of CYP17A1 (Nella et al. 
2016; Mallappa et al. 2015; Auchus et al. 2014; Nilsson et al. 2017). This treatment is 
the only one with the prospect of reduced metabolic side effects while maintaining 
equal efficacy compared to hydrocortisone however and has real potential to make an 
impact on patient morbidity and mortality.               the 
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